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Abstract
Cytokines are secreted proteins or glycoproteins that are responsible for mediating cell to
cell signals and orchestrating numerous biological events including the activation,
proliferation and differentation of the cells of the immune system. Cytokine signals are
mediated through specific transmembrane receptors on the surface of their target cells.
The binding of a hematopoietic cytokine to its receptor triggers the activation of receptor-
associated Janus kinases (JAKs). This is followed by the activation of their downstream
targets, Signal transducers and activators of transcription (STATs) through tyrosine
phosphorylation. Activated STATs dimerize and translocate to the nucleus, where they
modulate the transcription of their target genes. The activity of this signaling cascade is
under the control of regulatory proteins, such as Protein inhibitors of activated STAT
(PIAS), Suppressors of cytokine signaling (SOCS) and various protein tyrosine
phosphatases (PTPs). Moreover, JAKs and STATs are regulated by different post-
translational modifications, like in the case of STAT1 and STAT5 through the covalent
conjugation of a small ubiquitin-like modifier (SUMO).
The JAK/STAT pathway has been conserved throughout evolution. In the fruit fly,
Drosophila melanogaster, the JAK/STAT cascade plays a crucial role in various
developmental events as well as in the immune response, and it is activated by a set of
secreted mediators called Unpaired (Upd). In this thesis Drosophila melanogaster was
used as a model organism to study the regulation of the JAK/STAT pathway. The only
known Drosophila STAT transcription factor, Stat92E, was shown to be modified with
SUMO at a single lysine, K187. Mutating this SUMO conjugation site increased the Upd-
induced transcriptional activity of Stat92E, suggesting that the sumoylation of Stat92E
negatively regulates the Drosophila JAK/STAT pathway. This indicates that sumoylation
is an evolutionary conserved regulatory mechanism of STAT-mediated signal
transduction.
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RNA interference (RNAi) has been found to function exceptionally well in Drosophila
cells, and also in vivo in adult flies. A genome-wide RNAi screen was conducted in
Drosophila S2 cells to reveal novel JAK/STAT pathway associated genes. As a result six
potential JAK/STAT pathway regulating genes were found, of which two; Eye
transformer (ET) and Not4 were studied in more detail. ET encodes a gp130-related
transmembrane protein that was found to inhibit Upd-induced Stat92E tyrosine
phosphorylation, thus it functions as a negative regulator of the Drosophila JAK/STAT
pathway. RNAi of Not4 was found to repress the Drosophila JAK/STAT pathway target
gene expression in Drosophila cells, indicating that Not4 is needed for the JAK/STAT
pathway to function properly. Furthermore, overexpression of Not4 resulted in enhanced
Stat92E-mediated gene responses, confirming Not4 as a positive regulator of the
Drosophila JAK/STAT pathway. We found that Not4 is able to interact with Stat92E, but
does not affect Stat92E tyrosine phosphorylation. Finally, our experiments indicated that
Not4 is needed for Stat92E to properly bind to its target DNA sequence at the promoter
of the stress gene TurandotM (TotM). The Not4 mammalian homologue CNOT4 was also
shown to participate in STAT1- and STAT6-mediated gene expression in human cells,
indicating that Not4/CNOT4 is an evolutionary conserved regulator of JAK/STAT
signaling.
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Tiivistelmä
Sytokiinit ovat liukoisia välittäjäaineita, jotka säätelevät monia biologisia tapahtumia
vaikuttamalla kohdesolujensa toimintaan. Sytokiinien vaikutukset välittyvät kohdesolujen
pinnalla olevien reseptorimolekyylien kautta. Hematopoieettisen sytokiinin
kiinnittyminen sille spesifiseen reseptoriin laukaisee reseptorialayksiköiden solunsisäisiin
osiin liittyneiden JAK (Janus kinase) -proteiinien aktivaation. Aktivoidut JAK-proteiinit
fosforyloivat reseptorimolekyylien solun sisäisissä osissa tietyt tyrosiini-
aminohappotähteet, joihin sytoplasmassa vapaana olevat STAT (Signal transducer and
activator of transcription) -transkriptiotekijät voivat kiinnittyä, tullen niin ikään
fosforyloiduiksi JAK-proteiinien toimesta. Aktivoiduttuaan fosforylaation seurauksena
STAT-proteiinit pariutuvat ja siirtyvät solun tumaan, missä ne sitoutuvat spesifisten
kohdegeenien promoottorialueille aiheuttaen muutoksia kohdegeenien ilmentymisessä.
JAK/STAT -tiedonsiirtoreitin aktiivisuus on tarkoin säädelty useiden
säätelijämolekyylien kautta, joista tutkituimpia ovat PIAS (Protein inhibitor of activated
STAT) ja SOCS (Suppressor of cytokine signaling) -proteiinit sekä
proteiinityrosiinifosfataasit. Myös erityyppiset JAK- ja STAT-proteiinien translaation
jälkeiset muokkaukset ovat tärkeässä osassa reitin aktiivisuuden säätelyssä. Tästä
esimerkkinä voidaan mainita SUMO (Small ubiquitin-like modifier) -nimisen proteiinin
kovalenttinen liittyminen STAT1- ja STAT5-proteiineihin, aiheuttaen niiden
aktiivisuuden hiljentymisen.
JAK/STAT -tiedonsiirtoreitti on säilynyt muuttumattomana eläinlajien evoluutiossa.
Banaanikärpäsessä (Drosophila melanogaster) JAK/STAT -reitin on osoitettu
osallistuvan immuunipuolustuksen ja useiden eri elinten kehityksen säätelyyn. Tässä
tutkimusprojektissa käytettiin banaanikärpästä malliorganismina tavoitteena löytää uusia
JAK/STAT -signalointireitin säätelyyn osallistuvia proteiineja sekä selvittää,
säädelläänkö banaanikärpäsen ainoaa STAT-transkriptiotekijää, Stat92E:tä, SUMO-
konjugaation välityksellä. Tulostemme perusteella SUMO kiinnittyy Stat92E-proteiinissa
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lysiini 187 aminohappotähteeseen. Kun SUMO:n kiinnittyminen Stat92E:hen estettiin
mutatoimalla kyseinen aminohappotähde arginiiniksi, lisääntyi JAK/STAT kohdegeenien
luenta, kun reitti aktivoitiin yli-ilmentämällä sen kautta vaikuttavaa välittäjäainetta,
Upd:ta. Tämä osoittaa, että nisäkäshomologiensa STAT1:n ja STAT5:n tavoin Stat92E
on negatiivisesti säädelty sumolaation välityksellä.
Geenien hiljentämisen RNA-häirintämenetelmällä (RNAi) on osoitettu toimivan erityisen
hyvin banaanikärpäsen soluissa, kuten myös elävissä kärpäsissä. Tätä ominaisuutta
hyödyntäen banaanikärpäsen S2-solulinjassa tehtiin koko genomin kattava RNA-
häirintään perustuva seula, jonka tarkoituksena oli löytää uusia JAK/STAT -reitin
aktiivisuuteen vaikuttavia geenejä. Tuloksena löydettiin kuusi potentiaalista geeniä, joista
kaksi, ET ja Not4 valittiin tarkempiin jatkotutkimuksiin. Osoitimme, että ET-proteiini
toimii banaanikärpäsen JAK/STAT -reitin negatiivisena säätelijänä, joka inhiboi Upd-
induktion aikaansaamaa Stat92E:n tyrosiinifosforylaatiota. Not4 geeniekspression
hiljentäminen banaanikärpäsen soluissa vähensi huomattavasti JAK/STAT -reitin
kohdegeenien ilmentymistä. Not4 geenin yli-ilmentämisen banaanikärpäsessä huomattiin
puolestaan lisäävän merkittävästi Stat92E:n kohdegeenien luentaa. Biokemialliset
kokeemme osoittivat, että Not4 kykenee sitoutumaan Stat92E-proteiiniin mutta ei vaikuta
sen tyrosiinifosforylaatiotasoon. Osoitimme lisäksi, että Not4 vaaditaan Stat92E-
transkriptiotekijän DNA:han sitoutumiseen. Ihmissoluissa tekemiemme kokeiden
perusteella päättelimme, että Not4-proteiinin ihmishomologi CNOT4 osallistuu STAT1-
ja STAT6-välitteiseen kohdegeenien ilmentymiseen, osoittaen Not4/CNOT4:n olevan
JAK/STAT -signalointireitin evolutiivisesti konservoitunut säätelijä.
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1. Introduction
Myriad soluble mediators are responsible for the fate of cells. These growth factors and
hormones regulate the maintenance, differentiation and proliferation of cells, as well as
their death. The immune system is orchestrated by secreted glycoproteins called
cytokines that signal through their specific cell membrane anchored receptors. The
intracellular signals of the hematopoietic cytokines from the receptor into the nucleus are
mediated via a defined Janus kinase (JAK)/Signal transducer and activator of
transcription (STAT) signaling pathway. This tyrosine phosphorylation driven cascade is
activated when a hematopoietic cytokine binds to its cell surface receptor leading to
receptor dimerization or oligomerization following the transphosphorylation of receptor-
associated JAKs. Activated JAKs then phosphorylate specific tyrosine residues in the
receptors, and in this manner produce docking sites for their cytoplasmic downstream
targets, STATs. When bound to receptors via their SH2 domains, STATs become
activated through JAK-mediated tyrosine phosphorylation. In response to activation
STATs rapidly dimerize and translocate to the nucleus where they bind to their target
gene promoters in order to activate gene expression. With multifold JAKs and STATs,
mammalian cells provide the possibility for each hematopoietic cytokine to signal
through a particular combination of JAKs and STATs, thus making the mammalian
JAK/STAT pathway highly redundant.
The JAK/STAT pathway has been well conserved during evolution from small insects to
humans. In the fruit fly, Drosophila melanogaster the JAK/STAT pathway contains only
one transmembrane receptor, Domeless (Dome), one JAK (Hopscotch) and a single
STAT (Stat92E), which mediate the signals of three secreted ligands termed Unpaired
(Upd, Upd2, Upd3). Nonetheless, the Drosophila JAK/STAT pathway is  highly similar
to the mammalian cascade, offering a less redundant model for studying the function of
the pathway. In addition to maintaining the function of hematopoietic cells, the
JAK/STAT cascade is also responsible for the regulation of multiple steps in Drosophila
development.
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The JAK/STAT pathway needs to be under strict control at every level of the cascade.
Factors that are responsible for the fine tuning and for shutting down the JAK/STAT
pathway include protein tyrosine phosphatases, Protein inhibitor of activated STAT
(PIAS) proteins and Suppressor of cytokine signaling (SOCS), all of which are conserved
in Drosophila melanogaster. Like numerous other transcription factors, mammalian
STAT1 and STAT5 are also negatively regulated by the covalent conjugation of a small
ubiquitin-like modifier (SUMO).
Still, to date the molecular mechanisms of the regulation of the JAK/STAT pathway are
largerly unknown, and it is very likely that all of the JAK/STAT pathway associated
regulators have not yet been discovered. This study was aimed at exploring the molecular
mechanisms of the JAK/STAT pathway regulation using Drosophila melanogaster as  a
model organism.
16
2. Review of the literature
2.1 Cytokines and the immune system
Humans and other animals are constantly threatened by infectious pathogens that can
cause various diseases. During evolution organisms have developed efficient and
sophisticated mechanisms to overcome these intruders. In humans, the immune system
consists of an innate and an adaptive immunity. The innate immunity provides a fast
defence against pathogens, whereas the adaptive immune system provides a more
specific, but slower response (Kvell et al. 2007). The immune system is orchestrated by
soluble mediators called cytokines. Cytokines are proteins or glycoproteins, which are
released basically from any nucleated cell in response to infection or injury. Cytokines
signal through cell surface receptors that are specific to each cytokine. When bound to a
receptor, cytokines activate intracellular signaling cascades leading to altered gene
expression in the target cell. This way, cytokines are able to drive the proliferation,
differentiation or survival of their target cells (Oppenheim 2001). The first cytokines
were found as early as is the 1950s, and were named interferons (IFNs) (Isaacs and
Lindenmann 1957). After that, a growing number of cytokines with various functions
have been described (Oppenheim 2001, O'Shea and Plenge 2012).
Cytokines are divided into various groups according to their structural and functional
characteristics as well as the type of receptor they bind. Based on their structural features
cytokine receptors can be divided into two families, class I and class II cytokine receptors
(Table 1). Cytokines that signal through class I receptors are commonly called
hematopoietic cytokines, because they mainly target blood cells. Hematopoietic
cytokines include the majority of interleukins (IL), erythropoietin (Epo), thrombopoietin
(Tpo), ciliary neurotrophic factor (CNTF), leukemia inhibitory factor (LIF), oncostatin M
(OSM), colony-stimulating factors for granulocytes (G-CSF) and granulocyte-
macrophages (GM-CSF). Class I cytokine receptors also mediate the signals of some
hormones such as growth hormone (GH) and prolactin (PRL). Class I cytokine receptors
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are divided into four subfamilies based on the number of their subunits and the utilization
of the common signaling chains. The first subfamily is composed of single chain
receptors, which both bind the cytokine and pass on the signal after ligand induced
homodimerization or oligomerization. Receptors in the other three subgroups contain a
cytokine specific ligand binding subunit coupled to a common signal transducing
receptor subunit. These three subfamilies are the common ?-chain, common ?-chain and
gp130 or gp130-related subunit class I cytokine receptor families (Silvennoinen et al.
1997).
Class II cytokine receptors use at least two different subunits, which are both capable of
ligand binding and signal transduction (Silvennoinen et al. 1997). Class II cytokine
receptors can be divided into four smaller subgroups: type I IFN receptors, which mediate
the signals of 13 different IFN-?s, IFN-? and IFN-?, IFN-? and IFN-?; type II IFN
receptor is a IFN-? receptor; the third subgroup contains the receptors for IL-10 and IL-
10-related cytokines (IL-19, IL-20, IL-22, IL-24 and IL-26),  and the fourth subgroup,
which is the most recently discovered subclass of class II cytokine receptors, is a type III
IFN receptor complex that mediates signals for interleukins 28A, 28B and 29 (also
known as IFN-?2, IFN-?3 and IFN-?1, respectively)  (Kotenko and Pestka 2000,
Fickenscher et al. 2002, Kotenko et al. 2003, Kotenko and Langer 2004, Kotenko 2011).
The type III IFN receptor complex consists of two subunits: IFN-?R1 and IL-10R2 (IL-
10R?), which is also shared with the IL-10 receptor and some other IL-10 family receptor
complexes (Kotenko 2011). The signal transducing receptor subunits of the cytokine
receptors are responsible for the activation of the intracellular signal transduction
cascades that mediate the secondary message of the cytokine to the cell nucleus. The
most common signaling cascade is the JAK/STAT pathway that mediates the secondary
messages of the hematopoietic cytokines and most of the cytokines that use class II
cytokine receptors, discussed in more detail in the next chapter (Silvennoinen et al. 1997,
Kotenko and Pestka 2000).
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Table 1. Cytokine receptor families (Silvennoinen et al. 1997, Kotenko and Langer
2004, Schindler and Plumlee 2008, Kotenko 2011).
Cytokine receptor family Ligands
Class I cytokine receptors
Single chain receptors Epo, Tpo, GH, PRL
Receptors that share common ?-chain IL-2, IL-4, IL-7, IL-9, IL-13, IL-15, IL-21
Receptors that share common ?-chain IL-3, IL-5, GM-CSF
gp130 family IL-6, IL-11, LIF, CNTF, OSM, G-CSF*,
CT-1, IL-12*, IL-23, IL-27, IL-31, IL-35
Class II cytokine receptors
Type I IFN receptors IFN-?, IFN-?, IFN-?, IFN-?, IFN-?
Type II IFN receptors IFN-?
Receptors for IL-10 family of cytokines IL-10, IL-19, IL-20, IL-22, IL-24, IL-26
Type III IFN receptors IL-28A, IL-28B, IL-29
*Receptors for G-CSF and IL-12 share structural features with gp130, but does not
require interaction with gp130 for signal transduction.
2.2 The JAK/STAT pathway
The signal from the receptors of the hematopoietic cytokines and class II cytokine
receptors to the nucleus is mediated through a defined evolutionary conserved signal
transduction cascade called the JAK/STAT pathway. Mammals have four members of the
Janus  kinase  (JAK)  family:  JAK1,  JAK2,  JAK3  and  TYK2  (tyrosine  kinase  2).  JAKs
activate their downstream targets, Signal transducers and activators of transcription
(STATs), a family of transcription factors, which contains seven members in mammals:
STATs 1–4, STAT5A, STAT5B and STAT6 (Leonard and O'Shea 1998). Depending on
the cytokine receptor, JAKs and STATs form different combinations thus adding
variability to the signaling cascade.
The activation of the JAK/STAT pathway is mediated through the tyrosine
phosphorylation of signaling molecules inside the cell. Hematopoietic cytokine receptors
lack tyrosine kinase activity, and are therefore dependent on JAKs that are associated
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with the intracellular regions of the receptors. Signaling is initiated when a ligand binds
to its receptor leading to receptor dimerization or oligomerization depending on the
receptor type. A subsequent conformational change in the receptor subunits allows the
associated JAKs to transphosphorylate one another on specific tyrosine residues. JAK-
mediated tyrosine phosphorylation of the receptors creates a docking site for inactive
cytoplasmic STAT molecules. When bound to receptors via their SH2 domains, STAT
molecules too become activated through JAK mediated tyrosine phosphorylation.
Following tyrosine phosphorylation STAT transcription factors dimerize via an SH2
domain phospho-tyrosine-mediated interaction creating either homo- or heterodimers that
rapidly translocate to the nucleus in order to activate the expression of their target genes
(Silvennoinen et al. 1997, Schindler 1999, Schindler 2002).
2.2.1 Biological roles of the JAK/STAT pathway
The JAK/STAT signaling cascade is important for the regulation and maintenance of
hematopoietic cells, and disturbances in the pathway can lead to various pathological
consequences such as tumorigenesis. STAT3 has been found to be constitutively active in
over 50% of lung and breast tumors and in more than 50% of head and neck tumors
(Dreesen and Brivanlou 2007). Like STAT3, the persistent activation of STAT5 has been
linked to various solid tumors. This is due to increased secretion of cytokines and growth
factors by tumor and stromal cells as well as dysfunction of JAK/STAT pathway
regulators in tumor cells (Seavey and Dobrzanski 2012). Like in solid tumors, the
JAK/STAT cascade is involved in a majority of hematopoietic tumors and disturbances
(Seavey and Dobrzanski 2012). For example, JAK3 has been reported to be consitutively
active in several cases of B-lineage lymphoid malignancies, including B-lineage acute
lymphoblastic leukemia (Uckun et al. 2011). According to the most recent results,
somatic mutations in the Stat3 gene were found in 40% of patients with T-cell large
granular lymphocytic leukemia. Furthermore, the patients with a mutated Stat3 suffered
more often of neutropenia and rheumatoid arthritis than patients with no Stat3 mutations
(Koskela et al. 2012). Several mutations in the JAK-homology 2 (JH2) domain of JAK2
have been linked to human hematological diseases, among them the V617F mutation,
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which results in a constitutively active JAK2, and is found in up to 97% of cases of
polycythaemia vera and in approximately 50% of patients with essential
thrombocythaemia or idiopathic myelofibrosis (Baxter et al. 2005, James et al. 2005,
Jones et al. 2005, Kralovics et al. 2005). The JAK/STAT pathway regulates signaling in
the immune response and therefore dysregulation or altered activity of the pathway may
also cause several immunological diseases, such as severe combined immune deficiency
(SCID) where a mutation in the Jak3 gene is seen in some patients (Macchi et al. 1995).
As another example, STAT6 has been shown to have a central role in the pathogenesis of
asthma due to an increased density of STAT6 expressing cells in the airways of asthma
patients. This leads to the hyperexpression of IgE (Christodoulopoulos et al. 2001).
2.2.2 Domain structure of JAKs
JAK1-3 and TYK2 form the family of Janus kinanes, which range from 120 kDa to
140 kDa in size. JAK1, JAK2 and TYK2 are ubiquitously expressed, whereas JAK3 is
normally expressed by hematopoietic cells and associates with the ?-chain of the
receptors for IL-2, IL-4, IL-7, IL-9, IL-15 and IL-21   (Schindler et al. 2007). JAKs share
a structure, which consists of seven JAK-homology (JH) domains (Fig. 1). JH domains
are numbered from the carboxyl-terminus (C-terminus) to the amino-terminus (N-
terminus). The JH1 domain in the C-terminus harbors the essential kinase activity. This
domain is regulated by the adjacent JH2 domain, known as the pseudokinase domain.
Recently, the pseudokinase domain in JAK2 was shown to harbor a kinase activity and to
regulate JAK2 activity by phosphorylation of two negative regulation sites in JAK2:
serine 523 and tyrosine 570 (Ungureanu et al. 2011). The N-terminal JH7-5 domains and
half of the JH4 domain form the FERM domain that mediates receptor association
(Schindler et al. 2007). The rest of the JH4 domain and the JH3 domain between the
FERM and the pseudokinase domain constitute the SH2-like domain with no well-
defined function (Schindler et al. 2007).
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Figure 1. Domain organization of JAKs. JAKs are composed of seven JH domains
which are numbered from the C-terminus to the N-terminus of the protein. The JH1
domain harbors a kinase activity, which is essential for JAK function. The regulatory JH2
domain is also known as the pseudokinase domain. The SH2-like domain is located in the
middle of the protein. The N-terminal FERM domain mediates receptor interactions.
Phosphorylation sites are not illustrated in the figure.
2.2.3 Domain structure of STATs
All of the seven mammalian STATs share a conserved domain structure illustrated in
Figure 2. The first, approximately 125 amino acid residues compose the N-terminal
domain that mediates the dimerization of inactive STATs (Baden et al. 1998, Meyer and
Vinkemeier 2004, Mao et al. 2005). Deletion of the N-terminal domain was shown to
result in a constitutively active STAT1, implying that the N-terminal domain is required
for the dephosphorylation of tyrosine 701, the amino acid responsible for STAT1
activation (Shuai et al. 1996). The N-terminal domain also mediates interactions between
STATs and other proteins, for example STAT1 is shown to interact with the CREB-
binding domain of the transcriptional co-activator CBP/p300 via its N-terminal domain
(Zhang et al. 1996). Furthermore, the N-terminal domain has been suggested to
participate in the nuclear import and export of STATs as well as in cooperative DNA
binding to tandem GAS-elements (Xu et al. 1996, Strehlow and Schindler 1998,
Schindler et al. 2007).
Next to the N-terminal domain is a coiled-coil domain that consists of 4 ?-helices and
mediates interactions with other proteins and the nuclear export machinery (Chen et al.
1998, Becker et al. 1998, Begitt et al. 2000, Mowen and David 2000, Schindler et al.
2007). The DNA binding domain, located between amino acids ~320-480 consists of a ?-
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barrel immunoglobulin fold, and mediates the DNA binding of STATs (Schindler et al.
2007). A linker domain connects the DNA binding domain with dimerization domains,
and is also thought to participate in the nuclear export of STATs through its nuclear
export signal (Bhattacharya and Schindler 2003).
The SH2 domain is the most highly conserved domain found in STATs. It mediates
interactions with the phosphorylated receptor, thus playing a critical role in the activation
and dimerization of activated STATs (Schindler 2002). Upon activation by JAKs, a
specific tyrosine residue within the C-terminal tail segment of the SH2 domain (amino
acid ~700) is phosphorylated and this phospho-tyrosine interacts with the SH2 domain of
another STAT allowing parallel dimer conformation to occur (Chen et al 1998, Schindler
2002). The C-terminus of the STATs is the least conserved region between different
STATs and is responsible for transcriptional activation, and is thus called the
transactivation domain (TAD). The TAD mediates many interactions with proteins
involved in transcription, such as histone acetyltransferases CBP/p300, reported to
function as coactivators for all STAT family members (Zhang et al. 1996, Bhattacharya
et al. 1996, Pfitzner et al. 1998, Gingras et al. 1999, McDonald and Reich 1999, Paulson
et al. 1999). In addition to tyrosine phosphorylation of the C-terminal tail segment of the
SH2 domain, also serine phosphorylation of TAD participates in the regulation of STAT-
mediated signaling. Serine 727 phosphorylation of STAT1 modulates interactions with
co-activators such as MCM5 (a member of mini-chromosome maintenance protein
family) and selectively enhances STAT1 target gene expression (Zhang et al. 1998,
Varinou et al. 2003). Moreover, serine 727 phosphorylation is known to enhance STAT1
sumoylation (serine phosphorylation is discussed in more detail in the Chapter 2.3.4.1)
(Vanhatupa et al. 2008).
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Figure 2. Schematic presentation of the STAT domain architecture. The N-terminal
domain and coiled-coil domain participate in molecular interactions. The SH2 domain
mediates interactions with phosphorylated tyrosine residues. DNA BD stands for DNA
binding domain and TAD for C-terminal transactivation domain. The tyrosine
phosphorylation site located approximately at amino acid 700 in the C-terminal tail
segment of the SH2 domain is illustrated with a red phosphate.
2.3 Regulation of the JAK/STAT pathway
The JAK/STAT pathway is activated through ligand binding to the cytokine receptor
followed by the rapid tyrosine phosphorylation of JAKs, intracellular domains of the
receptors and STATs, leading to the nuclear translocation of dimeric STATs. To avoid
hyperactivity, and in order to switch off the pathway, several conserved mechanisms take
place in the cells. These regulatory mechanisms include various post-translational
modifications of JAKs and STATs, as well as the action of regulatory proteins such as
protein tyrosine phosphatases, Suppressors of cytokine signaling (SOCS) and Protein
inhibitors of activated STATs (PIAS). These regulatory mechanisms are discussed in
more detail in the next chapters.
2.3.1 Protein tyrosine phosphatases
Dephosphorylation by protein tyrosine phosphatases (PTPs) is essential in order to
inactivate JAKs and STATs. Several mammalian PTPs have been shown to
dephosphorylate JAKs and STATs, including SHP1, SHP2, CD45, PTP1B, T cell PTP
(TC-PTP), Receptor-type tyrosine-protein phosphatase T (PTPRT) and PTP-Basophil
like (PTPBL) (Xu and Qu 2008).
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SHP1 is an SH2 domain containing PTP, expressed in hematopoietic cells (Neel et al.
2003). SHP1 has been shown to downregulate erythropoietin (Epo) signaling by binding
to the Epo receptor and by dephosphorylating Epo receptor-associated JAK2
(Klingmüller et al. 1995). SHP1 has also been suggested to dephosphorylate JAK1, JAK3
and STAT3. The silencing of SHP1 is associated with leukemia and lymphomas (David
et al. 1995, Chim et al. 2004, Han et al. 2006, Xu and Qu 2008). SHP2 shares structural
similarities with SHP1, but it is ubiquitously expressed (Xu and Qu 2008). Enhanced and
prolonged interferon-?-induced STAT1 Tyr701 and Ser727 phosphorylation was
observed in Shp2-/- cells, and purified GST-SHP2 was shown to dephosphorylate STAT1
on Tyr701 and Ser727 (Wu et al. 2002). In addition to STAT1, SHP2 has also been
suggested to interact and dephosphorylate STAT5 and to negatively regulate STAT3
mediated signaling (Yu et al. 2000, Chen et al. 2003, Xu and Qu 2008).
The regulatory affect of protein phosphatases on JAK/STAT signaling may not always be
inhibitory, SHP2 has also been suggested to promote JAK2/STAT5 mediated prolactin
signaling by dephosphorylating Tyr1007 in JAK2, a phosphotyrosine that mediates the
interaction of JAK2 with its inhibitor SOCS1. When this residue was dephosphorylated
by SHP2 in vitro, JAK2 was released from the inhibitory effects of SOCS1 (Ali et al.
2003). This indicates that SHP2 may first promote prolactin signaling at the level of
JAK2, and then inhibit the activated pathway by dephosphorylating STAT5.
CD45 is a transmembrane protein, which is highly expressed in hematopoietic cells, and
has an important role in the regulation of T and B cell receptor signaling. CD45 can
dephosphorylate all of the JAK family members in murine cells, and it has been reported
to dephoshorylate JAK1 and JAK3 in human cells as well (Irie-Sasaki et al. 2001,
Yamada et al. 2002, Xu and Qu 2008). A recent study revealed a loss of function
mutation in a gene encoding CD45 in patients with T cell acute lymphoblastic leukemia
(T-ALL), resulting in increased activation of the JAK/STAT pathway. Furthermore,
knockdown of CD45 significantly increased JAK1 and STAT5 phosphorylation levels in
the human T-ALL cell line KE-37 (Porcu et al. 2012).
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PTP1B  is  a  phosphatase  expressed  in  many  tissues,  and  it  has  been  shown  to
dephosphorylate the JAK2 and TYK2 kinases (Myers et al. 2001). TC-PTP shares
structural similarities with PTP1B, but is mainly expressed in hematopoietic cells and
contains a nuclear localization signal in its C-terminus. TC-PTP has been shown to
dephosphorylate STAT1 and STAT5A and STAT5B in the nucleus (Aoki and Matsuda
2002, Ten Hoeve et al. 2002, Bourdeau et al. 2005). Moreover, JAK1, JAK3 and STAT3
are thought to be TC-PTP substrates (Simoncic et al. 2002, Yamamoto et al. 2002).
One of the STAT3 phosphatases is a Receptor-type tyrosine-protein phosphatase T
(PTPRT). Overexpression of PTPRT in colorectal cancer cells significantly reduced the
expression of STAT3 target genes (Zhang et al. 2007). Of other phosphatases PTP-
Basophil like (PTP-BL) was found to interact with STAT4 in a yeast two-hybrid screen
and was shown to dephosphorylate STAT4 and STAT6. Depletion of PTP-BL from
CD4+ T cells enhanced Th1 and Th2 differentation in response to increased and
prolonged STAT4 and STAT6 activation (Nakahira et al. 2007).
A growing amount of evidence indicates that various protein tyrosine phosphatases play
an essential role in the regulation of JAK/STAT signaling. Still, their specificity and the
exact molecular mechanism of their function remain elusive.
2.3.2 Suppressors of cytokine signaling, SOCS
The suppressor of cytokine signaling (SOCS) protein family consists of eight members,
SOCS1–7 and cytokine inducible SH2-containing protein (CIS). SOCS have been linked
to the regulation of over 30 cytokines, including IFN-?, IL-2, IL-4 and IL-6 (Croker et al.
2008). All eight SOCS contain a central SH2 domain, which is able to bind
phosphorylated tyrosines, and a 40 amino acid SOCS box domain at the C-terminus of
the protein. The SOCS domain is known to interact with elongins B and C and Cullin5 in
order to catalyze the ubiquitination of target proteins such as JAK2 for SOCS1 (Zhang et
al. 1999, Kamizono et al. 2001, Ungureanu et al. 2002, Babon et al. 2009). The amino-
terminal region in SOCS proteins is variable in length and does not contain any known
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functional domains, except a kinase inhibitory region (KIR) in SOCS1 and SOCS3,
adjacent to the SH2 domain. This 12 amino acid long region directly inhibits the
catalytical activity of JAKs. SOCS proteins may also compete with STATs for binding to
tyrosine phosphorylated receptors (Croker et al. 2008). Recently SOCS3 was shown to
downregulate JAK1, JAK2 and TYK2 but not JAK3. This selection is based on a three-
amino acid motif, GQM, in the JAK insertion loop. The motif is present in JAK1, JAK2
and TYK2 but absent in JAK3. Mutations in the first and last amino acid of this motif
abolished SOCS3 mediated inhibition of JAK2, while a mutation in the middle residue
(Q1072 in JAK2) had only a minor effect on JAK2 activity. An NMR analysis in the
same study suggested that SOCS3 interacts simultaneously with JAK2 and cytokine
receptor subunit gp130. Furthermore, it was shown that SOCS3 does not compete in
binding with either ATP or substrate, and therefore acts as a noncompetitive inhibitor of
JAK2. Moreover, SOCS3 did not reduce ATP hydrolysis by JAK2, but instead inhibited
phosphate transfer to a tyrosine residue of the substrate (Babon et al. 2012).
Several SOCS genes have a STAT binding site in their promoter region and the
expression of SOCS is induced by various cytokines, such as IFN-?, Epo and numerous
IL-family members. Due to this, SOCS proteins are thought to form a negative feedback
loop in the regulation of the JAK/STAT signaling pathway (Matsumoto et al. 1997,
Greenhalgh and Hilton 2001, Alexander and Hilton 2004, Croker et al. 2008).
2.3.3 Protein inhibitors of activated STAT, PIAS
Four different protein inhibitors of activated STAT (PIAS) proteins have been described
in mammals; PIAS1, PIAS3, PIASx (PIAS2) and PIASy (PIAS4), and all of these, except
PIAS1, have two isoforms (Shuai 2006, Rytinki et al. 2009). The size of PIAS proteins
varies from the 510 amino acids of PIASy to the 651 amino acids of PIAS1 and the
proteins share a conserved domain architecture, illustrated in Figure 3. The N-terminal
SAP (scaffold attachment factor-A/B, acinus and PIAS) domain is involved in DNA
binding (Aravind and Koonin 2000, Rytinki et al. 2009). Incorporated within the SAP
domain, PIAS proteins have an LxxLL motif that has been suggested to mediate
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interactions with the nuclear receptors. It has also been shown that the LxxLL motif in
PIASy is  essential  for  the  PIASy mediated  downregulation  of  STAT1 activity,  but  it  is
not required for the STAT1-PIASy interaction (Heery et al. 1997, Liu et al. 2001). Next
to the SAP domain lies the PINIT domain, which is thought to regulate the subcellular
localization of at least PIAS3L, the long form of PIAS3, found in mouse embryonic stem
cells (Duval et al. 2003, Rytinki et al. 2009). The RING-finger-like zinc-binding domain
(RLD) in the middle of the protein is the most conserved region among the PIAS family
members, and is needed for the SUMO (small ubiquitin-like modifier) E3 ligase function
of PIAS proteins (Hochstrasser 2001, Rytinki et al. 2009). Adjacent to the RING domain
lies a SUMO interacting motif (SIM), which possibly mediates noncovalent interactions
with SUMO (Rytinki et al. 2009). The C-terminal serine/threonine-rich region (S/T) is
the least conserved region in PIAS proteins, and is not present in PIASy (Sharrocks 2006,
Rytinki et al. 2009).
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Figure 3. Schematic illustration of the PIAS protein structure. The N-terminal SAP
domain mediates DNA binding and protein interactions. SAP domain contains an LxxLL
motif. PINIT and RING domains are located in the central part of the protein. The SIM
domain mediates interactions with SUMO. The C-terminal region is the least conserved
among PIAS family members and the S/T region is absent from PIASy.
PIAS proteins were initially described as regulators of STAT3 and STAT1 signaling, and
were correspondingly named PIAS3 and PIAS1. PIAS3 was found to interfere with
STAT3 DNA binding without having an effect on STAT1, while PIAS1 inhibited STAT1
DNA binding and transcriptional activity (Chung et al. 1997, Liu et al. 1998). The
interaction between PIAS and STAT requires cytokine stimulation, and it has been
suggested that PIAS proteins interact only with dimeric STATs (Liao et al. 2000). While
at first PIAS proteins were found to interrupt STAT1 and STAT3 DNA binding,
nowadays PIAS proteins are known to affect STAT-mediated gene responses also
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through other mechanisms. For example, PIASy and PIASx have been shown to inhibit
STAT1 and STAT4 activity, respectively, without having an effect on DNA binding
activity. PIASx was shown to interact with DNA bound STAT4 and a histone deasetylase
inhibitor abolished PIASx mediated inhibition suggesting that PIASx may function as a
co-repressor by recruiting HDACs to inhibit transcription on STAT4 responsive
promoters (Liu et al. 2001, Arora et al. 2003).
Pias1 knockout mice are viable, but smaller in size when compared to their wild type
littermates. Studies with Pias1-/- mice have revealed that PIAS1 selectively regulates
interferon responsive gene expression. In their study, Liu et al. (2004) found that the
expression of only 9% of IFN-? target genes was altered in the absence of PIAS1. These
genes included Guanylate binding protein-1 (Gbp-1), CXC chemokine ligands 9 and 10
(Cxcl9 and Cxcl10), whereas the expression of genes such as Interferon regulatory
factor-1 (Irf-1), Socs1 and Inducible nitric oxide synthase 2 (Nos2) was not altered. In
chromatin immunoprecipitation assays Pias1 depletion resulted in enhanced STAT1
binding to the Gbp-1 promoter, without having an effect on binding to the Irf-1 gene
promoter under IFN-? stimulation. Although PIAS1 regulates only a subset of IFN-
inducible genes, the protein seems to be important for the innate immune response.
Pias1-/- cells showed increased antiviral activity towards mouse ?-herpes virus-68 (MHV-
68) infection, based on reduced expression of viral proteins in infected knockout
macrophages, when compared to infected wild type macrophages. Pias1-/- mice were also
more resistant to Listeria monocytogenes bacterial infection than wild type mice (Liu et
al. 2004).
In addition to STATs, PIAS proteins have also been shown to regulate a broad range of
other transcription factors, including Nuclear factor-?B (Nf-?B) and lymphoid enhancer-
binding factor 1 (LEF1) (Sharrocks 2006, Shuai 2006). PIAS proteins have also been
shown to function as SUMO E3 ligases promoting SUMO conjugation to target proteins,
such as STAT1 and STAT5 (Rogers et al. 2003, Ungureanu et al. 2003, Van Nguyen et
al. 2012). This role of PIAS proteins is discussed in Chapter 2.4.
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2.3.4 Post-translational modifications in the regulation of the JAK/STAT pathway
2.3.4.1 Tyrosine and serine phosphorylation, methylation, acetylation, O-glycosylation
and ISGylation
Of the known post-translational modifications to proteins, tyrosine phosphorylation plays
the most important role in terms of the regulation of the activity of the JAK/STAT
pathway. As discussed in Chapter 2.2, the activation of the JAK/STAT cascade is
dependent on the phosphorylation of the certain tyrosine residues in receptor-associated
JAKs, the cytoplasmic domains of the receptor subunits and in STATs. Ligand binding to
the receptor induces the auto- or transphosphorylation of several tyrosine residues in
JAKs. In the case of JAK2 more than 20 tyrosines are known to undergo phosphorylation
(Argetsinger et al. 2010). Tyrosine phosphorylation is essential for the activation of
JAK2, but certain tyrosine residues serve also as negative regulatory sites, like Tyr570,
which is phosphorylated by a regulatory JH2 domain (Argetsinger et al. 2004, Ungureanu
et al. 2011). JAKs are also regulated through serine phosphorylation. In its inactive state
JAK2 is consitutively phosphorylated at Ser523 and the JH2 domain has also been shown
to promote Ser523 phosphorylation (Ishida-Takahashi et al. 2006, Ungureanu et al.
2011).
In the canonical model of the JAK/STAT pathway, STATs are activated through the
JAK-mediated phosphorylation of a single tyrosine residue around position 700. In
addition to tyrosine phosphorylation, the activity of all of the STATs, with the exception
of STAT2, is modulated through serine phosphorylation on at least one serine residue,
which most often falls within the C-terminal TAD (Decker and Kovarik 2000, Schindler
et al. 2007). In both STAT1 and STAT3, Ser727 phosphorylation is required, together
with tyrosine phosphorylation, for full activation in response to IFNs and IL-6,
respectively (Wen et al. 1995, Varinou et al. 2003). Moreover, Ser727 phosphorylation in
STAT1 is required for proper association with the co-activators CBP and MCM5 (Zhang
et al. 1998, Varinou et al. 2003). Ser727 phosphorylation has also been linked to negative
regulation of STAT1 signaling by promoting the sumoylation of STAT1 (Vanhatupa et
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al. 2008). Furthermore, STAT1 is regulated through an additional serine, Ser708, which
is phosphorylated by I?B kinase ? (IKK?) (TenOever et al. 2007). Most recently, Ser708
phosphorylation was shown to inhibit STAT1 homodimerization, thus promoting
heterodimerization with STAT2 and an association with IRF9 for the formation of the
transcription factor complex IFN-stimulated gene factor 3 (ISGF3), which activates the
expression of the IFN-I responsive genes needed for a proper antiviral response (Ng et al.
2011). In their recent study, Chen et al. (2011) showed that upon viral infections STAT6
is recruited to the endoplasmic reticulum by an adaptor protein called STING (also called
MITA/ERIS). This is followed by Ser407 phosphorylation by TANK-binding kinase 1
(TBK1) and JAK-independent Tyr641 phosphorylation leading to the homodimerization
and nuclear translocation of Tyr/Ser -phosphorylated STAT6 in order to activate the
transcription of a specific set of target genes (Chen et al. 2011). This is an example of
how STATs can be phosphorylated also through alternative pathways, in addition to the
classical receptor/JAK-mediated activation mechanisms. Serine phosphorylation of
STATs can be induced by the cytokines responsible for their tyrosine phosphorylation but
also by an extracellular stimulus that does not lead to simultaneous tyrosine
phosphorylation. These include inflammatory stimuli such as LPS or TNF-? as well as
stress agents like ultraviolet radiation (Decker and Kovarik 2000). Many serine kinases
are responsible for STAT phosphorylation including p38-mitogen-activated protein
kinase (MAPK) in the case of STATs 1, 3 and 4; extracellular-signal-regulated kinase 2
(ERK2), c-Jun N-terminal kinase (JNK) and mammalian target of rapamycin (mTOR)
have been reported to phosphorylate Ser727 in STAT3. STAT1 Ser727 is also
phosphorylated by protein kinase C (PKC) and calcium/calmodulin-dependent protein
kinase (CaMK) II. These kinases have been mainly identified through the use of
inhibitors, dominant-negative alleles and in vitro kinase assays (Decker and Kovarik
2000, Yokogami et al. 2000, Schindler et al. 2007). Serine phosphorylation of STATs
offers a way for crosstalk between different intracellular signaling pathways, and
maintains cellular homeostasis and the proper expression of STAT regulated genes.
In addition to phosphorylation, other post-translational modifications such as
methylation, acetylation, O-glycosylsation and ISGylation have been reported to
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participate in the regulation of STAT-mediated signal transduction, but the mechanisms
and biological impacts of these modifications are not so well defined. As an example,
STAT3 is found to undergo reversible dimethylation on lysine 140, and this methylation
has been suggested to have a negative role on STAT3 transcriptional activity, at least at
some of the STAT3-dependent promoters (Yang et al. 2010, Stark and Darnell 2012).
2.3.4.2 Ubiquitination
Ubiquitin is a highly conserved 76 amino-acid protein that can be covalently linked to
lysine residues in other proteins through an enzymatic cascade that utilizes E1 (Ubiquitin
activating enzyme), E2 (Ubiquitin conjugation enzyme) and E3 (Ubiquitin ligase)
enzymes. Substrate proteins can be modified with a single ubiquitin molecule
(monoubiquitination) or with polyubiquitin chains, through coupling of further ubiquitin
proteins linked through integral lysine residues (polyubiquitination). All of the seven
lysines (K6, K11, K27, K29, K33, K48, and K63) in Ubiquitin can be further conjugated
by other Ubiquitins to form polyubiquitin chains (Chen and Sun 2009). In addition to
non-linear polyubiquitin chains linked through the internal lysine residues, Ubiquitins
may also polymerize in a linear manner, in which the carboxy terminus of one Ubiquitin
is linked to the amino-terminal methionine of the adjacent Ubiquitin (Jiang and Chen
2011). Target proteins can also be mono- or polyubiquitinated simultaneously through
multiple lysine residues in their amino acid sequence. The best charactericed
consequence of protein polyubiquitination is proteosomal degradation of the substrate
protein by 26S proteasomes, specifically in the case of proteins modified with K48 or
K11 linked polyubiquitin chains (Clague and Urbé 2010). Polyubiquitin chains linked
through the other internal lysines in Ubiquitin, linear polyubiquitin chains as well as
monoubiquitination have also been reported to have nonproteolytic functions (Chen and
Sun 2009). For example, K63-linked polyubiquitination has been suggested to play role
in DNA repair and protein kinase activation, largely through proteasome-independent
mechanisms (Liu and Chen 2010, Jiang and Chen 2011).
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Ubiquitination also has a role in the regulation of the JAK/STAT pathway. As discussed
in Chapter 2.3.2, SOCS proteins are able to mediate JAK degradation by the Ubiquitin-
proteosome pathway (Ungureanu et al. 2002, Croker et al. 2008). In addition to this
STAT proteins have also been reported to undergo ubiquitination through interactions
with nuclear E3 Ubiquitin ligase STAT-interacting LIM protein (SLIM). SLIM was
found to inhibit especially STAT1- and STAT4-mediated gene expression and to promote
STAT1 and STAT4 ubiquitination and proteosomal degradation. Furthermore, SLIM
enhanced STAT4 dephosphorylation independently of the proteosome pathway, thus
providing an additional mechanism for STAT inhibition (Tanaka et al. 2005, Ungureanu
and Silvennoinen 2005).  Of the post-translational modifications related to ubiquitination,
also sumoylation plays a role in the regulation of the activity of the JAK/STAT pathway,
and will be discussed in the next chapter.
2.4 Sumoylation
Small ubiquitin-like modifier (SUMO) is a ubiquitin-related protein moiety, which can be
covalently conjugated to a specific lysine residue in a target protein via an enzymatic
cascade that resembles the ubiquitination pathway. Yeasts and invertebrates contain only
one Sumo gene (known as Smt3 in Saccharomyces cerevisae and in Drosophila
melanogaster), whereas mammals have four: Sumo-1 – Sumo-4. SUMO-1 is ~11 kDa
protein that shares 18% sequence identity with Ubiquitin. SUMO-2 and -3 have very
similar structures, differing only by three N-terminal amino acids. Due to this similarity
SUMO-2 and -3 are often referred as SUMO-2/3. SUMO-1 shares approximately 50%
sequence identity with SUMO-2/3 (Johnson 2004, Wilkinson and Henley 2010). Similar
to Ubiquitin, SUMO-2/3 has the ability to form chain structures through internal lysine
residues (K11), whereas SUMO-1 has been reported to form chains only in vitro (Tatham
et al. 2001, M. Yang et al. 2006). In contrast to the Sumo-1 – Sumo-3 genes, the Sumo-4
gene lacks introns and has been proposed to be a pseudogene (Wilkinson and Henley
2010). Expression of Sumo-4 mRNA has been detected in certain tissues, but the
SUMO-4 protein has not been found anywhere (Bohren et al. 2004, Guo et al. 2004).
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Furthermore, the amino acid sequence of the SUMO-4 precursor suggests that the protein
is unable to mature and covalently conjugate to targets (Proline 90, which is absent from
other SUMOs, inhibits maturation) (Owerbach et al. 2005).
SUMO is conjugated to target proteins via an enzymatic cascade in a process called
sumoylation (illustrated in Figure 4). SUMO proteins are produced as precursors with a
C-terminal extension of 2-11 amino acids. SUMO becomes mature through C-terminal
cleavage by SENP (Sentrin/SUMO-specific protease) proteases. This proteolytical
processing exposes a di-glycine motif in the C-terminus of SUMO, which serves as the
site for the covalent linkage between SUMO and the target protein. SUMO is then
activated in an ATP-dependent manner by an activating enzyme complex, a heterodimer
(E1) that contains SAE1 and SAE2 (SUMO-activating enzyme 1 and 2), also known as
Aos1 and Uba2, repectively. In this step SUMO forms a thioester bond between the
active site cysteine residue of SAE2 and the C-terminal glycine residue of SUMO. In the
second step SUMO is passed on to the active site of the conjugating (E2) enzyme Ubc9
(Ubiquitin-conjugatin 9), again via a thioester bond. Finally SUMO is covalently
conjugated to a specific lysine residue in the substrate protein by Ubc9 via C-terminal
glycine residue of SUMO. Most often the lysine residue in the target protein is located
within the sumoylation consensus motif ?KxD/E (where ? stands  for  a  large
hydrophobic amino acid, x can be any amino acid). It has been proposed that the
conjugating enzyme Ubc9 itself first binds to a consensus motif and that this interaction
is required for SUMO transfer to the lysine residue (Sternsdorf et al. 1999, Sampson et al.
2001, Kim and Baek 2009, Wilkinson and Henley 2010). The presence of this consensus
sequence is not absolutely essential for sumoylation, and not all proteins containing this
motif are sumoylated. According to the literature in approximately 75% of the reported
sumoylation sites the lysine is surrounded by this consensus motif (Xu et al. 2008).
The transfer of SUMO to the substrate is promoted by growing number of E3 ligases.
These ligases are not known to form a covalent linkage with SUMO, but they are able to
interact with the SUMO-Ubc9 complex and to bring it into contact with the substrate or
additionally, to hold the SUMO-Ubc9 thioester bond in a position favorable for the
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transfer of SUMO to the substrate. The first SUMO E3 ligases identified were the yeast
Siz1 and Siz2 proteins that contain a RING domain homologous to the one in Ubiquitin
E3 ligases. Deletion of these genes almost completely abolished sumoylation in yeast
Saccharomyces cerevisiae in vivo (Johnson and Gupta 2001, Takahashi et al. 2001).
Human PIAS proteins are homologues to Siz proteins and have also been shown to
function as SUMO E3 ligases (Wilkinson and Henley 2010). In addition to the PIAS
protein family, other RING domain containing proteins have been described to function
as SUMO E3 ligases as well. One of these is TOPORS (Topoisomerase I-binding,
arginine/serine-rich), a protein that is capable of transferring both SUMO and Ubiquitin
to the substrate molecules (Weger et al. 2005).
Another type of mammalian SUMO E3 ligase is Ran-binding protein 2 (RanBP2), a large
protein located in nuclear pore complexes. RanBP2 binds both Ubc9 and SUMO-1 and
promotes sumoylation of Sp100, Histone deacetylase 4 (HDAC4) and Promyelocytic
leukemia protein (PML). Interestingly, RanBP2 lacks the RING domain and does not
bind directly to its substrate, meaning that it has an alternative E3 ligase function
mechanism (Kirsh et al. 2002, Pichler et al. 2002, Tatham et al. 2004). Another example
of  an  E3  ligase  that  does  not  contain  a  RING  domain  is  the  Polycomp2  (Pc2)  protein,
suggested to function as a scaffold by binding directly to its substrate protein CtBP (C-
terminal-binding protein) and the SUMO-Ubc9 complex (Kagey et al. 2003).
Sumoylation is a reversible post-translational protein modification, and SUMO may be
cleaved from the target protein by the same SENP proteases that in the maturation
process cleave the C-terminus of SUMO precursors. The SUMO-specific proteases Ulp1
and Ulp2 were first identified in budding yeast (Li and Hochstrasser 1999, Li and
Hochstrasser 2000). Six SENP variants have been described in mammals: SENP1–3 and
SENP5–7. The numbering lacks SENP4, because originally it was identified as a gene
with sequence similarities with Ulp1, but then SENP3 and 4 turned out to be the same
protein (Kim and Baek 2009). The different SENPs vary in their subcellular localization,
SUMO paralogue specificity and selectivity for their SUMO maturation versus
deconjugation activities. SENPs can be divided into three groups. The first group is
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shared with SENP1 and SENP2, known to function in precursor processing and
deconjugation of both SUMO-1 as well SUMO-2/3 from numerous substrates. SENP1
localizes to the nucleous, and SENP2 is found in nuclear envelope associated
compartments and nuclear pores (Gong et al. 2000, Nishida et al. 2001, Hang and Dasso
2002, Zhang et al. 2002, Wilkinson and Henley 2010). SENP3 and SENP5 have
nucleolar localization and prefer to deconjugate monomeric SUMO-2/3 from substrates
(Nishida et al. 2000, Di Bacco et al. 2006, Gong and Yeh 2006). The third group consists
of SENP 6 and 7, which are found in the nucleoplasm. They are responsible for editing
and deconjugating SUMO-2/3 polychains (Mukhopadhyay et al. 2006, Mukhopadhyay
and Dasso 2007, Shen et al. 2009, Wilkinson and Henley 2010).
Recently, a completely novel SUMO cleaving enzyme called DeSumoylating
Isopeptidase-1 (DeSI-1) was found. DeSI-1 was shown to desumoylate, but not to
deubiquitinate, the transcriptional repressor BZEL (the BTB-ZF protein expressed in
effector lymphocytes). Furthermore, DeSI-1 was able to desumoylate both SUMO-1 and
SUMO-2/3 modified BZEL as well as to break SUMO-2/3 polychains, but did not
participate in SUMO precursor processing. The substrate specificity and cellular
localization of DeSI-1 differs from those of SENPs. DeSI-1 is also expressed in the
cytoplasm instead of only in the nucleus or nuclear structures like are the SENPs (Shin et
al. 2012).
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Figure 4.  SUMO conjugation pathway. Pre-SUMO is maturated through C-terminal
cleavage by SENPs (1.), followed by the formation of a thioester bond with a cysteine in
the activating enzyme complex E1 (2.). The activated SUMO is then transferred to the
conjugating E2 enzyme, Ubc9 (3.). Ligation to a spesific lysine of the substrate protein is
promoted by an associated E3 ligase (4. and 5.). Sumoylation is a reversible post-
translational modification and SUMO may be cleaved from the substrate by SENPs (6.).
2.4.1 Physiological consequences of protein sumoylation
To date, hundreds of proteins from diverse functional categories have been reported to
undergo sumoylation. These proteins include chromatin modifying factors, DNA repair
and genome stability proteins, stress-related proteins, proteins involved in translation and
RNA processing, metabolic enzymes and transcription factors (Kim and Baek 2009, van
der Veen and Ploegh 2012). Sumoylation leads to various molecular consequences on the
target proteins. SUMO binding may block the substrate binding site of an enzyme, or
disrupt protein-protein or protein-DNA interactions. Conversely, sumoylation may also
recruit new protein interaction partners by creating a new binding face on the target
protein. SUMO conjugation may also change substrate protein conformation leading to
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altered target protein activity, or reveal binding sites that have been masked in the
unconjucated substrate (Gill 2005, Wilkinson and Henley 2010). Sumoylation has also
been reported to antagonize ubiquitination, an example of which is the Nf-?B regulator
???? (inhibitory ???) (Desterro et al. 1998). Furthermore, sumoylation has been
suggested to regulate protein ubiquitination by modifying enzymes that are are part of the
ubiquitination machinery (Wilkinson and Henley 2010).
One important target protein group of SUMO is transcription factors, and in most cases
sumoylation has a repressive role in regulating their activity. This has been mainly
studied by overexpressing proteins with mutated sumoylation sites in cultured cells. The
mechanisms for how SUMO inhibits transcription are in most cases unknown. It has been
suggested that SUMO conjugation may cause changes in protein interactions or DNA
binding. SUMO attachment may block or compete with other modifications in the
transcription factor. One mechanism for how sumoylation is postulated to inhibit
transcription factor activity is through the recruitment of repressor complexes or histone
deacetylases (HDACs), to the promoter site (Gill 2005). This has been reported to occur
with the transcription factor E twenty six-like-1 (Elk-1). When sumoylated, Elk-1
associates with HDAC2, leading to decreased histone acetylation and downregulation of
the transcription of the Elk-1 target genes (Yang and Sharrocks 2004). Another SUMO
associated co-repressor is a protein called Daxx, which interacts with the sumoylated
transcription factor Smad4, leading to repressed Smad4 transcriptional activity (Chang et
al. 2005). Transcription factor sumoylation may also play a role in DNA methylation, like
in case of the murine transcription factor Sp3. Stielow et al. (2010) found that lack of Sp3
sumoylation in mice expressing sumoylation deficient Sp3 E553D caused aberrant
expression of certain spermatocyte-specific genes (Dmc1 and Dnahc8) and certain
neuronal genes (Paqr6, Rims3 and Robo3) in somatic tissues and in non neuronal tissues,
respectively. Furthermore, there was a loss of H3K9 and H4K20 tri-methylation,
impaired recruitment of repressive chromatin modifying enzymes and a loss of DNA
methylation on the promoters of these Sp3 target genes in mouse embryonic fibroblasts
(MEFs) expressing Sp3 E553D mutant, indicating that sumoylation of Sp3 is essential for
maintenance of tissue-spesific gene silencing.
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2.4.2 Sumoylation of STATs
STAT1 was found to be sumoylated at Lys703 by two independent research groups in
2003 (Rogers et al. 2003, Ungureanu et al. 2003). Both studies suggested that
overexpression of PIAS proteins increased the amount of modified STAT1, indicating
that PIAS proteins may function as E3 ligases in the STAT1 sumoylation process.
STAT1 has a SUMO consensus sequence in its transactivation domain from isoleucine
702 to glutamate 705 (702IKTE705). Mutating lysine 703 to arginine totally abolished the
sumoylation  of  STAT1,  indicating  that  Lys703  is  the  only  SUMO  site  in  STAT1.  In
addition to Lys703, also isoleucine 702 and glutamate 705 are indispensable for STAT1
sumoylation. Sumoylation deficient STAT1 showed increased transcriptional activity on
certain STAT1 responsive promoters. These included the Gbp-1 and Tap-1 (Transporter
associated with antigen presentation-1) genes, which have low affinity STAT1
responsive promoters, whereas Irf-1 gene expression, from a high affinity promoter, was
not affected by the STAT1 K703R mutation. Interestingly, this expression profile of the
Gbp-1 and Irf-1 genes corresponded with findings from Pias1-/- mice, further suggesting
that PIAS1 might have role in STAT1 regulation through sumoylation (Liu et al. 2004,
Ungureanu et al. 2005). Sumoylation deficient STAT1 K703R also showed prolonged
nuclear localization and DNA binding upon an IFN-? stimulus (Ungureanu et al. 2005,
Song et al. 2006). IFN-? mediated activation of STAT1 enhanced the sumoylation of
STAT1 (Ungureanu et al. 2003). Furthermore, serine 727 phosphorylation of STAT1,
mediated by MAP-kinases was found to promote sumoylation, indicating that also other
signaling cascades may participate in the SUMO-mediated regulation of STAT1
(Vanhatupa et al. 2008).
The sumoylation target Lys703 is in a close proximity of the STAT1 activating Tyr701
phosphorylation site. The first studies of STAT1 sumoylation suggested that the
phosphorylation status of Tyr701 would not be significantly altered in response to
sumoylation. These studies were based on a comparison of the wild type STAT1
phosphorylation status to the phosphorylation rate of a sumoylation deficient STAT1
mutant (Ungureanu et al. 2005, Song et al. 2006). Later it was shown that sumoylated
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STAT1 is much less Tyr701 phosphorylated compared to the unmodified STAT1 both in
vivo and in vitro, using the Ubc9 fusion-directed SUMOylation system (UFDS). In this
system a STAT1-Ubc9 fusion protein is sumoylated up to 40% on Lys703 with
endogenous SUMO, yielding considerably more STAT1 sumoylation than by only
overexpressing SUMO in cells (Jakobs et al. 2007). Furthermore, Tyr701
phosphorylation of STAT1 was found to hinder the sumoylation of Lys703, suggesting
that sumoylation and phosphorylation at Tyr701 would be mutually exclusive
modifications (Zimnik et al. 2009). More recently, tyrosine phosphorylated STAT3
transcription factors were suggested to form paracrystal structures within the nucleus and
to serve as a reservoir for activated STAT3s. STAT1 was able to form similar structures
only when sumoylation was inhibited by mutating the SUMO conjugation site (Droescher
et al. 2011a). In the same study, it was proposed that sumoylation, by inhibiting Tyr701
phosphorylation, drove STAT1s into semiphosphorylated dimer structures, interacting
through their N-terminal domains instead of a phospho-tyrosine-SH2 domain-mediated
interaction, which is typical for an activated STAT1 dimer (Droescher et al. 2011a).
Additional studies using cells from knock in mice expressing SUMO-free STAT1 further
strengthened this hypothesis. Furthermore, SUMO-induced STAT1 paracrystal
dissolution was suggested to lead to accelerated dephosphorylation of STAT1. STAT1
sumoylation was postulated to protect cells from hyperresponsiveness to IFN-? (Begitt et
al. 2011, Droescher et al. 2011b). Although SUMO modulation of STAT1 has been
widely studied, results are controversial and many aspects of this regulatory mechanism
of STAT1-mediated IFN signal transduction remain elusive.
More recently murine STAT5 too was reported to be a target for SUMO-2 conjugation.
STAT5 sumoylation reduced both tyrosine phosphorylation and lysine acetylation and led
to STAT5 inactivation. In Senp1-/- mice T and B cell development was impaired, and
sumoylated STAT5 was found to accumulate in these cell lineages, but not in myeloid
cells. These results indicate that SENP1 is a crucial regulator of B and T cell
development acting as a SUMO protease that cleaves SUMO-2 from conjugated STAT5.
After SUMO is removed, STAT5 can re-enter the activation-inactivation cycle. (Van
Nguyen et al. 2012).
40
2.5 Drosophila as a model organism in biomedical research
Drosophila melanogaster, or the fruit  fly,  has been used as a model organism since the
beginning of the 20th century. This small insect has several benefits: its life-cycle is
relatively short, and it is easy and cheap to rear, Drosophila melanogaster is also seen as
ethically more acceptable for scientific studies, than are more developed organisms such
as mice, which are also widely used as model organisms in biomedical research. The
complete Drosophila genome has been sequenced and it is known to contain ~15,000
genes divided into four pairs of chromosomes (Adams et al. 2000, St Johnston 2002). An
analysis of the Drosophila genome sequence revealed that Drosophila genes are very
similar to mammalian genes. Furthermore,  it  is  estimated  that  up  to  77% of  the  known
human disease genes have a Drosophila homolog, this makes Drosophila an exellent
model for genetic research (Rubin and Lewis 2000, Reiter et al. 2001, St Johnston 2002).
Drosophila melanogaster has been widely used for RNAi-based genome-wide screens.
Transfection of Drosophila S2 cells with syntethic dsRNA corresponding to a sequence
of a desired target gene induces very efficient nuclease mediated degradation of the
mRNA products of the target gene, thereby resulting in gene silencing (Hammond et al.
2000). To date, several genome-wide dsRNA mediated RNAi screens have been
performed in Drosophila cells to identify components participating in cellular processes,
such as signaling pathways and phagocytosis (Rämet et al. 2002a, Baeg et al. 2005,
Müller et al. 2005, Valanne et al. 2010).  In addition to cell culture based methods, RNAi
can be used effectively also in vivo in flies through the tissue-spesific expression of RNAi
constructs with the UAS-GAL4 expression system (Brand and Perrimon 1993). The
availability of  a genome-wide collection of RNAi fly lines has further speeded-up and
simplified genetic research in Drosophila (Dietzl et al. 2007).
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2.6 Overview of the Drosophila immune system
The immune system of Drosophila differs from the human immune system in that it lacks
an adaptive immunity. Still, Drosophila has very powerful innate defence mechanisms to
combat infections. The Drosophila innate immune response can be divided into the
cellular response orchestrated by spesific hemocytes, and the humoral response, which is
mediated by secreted effector molecules. In addition to these, also the cuticles of the fly
and its epithelial cells have their own defence mechanism towards infective agents. The
first line of defence in Drosophila, like in every organism, is the physical barrier formed
by epithelia on the surface of body parts that come into contact with the environment,
such as the alinmentary tract and trachea (Lemaitre and Hoffmann 2007). In addition to
being a physical barrier, epithelial cells are able to produce antimicrobial peptides
(AMPs) and reactive oxygen species (ROS), when they come into contact with microbes.
This so-called local immune response is essential for flies living in and feeding in
decomposing materia full of bacteria and other microbes. AMP gene expression has been
detected in cells of the epidermis, respiratory tract, reproductive tract and alinmentary
tract (Tzou et al. 2000, Ferrandon et al. 1998). Some AMPs are constitutively expressed,
while others are expressed only upon bacterial infection. This inducible local AMP
expression has been found to be triggered only by a Gram-negative bacterial infection
through the Immune deficiency (Imd) pathway (discussed in the Chapter 2.6.2) (Tzou et
al. 2000). ROS production is independent of the Imd pathway and is induced rapidly in
Drosophila, providing an additonal local response to the bacterial challenge (Lemaitre
and Hoffmann 2007).  The AMPs are discussed in more detail in the Chapter 2.6.2.
2.6.1 Cellular response
Drosophila lacks a closed circulatory system. Instead, hemolymph floats freely inside its
body cavity. In addition to the local immune response Drosophila has  a  repertoire  of
hemocytes in its hemolymph to combat microbes and participate in wound healing.
Drosophila hemocytes are divided into three subgroups according to their structural and
functional characteristics: plasmatocytes, crystal cells and lamellocytes. These cells
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resemble mammalian myeloid lineages. Due to the lack of an adaptive immune system,
Drosophila has no equivalent of a lymphoid lineage (Meister and Lagueux 2003,
Lemaitre and Hoffmann 2007).  The most common hemocytes are plasmatocytes, which
are responsible for the phagocytic removal of microbial pathogens and dead cell depris.
In an uninfected animal up to 95% of the hemocytes in its hemolymph are plasmatocytes
(Williams 2007). Approximately 5% of circulating cells represent crystal cells, which are
responsible for the melanization of invading pathogens and for wound healing (Meister
and Lagueux 2003, Williams 2007). The third cell type, lamellocytes, are not present in
the hemolymph under normal conditions. Lamellocytes are large and flat cells, which
participate in the encapsulation of pathogens, such as parasitoid wasp eggs, that are too
large for phagocytosis. And like crystal cells, lamellocytes are also involved in
melanization (Agaisse and Perrimon 2004, Williams 2007).
Phagocytosis and encapsulation are the most essential mechanisms of the cellular
immune response of Drosophila. Phagocytosis is an evolutionary conserved defence
mechanism against intruders such as bacteria and yeast. The initiation of phagocytosis
requires receptor mediated recognition of the particle, which is to be ingested into the
phagocytic cell into vesicles called phagosomes, which then fuse together with lysosomes
to create phagolysosomes. Finally, the phagocytosed particles are enzymatically degraded
at the optimal pH in the phagolysosome (Stuart and Ezekowitz 2005, Ulvila et al. 2011).
Still, the exact mechanism for how these foreign objects are destroyed remains elusive.
Several groups of the phagocytic receptors have been identified on the surface of
plasmatocytes. Among these Croquemort, a member of the CD36 superfamily has been
shown to participate in the phagocytosis of apoptotic cells (Franc et al. 1996). Originally,
it was believed that Croquemort does not participate in bacterial uptake, but later it was
reported that it binds and mediates the internalization of Staphylococcus aureus bacteria
into plasmatocytes (Franc et al. 1999, Stuart et al. 2005).  Another member of this family
is a protein called Peste, which is important for the phagocytic uptake of mycobacteria
(Philips et al. 2005). Other known receptors involved in bacterial recognition include a
member of the scavenger receptor family (dSR-CI), and the EGF-like repeat containing
proteins Nimrod C1 and Eater (Pearson et al. 1995, Rämet et al. 2001, Kocks et al. 2005,
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Kurucz et al. 2007). Eater is expressed primarily on plasmatocytes and on their
precursors, whicn are known as prohemocytes, and which have a crucial role in
mediating the phagocytosis of both Gram-negative and Gram-positive bacteria (Kocks et
al. 2005). Also other receptors involved in phagocytosis are known, including Down
syndrome cell adhesion molecule (Dscam) and peptidoglycan recognition protein LC
(PGRP-LC), which is involved in the phagocytosis of Gram-negative but not Gram-
positive bacteria (Rämet et al. 2002a, Watson et al. 2005). The most recent addition to the
growing list of Drosophila phagocytic receptors is Integrin ?v. Flies that lack Integrin ?v
showed reduced phagocytosis of Staphylococcus aureus and had an increased sensitivity
to fatal septic Staphylococcus aureus infections when compared to wild type flies.
Integrin ?v was found to cooperate with a receptor called Draper in bacterial recognition
(Shiratsuchi et al. 2012). In addition to transmembrane receptors, also opsonization has
been shown to play a role in the phagocytosis in Drosophila. Here, thioester-containing
proteins (TEPs), six variants of which are encoded by the Drosophila genome (TEPs 1-
6),  are  thought  to  have  at  least  a  modest  role  in  the  phagocytosis  of Escherichia coli,
Staphylococcus aureus and Candida albicans (Stroschein-Stevenson et al. 2005).
In addition to phagocytosis, Drosophila larvae can combat an invading organism by
encapsulation (Williams 2007). This reaction takes place when the object is too big for
plasmatocyte-mediated phagocytosis. This reaction has been found to occur when for
example parasitoid wasps lay their eggs into Drosophila larvae. Initially wasp eggs are
recognized and surrounded by plasmatocytes. This activates the differentiation of
numerous lamellocytes in the lymph glands. Once they are released from the lymp
glands, lamellocytes are attracted to the site of the parasite by plasmatocytes in order to
form a multilayered capsule around the wasp egg, following blackening of the capsule
due to melanization by lamellocytes and activated crystal cells. Eventually the parasite is
killed by released ROS and intermediates of the melanization cascade. Encapsulation
requires that all hemocytes types function synergistically. The JAK/STAT signaling
cascade and the Toll pathway are thought to be activated during the encapsulation
process (Wertheim et al. 2005, Lemaitre and Hoffmann 2007, Williams 2007).
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Melanization occurs rapidly at the cuticle wound sites, and after the encapsulation of
intruders. Crystal cells serve as storage cells for large amounts of prophenoloxidase (pro-
PO) in their cytoplasmic granules (or crystals, where the name of the cell type comes
from). In melanization activated crystal cells release their content into the hemolymph.
After release, the pro-PO is converted to the active phenoloxidase (PO) by a cascade of
serine proteases. Active PO then catalyzes melanin polymerization, which is important in
wound healing (Rämet et al. 2002b, Meister and Lagueux 2003, Bidla et al. 2007). At the
injury sites melanization is mediated solely by crystal cells, but in encapsulation also by
lamellocytes, which are known to express one pro-PO called DoxA3 (Irving et al. 2005).
In wound healing, as far as it is known, melanization is triggered through a JNK
pathway-mediated signal (Rämet et al. 2002b).
2.6.2 Humoral response
The humoral response against invading pathogens is mainly mediated by AMPs secreted
from the fat body, an organ with characteristics comparable to the mammalian liver
(Lemaitre and Hoffmann 2007). The fat body is a large organ, which is surrounded by
hemolymph and is able to detect floating microbes in the hemolymph (Lemaitre and
Hoffmann 2007). Shia et. al (2009) found that ablation of hemocytes from Drosophila
larvae caused a significant decrease in AMP expression in the fat body upon both septic
injury and oral infection. Furthermore, they suggested that signaling between hemocytes
and the  fat  body would  be  mediated  by  the  Toll  pathway ligand Spätzle.  Still,  it  is  not
completely understood how considerable role the hemocytes play in the initiation of the
humoral response. AMPs are not expressed under normal conditions, but during infection
AMPs are rapidly expressed and secreted into the hemolymph. This process is mediated
by two distinct signaling pathways, the Toll and the Imd pathway, which will be
discussed in more detail further on. The family of AMPs is composed of four variants of
Attacins, four Cecropins, two Diptericins, seven Drosomycins and single variants of
Drosocin, Defencin and Metchnikowin, with partly overlapping microbe specifities
(Lemaitre and Hoffmann 2007). The exact molecular mechanism for how AMPs
inactivate or kill their target microbes is still elusive.
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The Drosophila Toll pathway is activated in response to Gram-positive bacteria and
fungi. It also has an important role in the development of the Drosophila embryo, but this
chapter concentrates on the Toll pathway’s role in the immune response (Lemaitre and
Hoffmann 2007). Drosophila Toll is a transmembrane cytokine receptor that is not able
to directry bind to the pathogens. Instead, bacterial recognition is mediated by circulating
pattern recognition factors, including peptidoglycan recognition protein SA (PGRP-SA)
(Michel et al. 2001). The recognition of the pathogen leads to proteolytic activation of the
soluble Toll ligand Spätzle, which then binds to Toll and induces the activation of a
intracellular signaling cascade that resembles mammalian Nf-?B signaling. Toll activates
an oligomeric complex that contains MyD88, Tube and a kinase called Pelle,
consequently leading to the phosphorylation and proteolytic degradation of the NF-?B
inhibitory protein Cactus. Normally Cactus is bound to the transcription factors Dif and
Dorsal and in this manner inhibits their function. The degradation of Cactus releases Dif
and Dorsal allowing them to translocate into the nucleus, where they bind DNA and
activate the expression of their target genes, such as the AMPs Drosomycin and Defencin
(Meng et al. 1999, Valanne et al. 2011).
Another important signaling cascade in AMP production is the Imd pathway, responsible
for the immune response against Gram-negative bacteria (Lemaitre et al. 1995).
Peptidoglycan (PGN), produced by Gram-negative bacteria, is recognized by two
peptidoglycan recocnition proteins (PGRPs),  PGRP-LC and PGRP-LE. PGRP-LC
functions as a transmembrane receptor in the Imd pathway (Choe et al. 2002, Gottar et al.
2002, Rämet et al. 2002a, Rämet et al. 2002b, Choe et al. 2005), whereas PGRP-LE has
both, intra- and extracellular functions (Kaneko et al. 2006). Full-length PGRP-LE is
known to act as an intracellular receptor for the diaminopimelic acid-containing (DAP-
type) PGN of intracellular bacteria such as Listeria monocytogenes, whereas the shorter
form of PGRP-LE, which contains only the PGRP domain, is secreted into the
extracellular matrix and enhances PGRP-LC-mediated peptidoglycan recognition on the
cell suface (Kaneko et al. 2006). The binding of the peptidoglycan of Gram-negative
bacteria to PGRP-LC activates the intracellular Imd-protein through an interaction
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between the death domain of Imd and the intracellular domain of PGRP-LC. This leads to
the activation of a complex protein cascade that finally activates the transcription factor
Relish through C-terminal cleavage. Active Relish translocates to the nucleus and induces
the transcription of AMPs such as Diptericin (Kaneko and Silverman 2005, Lemaitre and
Hoffmann 2007). For a long time it was believed that the Drosophila JAK/STAT
pathway does not participate in AMP production, but in their recent study Goto et al.
(2010) found that the expression of a novel AMP-like protein called Listericin, which is
active against Listeria monocytogenes, is cooperatively regulated by PGRP-LE and the
JAK/STAT pathway.  This, and the role of the JAK/STAT pathway in the regulation of
other essential functions of the Drosophila immune system, are discussed in the Chapter
2.7.1.
2.7 The Drosophila JAK/STAT pathway
The JAK/STAT pathway has been conserved in evolution, and all the main components
of the pathway, discussed in Chapter 2.2, are present in Drosophila melanogaster. An
overview of the Drosophila JAK/STAT pathway is shown in Figure 5. In Drosophila the
JAK/STAT pathway is activated through a single transmembrane receptor, called
Domeless (Dome or Mom) and the intracellular signal is transduced via a single Janus-
kinase, Hopscotch (Hop) and a single STAT transcription factor Stat92E (also known as
Marelle) (Hanratty and Dearolf 1993, Binari and Perrimon 1994, Brown et al. 2001, Chen
et al. 2002, Hou et al. 1996, Yan et al. 1996a). The extracellular part of Dome contains
five fibronectin type domains, two of which resemble the cytokine binding module
(CBM) found in class I mammalian cytokine receptors. Due to sequence similarities
Dome has been suggested to be ancestor of  the IL-6 family of cytokine receptors, sharing
18% identity with LIFR and 26% identity with CNTFR (Brown et al. 2001, Chen et al.
2002). Dome is activated when the ligand Unpaired (Upd) binds to its extracellular
domain (Chen et al. 2002). The Drosophila genome encodes three Upd genes; Upd, Upd2
and Upd3 (Harrison et al. 1998, Agaisse et al. 2003, Hombría et al. 2005). The first
identified Upd was reported to be a secreted glycoprotein that associates with the
extracellular matrix, thereby functioning locally to activate the JAK/STAT pathway
47
(Harrison et al. 1998).  The exact molecular mechanism for how ligand binding activates
Dome  is  still  more  or  less  unclear.  In  the  canonical  model  of  the  JAK/STAT  pathway
ligand binding induces rapid receptor dimerization followed by the activation of
downstream targets. It has been suggested that, in addition to monomeric reseptor
subunits, Drosophila Dome also forms homodimer structures in the resting state,
independently of ligand binding. Furthermore, the same study presented evidence that
Upd was only capable of activating the JAK/STAT pathway in cells where Dome was in
a pre-dimerized state. In this model, ligand binding is predicted to cause conformational
changes in the receptor homodimer, allowing interaction between associated Hop-
molecules (Brown et al. 2003).
The Hopscotch gene encodes a 1117 amino acid protein, which shares 27% identity with
human JAK2 (Binari and Perrimon 1994). The single Drosophila Stat92E locus encodes
two highly similar splicing variants. The larger protein product is 761 amino acids long,
while the smaller one is seven amino acids shorter. Stat92E shares 37% sequence identity
with human STAT5 and approximately 35% identity with human STAT6, its domain
structure is similar to that of mammalian STATs. The region with the highest identity
was mapped to the SH2 domain, which is also the most conserved domain in mammalian
STATs. Stat92E is phosphorylated on the conserved tyrosine 711 (Tyr704 in the short
splicing variant) in response to Hop-mediated activation (Hou et al. 1996, Yan et al.
1996a). The phosphorylated Stat92E is then believed to form a homodimer, which is
followed by nuclear translocation. Phosphorylated Stat92E binds to a spesific consensus
sequence TTCnnnGAA on the promoters of its target genes. Stat92E is able to bind and
activate transcription through both 3n and 4n spaced binding sites, but according to
EMSA experiments by Rivas et al. (2008), it seems to prefer 3n consensus sequences.
Several target genes for Stat92E have been described, and they participate in various
biological processes. These include the pair-rule gene even skipped (eve),  a gene that is
responsible for proper embryonic segmentation, Socs36E, a negative regulator of
Stat92E signaling, complement-like protein Tep-1 and the Turandot (Tot) stress genes
(Yan et al. 1996a, Hou et al. 1996, Karsten et al. 2002, Agaisse et al. 2003, Lagueux et al.
2000).
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Figure 5. Schematic presentation of the Drosophila JAK/STAT pathway. Binding of
Upd to its receptor Dome induces Hop-mediated Stat92E tyrosine phosphorylation and
homodimerization. Stat92E homodimers translocate to the nucleus and bind to responsive
DNA elements in the promoters of target genes and initiate gene expression.
2.7.1 Roles of the JAK/STAT pathway in Drosophila development and the immune
response
Drosophila melanogaster has been used extensively as a model organism in
developmental research. These studies have revealed the essential role of the the
JAK/STAT pathway in many developmental processes. When first described, the Hop
and Stat92E genes were found to participate in embryonic segmentation through eve gene
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activation (Binari and Perrimon 1994, Hou et al. 1996, Yan et al. 1996a). The JAK/STAT
pathway was also found to be required for stem cell maintenance in male gonads, as the
inactivating mutations in Hop and Stat92E caused male sterility. (Kiger et al. 2001,
Tulina and Matunis 2001). Furthermore, the JAK/STAT pathway also has an essential
role in oogenesis in female flies (McGregor et al. 2002).  In addition to fly fertility, the
JAK/STAT pathway is indispensable for the organogenesis of, for example, the trachea
and the eye, and it takes part in sculpting wing veins (Yan et al. 1996b, Luo et al. 1999,
Brown et al. 2001).
Like in mammals, the JAK/STAT pathway participates in the regulation of the immune
response in Drosophila. As was discussed in Chapter 2.6, the Drosophila immune
response is divided into the humoral and cellular responses. As part of the humoral
response and in cooperation with PGRP-LE, the JAK/STAT pathway regulates the
expression of an AMP called Listericin upon Listeria monocytogenes infection.
L. monocytocenes is a Gram-positive intracellular pathogen, which exeptionally
expresses a DAP-type PNG on its surface, and is thus recogniced by cytoplasmic PGRP-
LE (Bierne and Cossart 2007, Yano et al. 2008). Listericin was found to suppress the
growth of DAP-type PNG containing bacteria, such as L. monocytogenes, as well as
Gram-negative bacteria, but it had no effect on the growth of lysine-type PGN-containing
Gram-positive bacteria. The promoter of the Listerincin gene contains a putative Stat92E
binding site, but it remains to be verified if Listerincin is a direct Stat92E target gene
(Goto et al. 2010). While the expression of AMPs is mainly regulated through the Toll
and Imd pathways, the JAK/STAT pathway plays a crucial role in regulating the
expression of other humoral factors in Drosophila. Upon septic injury Upd3 triggers
Stat92E activation in the fat body, which leads to expression of the TotA stress gene
(Ekengren et al. 2001, Agaisse et al. 2003). TotA belongs to a family of Turandot stress
genes, which are expressed under various stress conditions such as bacterial infection,
heat shock and ultraviolet radiation (Ekengren and Hultmark 2001, Ekengren et al. 2001).
Also the expression of other Tot family members  (TotC and TotM)  is  controlled by the
JAK/STAT pathway (Agaisse and Perrimon 2004). The exact mechanism for how the
protein products of these genes function is still elusive (Ekengren and Hultmark 2001).
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Another secreted Stat92E target gene product, Tep-1, was mentioned earlier. There is
evidence that TEP proteins may function as opsonins, which recognize microbes and
promote their phagocytosis (Stroschein-Stevenson et al. 2005). A recent study revealed
that TEPs are expressed in potential immune cells and tissues, such as in hemocytes, the
fat body and in some epithelia. Although the immune challenge normally induces TEP
expression in these tissues, Tep-1, Tep-2, Tep-3, Tep-4 deficient flies were not more
susceptible to bacterial infections compared to wild type flies, indicating that TEP
proteins are not essential for Drosophila immunity, but may still have a role in the
defence against a restricted subset of pathogens (Bou Aoun et al. 2011).
Gain-of-mutations in Hop (HopTum-l and T42) result in strong overproliferation of
lamellocytes that eventually contribute to melanotic tumors (Hanratty and Dearolf 1993,
Luo et al. 1995, Luo et al. 1997, Agaisse and Perrimon 2004). Furthermore, it has been
found that larvae carrying a loss-of-function mutation in Hop are unable to conduct
encapsulation upon wasp paratization (Agaisse and Perrimon 2004). Together, these
results indicate that the JAK/STAT pathway regulates lamellocyte differentation, thus
contributing to the cellular immune response. The JAK/STAT pathway also contributes
to the renewal of intestinal stem cells and to their differentation into enterocytes after
damage and stress-induced Upd production in the Drosophila midgut (Jiang et al. 2009).
In addition, the JAK/STAT pathway was shown to be important for the survival of flies
after an intestinal Serratia marcescens bacterial infection (Cronin et al. 2009). Stat92E
has been proposed to participate in the downregulation of Relish target genes in the
Drosophila immune response by forming a repressome complex with the transcription
factor AP-1 and Dsp1 (Dorsal switch protein 1). This complex was shown to replace
Relish at the Attacin-A gene promoter. Furthermore, this repressome complex was also
found to recruit histone deasetylases to the Relish-dependent promoter sites to inhibit
transcription. In this manner Stat92E participates in fine-tunig the strenght of the innate
immune response in Drosophila melanogaster (Kim et al. 2007).
The JAK/STAT pathway is also required for antiviral defence in Drosophila. Dostert et
al. (2005) found, using high-density DNA microarrays, that a Drosophila C virus (DCV)
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infection triggers a unique gene expression profile compared to genes activated in
bacterial and fungal infections. Moreover, some of these DCV-induced genes including
vir-1 (virus-induced RNA 1), CG12780 and CG9080, were found to contain Stat92E
binding sites in their 5’ upstream sequences, and a DCV-infection increased Stat92E
binding to its optimal DNA-binding sequence in EMSA experiments, suggesting that
Stat92E is activated upon viral infection. The expression of vir-1 and CG12780 was
reduced or abolished in DCV-infected Hop loss-of-function flies (HopM38/msvl), but these
genes were not overexpressed in HopTum-l flies, indicating that Hop is required, but not
sufficient, for an antiviral response against DCV in Drosophila (Dostert et al. 2005). The
upregulation of the same genes in response to an infection with three different DCV
strains was observed by Hedges and Johnson (2008) as well. Interrestingly, this
upregulation was not detected when flies were infected with inactivated DCV and only a
modest increase in CG12780 and CG9080 expression was observed when flies were
injected with purified DCV-dsRNA, indicating that viral dsRNA by itself is not sufficient
to activate the JAK/STAT pathway (Hedges and Johnson 2008).
2.7.2 Regulation of the Drosophila JAK/STAT pathway
The Drosophila JAK/STAT pathway shares similarities with the corresponding
mammalian cascade but has less redundancy. The regulatory mechanisms that affect the
Drosophila JAK/STAT pathway have been studied, but mostly their molecular details
remain enigmatic. Like in mammals, PIAS has been reported to influence STAT-
mediated signal transduction in Drosophila (Betz et al. 2001). dPias (also called Zimp) is
the only PIAS protein in Drosophila melanogaster, and is encoded by the Su(var)2-10
(Suppressor of variegation 2-10) locus (Hari et al. 2001). Drosophila Pias was shown to
interact with tyrosine phosphorylated Stat92E. Furthermore, genetic studies revealed that
depletion of dPias enhanced melanotic tumor formation in flies overexpressing a
constitutively active HopTum-l mutant. As expected, the overexpression of dPias was
found to reduce tumorigenesis caused by JAK/STAT pathway hyperactivation. In
addition, a balanced Stat92E/dPias ratio was shown to be crucial for normal eye
development. As a conclusion, these results indicate that dPias is a negative regulator of
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Stat92E (Betz et al. 2001). In addition to dPias, the Drosophila genome encodes three
SOCS proteins, Socs36E, Socs16D and Socs44A (Callus and Mathey-Prevot 2002,
Karsten et al. 2002, Rawlings et al. 2004). The Socs36E gene was identified first, and its
promoter region was found to contain 19 Stat92E binding sites. Moreover, Socs36E
mRNA expression was upregulated by ectopic activation of the JAK/STAT pathway, and
was significantly reduced in flies lacking either Upd or Hop, indicating that Socs36E is a
JAK/STAT pathway target gene (Karsten et al. 2002). Socs16D has not yet been
connected to the JAK/STAT pathway, whereas both Socs36E and Socs44A have been
reported to function as negative regulators of the Drosophila JAK/STAT pathway. Like
mammalian SOCS (described in detail in Chapter 2.3.2), Socs36E seems to form a
classical negative feedback loop in the regulation of the activity of the JAK/STAT
pathway (Rawlings et al. 2004, Stec and Zeidler 2011). In addition to full length Stat92E
the Drosophila genome encodes an N-terminally truncated Stat92E (?N-Stat92E), which
is able to dimerize with full length Stat92E and to bind DNA. Overexpression of ?N-
Stat92E suppressed Stat92E activity, indicating that ?N-Stat92E acts as a negative
regulator of Stat92E (Henriksen et al. 2002).
As discussed earlier, Drosophila offers an excellent tool for genome-wide RNAi screens.
In order to find novel genes that participate in the JAK/STAT signaling cascade, two
such screens have been conducted using dsRNAs targeting the majority of the Drosophila
transcriptome (Baeg et al. 2005, Müller et al. 2005). Both screens revealed a number of
potential regulators for Drosophila JAK/STAT signaling, but interrestingly the number of
common hits was very small. Müller et al. (2005) concentrated their further studies on
two novel JAK/STAT pathway regulators: a bromo-domain-containing protein disrupted
in leukemia 3 (also known as bromo-domain and WD repeat-containing protein 3,
BRWD3) and tyrosine phosphatase Ptp61F. BRWD3 was found to function as a positive
regulator of the JAK/STAT pathway, but the mechanism for this remain unclear. Ptp61F
was also found in the screen by Baeg et al. (2005). As expected, RNAi mediated
knockdown of Ptp61F resulted in an increase in JAK/STAT pathway driven reporter
gene expression in both screens, indicating that Ptp61F is a negative regulator of the
pathway. Furthermore, Ptp61F RNAi caused hyperphosphorylation of both Hop and
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Stat92E, thus raising the possibility that Ptp61F may function as a phosphatase, which
dephosphorylates Hop or both of these signaling molecules (Baeg et al. 2005). In the
same study Baeg et al. also found that dsRNA-mediated knockdown of Drosophila
homologs of RanBP3 (CG11763) and RanBP10 (CG10225) caused increase in phospho-
Stat92E nuclear accumulation upon Upd stimulation, indicating that these factors may
control nucleocytoplasmic transport of Stat92E.
54
3. Aims of the study
Drosophila melanogaster and vertebrates share the main components of the conserved
JAK/STAT signaling pathway. The regulatory mechanisms of the JAK/STAT pathway
have been widely studied, but little is known about the molecular details of the behaviour
of the known JAK/STAT pathway regulators, such as SUMO. Moreover, as it has
become evident that the regulation of the intracellular signaling cascades is generally
complex, it is most likely that critical factors involved in JAK/STAT-mediated signal
transduction remain to be discovered. The JAK/STAT pathway plays a crucial role in
many biological processes including blood formation and the regulation of immune
responses. Disturbances in JAK/STAT pathway-mediated signal transduction can lead to
various diseases, as discussed in the Chapter 2.2.1. So, it is essential to understand the
molecular basis of the JAK/STAT pathway regulation in order to develop treatments and
better diagnostic tools for these pathological conditions. Drosophila melanogaster is an
excellent model organism for studying signaling pathways with powerful genomic
approaches such as genome-wide RNAi screening. The aims of this study were to reveal
if sumoylation has an evolutionary conserved role in the regulation of STAT-mediated
signal transduction, and to characterize novel components of the JAK/STAT pathway,
using Drosophila melanogaster as a model organism.
The specific aims of the study were:
1. To study if the Drosophila transcription  factor  Stat92E  is  a  target  for  SUMO
modification and to reveal the functional effect of sumoylation on Stat92E-
mediated gene expression.
2. To analyze how ET/CG14225 participates in the regulation of the Drosophila
JAK/STAT pathway activation.
3. To investigate the role of Not4/CG31716 and its mammalian homolog CNOT4 in
STAT-mediated gene expression.
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4. Materials and methods
4.1. Plasmid constructs and cloning
The Drosophila Stat92E full length cDNA (clone RE13194) was purchased from the
Drosophila Genomics resource Center (Indiana University, Bloomington, IN, USA) and
was cloned between the Not1 and Kpn1 restriction sites in the pcDNA3.1(-) expression
vector after PCR amplification with the following the primers:
5’-CGGGCCGCGGCCGCGCCGCCATGAGCTTGTGGAAGCGC-3’ to the 5’-end
containing Not1 restriction site and 5’-CGCGGTACCCTACTACTTGTCATCGTCGTC
GTTGTAGTCAAAGTTCTCAAAGTTTGTAATC-3’ to the 3’-end containing Kpn1
restriction site and Flag epitope-tag.
In order to clone a Flag-tagged Stat92E into the Drosophila expression vector
pMT-V5-HisA (Invitrogen, Carlsbad, CA, USA), Stat92E (clone RE13194) was
amplified by PCR using primers as follows:
5’-CGGGCCGCGGCCGCGCCGCCATGAGCTTGTGGAAGCGC-3’ to the 5’-end
containing a Not1 restriction site and 5’-CGGGTTTAAACCTACTACTTGTCATCGT
CGTCCTTGTAGTCAAAGTTCTCAAAGTTTGTAATC-3’ with a Pme1 restriction site
and the Flag epitope-tag.
The pMT-Stat92E K187R-Flag mutant was created using the QuikChange® Site-directed
Mutagenesis kit (Stratagene, La Jolla, CA, USA) according to the manufacturer’s
instructions with the following primers: Forward primer: 5’-GGTATGGT
CACACCCAGGGTGGAGCTGTACGAG-3’ and Reverse primer: 5’-CTCGTACA
GCTCCACCCTGGGTGTGACCATACC-3’.
The pcDNA3-SUMO-1-Flag and the pcDNA3-SUMO-1-Flag-Flag expression vectors
were kindly provided by Dr. H Yasuda. pSG5-SUMO-1-His was a kind gift from Dr. A.
56
Dejean. SENP1-Flag, the catalytically inactive SENP-1 C603S-Flag, SUMO-1 GA-His
and SUMO-3-HA were provided kindly by Prof. J. Palvimo (Xu et al. 2006).
The pcDNA3-p53 expression vector and the PG-13-luciferase reporter containing 13
synthetic p53 binding sites were kind gifts from Dr. M. Laiho (Lee et al. 1997, Subler et
al. 1994).
The GAS-luciferase reporter construct contains a GAS sequence TTTCCCCGAAA
from the Irf-1 gene promoter region cloned upstream of the thymidine kinase (TK)
driving the firefly luciferase gene (Pine et al. 1994). The Ig?-luc (pfN?N4-luc) construct
contains four copies of IL-4 responsive elements inserted upstream of the c-fos minimal
promoter in front of the Photinus pyralis luciferase gene (Pesu et al. 2000).
The TotM-luc reporter and the Actin 5C-?-galactosidase reporter plasmids were provided
by Dr. J.-L. Imler. HopTum-l, which was provided by J.-L. Imler as well, contains a
substitution of glycine 341 to glutamic acid creating a constitutively active form of Hop
(Luo et al. 1995). The Smt3-HA plasmid was obtained from Dr. A.J. Courey (Bhaskar et
al. 2000) and the pMT-Upd expression vector was a generous gift from Dr. M. Boutros.
The 10xStat92E-luc construct contains five tandem repeats of the Stat92E binding sites
from the Socs36E enhancer region inserted upstream of a minimal heat shock promoter-
driven firefly luciferase gene (Baeg et al. 2005). This construct was kindly provided by
Dr. E. Bach.
The Drosophila CG31716/Not4 cDNA (clone RE04975) was purchased from Drosophila
Genomics resource Center (Indiana University, Bloomington, IN, USA). The cDNA was
amplified by PCR using the following oligonucleotides as primers: 5’-CACA
CAGCGGCCGCATGAACGGCCTGAGCAGC-3’ containing a Not1 restriction site and
5-‘CACACATCTAGAAACGAATTGACGGCTTTTTAAAAACG-3’ containing an
Xba1 restriction site. The PCR product was inserted into the pMT-V5-HisA expression
vector (Invitrogen, Carlsbad, CA, USA). The pCOHygro plasmid containing Hygromycin
resistance gene was purchased from Invitrogen (Carlsbad, CA, USA).
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4.2 Antibodies
Table 2. Antibodies used in the study.
Name Description Manufacturer Used in
Anti-Actin Clone C4,
mouse monoclonal
Millipore, Billerica,
MA, USA
III
Anti-Flag clone M2,
mouse monoclonal
Sigma-Aldrich, St.
Louis, MO, USA
I, III
Anti-HA
(anti-Influenza virus
hemagglutinin)
clone 16B12,
mouse monoclonal
Covance, Princeton,
NY, USA
I, III
Anti-phospho-
tyrosine
PY99,
mouse monoclonal
Santa Cruz
Biotechnology,
Santa Cruz, CA,
USA
II, III
Anti-Stat92E-N-
terminus
dN-17,
goat polyclonal
Santa Cruz
Biotechnology,
Santa Cruz, CA,
USA
I, II, III
Anti-V5 mouse monoclonal Invitrogen,
Carlsbad, CA, USA
III
Anti-STAT1
(N-terminus)
Clone 1,
mouse monoclonal
IgG1
BD Biosciences,
Franklin Lakes, NJ,
USA
Results, Fig. 8
Anti-phospho-
STAT1 (Y701)
rabbit polyclonal Cell signaling, Results, Fig. 8
4.3 Cell culture
Cos-7 (SV-40-transformed green monkey kidney cells) cells were cultured in Dulbecco’s
modified Eagle’s medium (DMEM) (Lonza, Basel, Switzerland) supplemented with 10%
(vol/vol) FBS (Gibco), 2 mM L-glutamine (Sigma-Aldrich St. Louis, MO, USA), 100
U/ml penicillin and 50 ?g/ml streptomycin (Lonza, Basel, Switzerland) at +37ºC.  Human
HeLa (cervix adenocarsinoma cell line) cells were cultured in DMEM supplemented with
10% (vol/vol) FBS (Gibco), 2 mM L-glutamine (Sigma-Aldrich St. Louis, MO, USA),
100U/ml penicillin and 50 ?g/ml streptomycin (Lonza, Basel, Switzerland) and
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1% (vol/vol) non-essential amino acids (Lonza, Basel, Switzerland) at +37 ºC.
Schneider 2 Drosophila cells (S2, derived from macrophage-like embryonic cell lineage)
were cultured in Schneider’s medium (Sigma-Aldrich, St. Louis, Mo, USA)
supplemented with 10% FBS (Gibco), 100 U/ml penicillin and 50 ?g/ml streptomycin at
+25ºC.
4.4 Generation of stable overexpression S2 cell lines
S2 cell lines for stable overexpression of the pMT-Not4-V5 or the pMT-V5-HisA control
plasmid were generated by transfecting S2 cells with 9.5 ?g of the pMT-Not4-V5 or pMT-
V5-HisA plasmids, together with 0.5 ?g of the pCOHygro plasmid (Invitrogen, Carlsbad,
CA, USA) using FuGENE® 6 transfection reagent (Roche, Basel, Switzerland) according
to the manufacturer’s instructions. After 72 hours 300 ?g/ml Hygromycin-B
(Calbiochem, San Diego, CA, USA) was added to the Schneider’s growth medium
supplemented with FBS and antibiotics as described earlier. Cells were cultured at +25ºC.
4.5 Transfections
A total amount of 5x106 Cos-7 cells were transfected using electroporation with a Bio-
Rad Gene Pulser® (Bio-Rad Laboratories, Hercules, CA, USA) at 260 V and 960 ?F. For
each transfection 3 µg of plasmid DNA was mixed with herring sperm DNA for a total
amount of 40 ?g of DNA in each sample. The DNA was mixed with Cos-7 cells in 250 ?l
of DMEM in GenePulser® electroporation cuvettes (Bio-Rad Laboratories, Hercules,
CA, USA) prior to electroporation. After electroporation, cells were incubated in the
cuvettes for 10 minutes at RT and then plated onto 10 cm diameter cell culture dishes.
Transfected cells were cultured at +37 ºC for 48 hours prior to cell lysis.
HeLa cells were transfected using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA)
according to the manufacturer’s instructions. Plasmids were mixed with
Lipofectamine 2000 in Opti-MEM® (Invitrogen, Carlsbad, CA, USA) and added to the
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plated cells. After 4 hours the medium was changed to the DMEM HeLa culture medium
described above.
S2 cells were transfected using either the L-PEI transfection reagent (Boussif et al. 1995,
Huh et al. 2007) or the FuGENE® 6 transfection reagent (Roche, Basel, Switzerland)
according to the manufacturer’s instructions. Approximately 1.5x107 S2 cells and a total
amount of 10 ?g of plasmid DNA were used in L-PEI transfections.
4.6 Immunoprecipitation, Co-immunoprecipitation and Western blotting
A total amount of 5x106 Cos-7 cells were transfected using electroporation with a total
amount of 3.0 ?g of indicated plasmid DNAs. To prepare Cos-7 whole cell lysates for the
detection of Stat92E sumoylation, cells were harvested by scraping them from culture
dishes and lysed in 1% Triton-X lysis buffer (50 mM Tris-HCl pH 7.5, 10% glycerol,
150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 50 mM NaF) supplemented with
vanadate, aprotinin PMSF and 5 mM NEM.
In order to study Stat92E sumoylation in Drosophila cells, S2 cells were transfected with
4 ?g of pMT-Stat92E-Flag or pMT-Stat92E K187R-Flag together with 6 ?g of Smt3-HA
plasmids using L-PEI as described in the articles of Boussif et al. (1995) and Huh et al.
(2007). Two hours after transfection the medium was changed and supplemented with
500 ?M CuSO4 to induce the expression of Stat92E WT and the K187R mutant from the
pMT expression vector. Cells were incubated for 72 hours and harvested by pipeting
from culture dishes into 15 ml Falcon tubes following centrifucation. The cell pellet was
then washed once with ice cold PBS and suspended in 1% Triton X lysis buffer
supplemented with aprotinin, vanadate, PMSF and 5mM NEM as described earlier.
Protein concentrations were measured using the Bio-Rad DC Protein Assay kit (Bio-Rad
laboratories, Hercules, Ca, USA).
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4.6.1 Immunoprecipitation
Equal amounts of protein lysates were subjected to immunoprecipitation assay using
either anti-Flag (Sigma-Aldrich) or anti-Stat92E (Santa Cruz) antibodies. Protein-
antibody complexes were then collected with Protein G Seprahose beads (GE Healthcare,
Little Chalfont, UK). Proteins were separated by SDS-PAGE and immunoblotted with
anti-Stat92E-N-terminal (Santa Cruz), anti-phospho-tyrosine (Santa Cruz) or anti-HA
(Covance) antibodies.
4.6.2 Co-immunoprecipitation
For co-immunoprecipitation experiments pMT-Not4-V5 overexpressing and
pMT-V5-HisA overexpressing control S2 cells were treated with 500 ?M CuSO4 in order
to induce transcription from the pMT-expression vector. After 48 hour of incubation at
+25ºC cells were lysed using a buffer containing 20 mM HEPES pH 8.0, 100 mM NaCl,
1% TritonX-100, 10% Glycerol, 1 mM EDTA, 50 mM NaF supplemented with vanadate,
aprotinin and PMSF. Equal amounts of protein lysates were incubated with either an
anti-Stat92E-N-terminal antibody (Santa Cruz) or an anti-HA antibody (Covance) as a
control for 2 hours rotating at +4ºC, followed by a one hour incubation with Protein G
Seprahose beads (GE Healthcare, Little Chalfont, UK). The beads were then washed four
times with TritonX-100 lysis buffer supplemented with inhibitors and the
co-immunoprecipitated proteins were released from the beads by adding 2xSDS loading
buffer. Co-immunoprecipitated proteins were separated by SDS-PAGE and detected by
immunoblotting using an anti-V5 antibody (Invitrogen).
4.6.3 Western blotting
Proteins were separated by SDS-PAGE and transferred onto Protran® nitrocellulose
filters (Whatman, Dassel, Germany). Membranes were blocked with 5% non-fat dried
milk in TBS 0.1% Tween 20 or with 5% BSA in TBS 0.1% Tween 20. Immunoblotting
was performed by incubating membranes with specific primary antibodies followed by
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incubation with biotinylated secondary antibodies (Dako A/S, Glostrup, Denmark) and
incubation with a strepavidin-biotin horseradish peroxidase complex (GE-healthcare,
Little Chalfont, UK). Immunodetection was performed with an enhanced
chemiluminescence (ECL) system (GE Healthcare, Little Chalfont, UK).
4.7 dsRNA synthesis and RNA interference
For RNA interference (RNAi) in S2 cells, targeted dsRNAs were generated. At first
double-stranded DNA was amplified by two-step PCR using gene specific primers and
Drosophila cDNA as a template. The primers for the second PCR contained T7 promoter
sequence (GAATTAATACGACTCACTATAGGGAGA) at their 5’-end. The product
from  the  second  PCR  was  then  used  as  a  template  for  dsRNA  synthesis  using  the  T7
MegaScript® RNA polymerase kit (Ambion, Austin, TX, USA) according to the
manufacturer’s instructions.
The following primers were used for dsRNA synthesis:
Stat92E 3’-UTR: 5’-CGTAATATGGTCCTCGTGTC-3’ and 5’-AACAACTTC
AGCTCACAGCC-3’ for the first PCR and 5’-GAATTAATACGACTCACTATAGGG
AGAGGCAATCGCATGTGGC-3’ and 5’-GAATTAATACGACTCACTATAG
GGAGAGGAATGTGTCCGCACG-3’ for the second PCR.
dPias: 5’-GCCATTTCCGTCTCTTCAGG-3’ and 5’-CTTTGACGTTTACGTTCGGCG-
3’ for the first PCR and 5’-GAATTAATACGACTCACTATAGGGAGATCTCAT
TCGCTGGACG-3’ and 5’-GAATTAATACGACTCACTATAGGGAGACTCC
ACCAGGCAAAAG-3’ for the second PCR.
A dsRNA containing the sequence for green fluorescent protein (GFP) was used as a
negative control. Other dsRNA constructs used are described in original communications
II and III.
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For siRNA experiments in HeLa cells gene specific siRNAs were purchased from
Ambion (Austin, TX, USA).
4.8 Luciferase reporter gene assay
A total amount of 0.1x106 HeLa cells were seeded on 24-well culture dishes 24 hours
prior to transfection with 0.2 ?g of the luciferace reporter and 0.1 ?g of the CMV-?-
galactosidase reporter plasmids simultaneously with 20 pmol of specific siRNA using
Lipofectamine 2000 transfection reagent (Invitrogen, Carlsbad, CA, USA) according to
the manufacturer’s instructions. After 24 hours cells were serum starved for an additional
24 hours and either treated or left untreated with 100 ng/ml of human IFN-? or 10 ng/ml
of human IL-4. Cells were lysed in Promega’s Reporter Lysis Buffer (RLB) (Promega,
Madison, WI, USA) following luciferase activity measurement using the Luciferace
Assay Substrate (Promega, Madison, WI, USA) and Luminoscan Ascent
(ThermoElectron Corporation, Finland). Luciferase values were normalized against
?-galactosidase values of the lysates.
For luciferase assay experiments in S2 cells, 1.0x106 cells were plated on 24-well culture
plates and transfected with the indicated plasmid DNAs and dsRNAs using FuGENE® 6
transfection reagent (Roche, Basel, Switzerland) according to the manufacturer’s
instructions. Cells were lysed 48 – 72 hours after the transfection following luciferase and
?-galactosidase activity measurements as described above.
4.9 RNAi screen to identify novel JAK/STAT pathway regulators
For the genome-wide RNAi screen a total of 16,025 dsRNAs were produced. Of these,
13,625 dsRNAs were synthesized using commercial Drosophila genome RNAi library
(MCR Geneservice) derived PCR products with dual T7 promoter sequences as
templates. An additional 2,400 dsRNAs were synthetized from a S2 cell-derived cDNA
library (Rämet et al. 2002a, Ulvila et al. 2006). The T7 MegaScript® RNA polymerase kit
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(Ambion, Austin, TX, USA) was used for dsRNA synthesis as described in the Chapter
4.7. The dsRNA concentrations were measured using the picoGreen® dsRNA
Quantitation kit. The dsRNA synthesis for the genome-wide RNAi screen is also
described  in  detail  in  the  doctoral  thesis  of  Jenni  Kallio.  The  activity  of  the
Stat92E-responsive TotM-luc reporter was used to monitor the activity of the JAK/STAT
pathway and the Actin 5C-?-galactosidase reporter was used to monitor cell viability. S2
cells were plated on 24-well culture dishes and transfected with 0.1 ?g of TotM-luc and
0.1 µg of Actin 5C-?-galactosidase reporters together with 0.5 µg of dsRNA using
FuGENE® 6 transfection reagent (Roche, Basel, Switzerland) according to the
manufacturer’s instructions. Stat92E dependent TotM-luc expression was activated by co-
transfecting the cells with 0.1 µg of HopTum-l and RNAi against Stat92E and GFP were
used as a positive and negative control, respectively. Cells were lysed 72 hours after the
transfection and luciferase and ?-galactosidase activities were measured as described in
the Chapter 4.8. Genes targeted by RNAi treatments that repeatedly decreased TotM-luc
activity by more than 50% without significantly affecting cell viability (Actin 5C-?-
galactosidase activity) were considered as novel positive JAK/STAT pathway regulators,
whereas genes targeted with dsRNA treatments that repeatedly increased TotM-luc
activity by more than 50% without significantly affecting cell viability were considered
potential negative JAK/STAT pathway regulators. The corresponding templates from the
original library were TA cloned and sequenced. Gene-specific primers for targeted
dsRNA synthesis against these novel regulators were designed based on sequencing data.
Targeted dsRNAs were synthetized as descriped in the Chapter 4.7. Transfections and
luciferase assay measurements were repeated with these targeted dsRNAs similarly as
described above, in order to confirm that the RNAi phenotypes in the original screen
were not caused by a contaminant dsRNA or any off-target effect. The endogenous TotM
and Actin 5C expression levels from HopTum-l and dsRNA transfected cells were measured
using qRT-PCR, in order to confirm that our screening results were not caused by
reporter assay related artifacts (described in the thesis book of Jenni Kallio).
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4.10 Electrophoretic mobility shift assay (EMSA)
S2 cells were transfected with 2.0 ?g of HopTum-l to induce the JAK/STAT pathway or
with an empty vector as a control together with 5.0 ?g of different dsRNAs using
FuGENE® 6 transfection reagent (Roche, Basel, Switzerland) according to the
manufacturer’s instructions. Cell were incubated for 48 hours at +25ºC and lysed with
lysis  buffer  10  mM  HEPES-KOH  pH  8.0,  10  mM  KCl,  0.1%  NP-40,  1  mM  EDTA
supplemented with 10 mM NaF, 1 mM DTT, vanadate, aprotinin and PMSF. After
centrifugation the supernatant was collected as cytoplasmic extract. The pellet was
resuspended into a buffer containing 20 mM HEPES-KOH pH 8.0, 400 mM NaCl,
10% glycerol, 1 mM DTT, 10 mM NaF supplemented with vanadate, aprotinin and
PMSF and rotated at +4ºC for 30 minutes following centrifugation in order to extract the
nuclear lysate. Double-stranded DNA (dsDNA) probes containing the Stat92E binding
site sequence (TTCTTAGAAT) from the TotM gene promoter region were generated by
annealing oligonucleotide 5’-CAAAAAAACAGTTCTTAGAATGCAATCAATAC-3’
with its complement. Annealed dsDNA probes were then end-labelled with [?-32P]-
labeled ATP using T4-polynucletide kinase. For the binding assay cytoplasmic and
nuclear lysates were mixed in a 3:1 ratio together with the [?-32P]-labeled dsDNA
oligonucleotides in the presence or without a Stat92E-N-terminal antibody (Santa Cruz)
in binding buffer (20 mM HEPES-KOH pH 8.0, 50 mM NaCl, 10% glycerol,
0.01% Triton X-100, 1 mM DTT) for 30 minutes at room temperature. The complexes
were resolved by 6% PAGE in 0.5 x TAE, before drying and autoradiography.
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5. Results
5.1 Sumoylation of Stat92E (Article I)
5.1.1 Lysine 187 is a putative sumoylation site in Stat92E
Numerous transcription factors are modified with a small ubiquitin-like modifier
(SUMO) (Gill 2005). Human STAT1 was the first STAT transcription factors shown to
be SUMO conjugated. This sumoylation on Lys703 in the C-terminal transactivation
domain of STAT1 was shown to inhibit the expression of certain STAT1 driven genes
(Rogers et al. 2003, Ungureanu et al. 2003, Ungureanu et al. 2005). The main
components of the Drosophila JAK/STAT pathway are comparable to those of the human
pathway. Also regulators of the human JAK/STAT pathway, such as PIAS and SOCS are
found in Drosophila melanogaster (Betz et al. 2001, Hari et al. 2001, Callus and Mathey-
Prevot 2002). In  order  to  find  out  if Drosophila Stat92E  is  sumoylated  like  its
mammalian counterpart STAT1, the sequence of Stat92E was analyzed for putative
sumoylation sites. Sumoylation most often occurs on lysine residues within the consensus
motif ?KxD/E (where ? stands for a large hydrophobic amino acid, and x can be any
amino acids) (Sternsdorf et al. 1999). A sequence analysis of Stat92E revealed one
complete SUMO consensus site in the coiled-coil domain region of Stat92E between
amino acids 186 and 189 (PKVE), where Lys187 would be the SUMO acceptor. The
sumoylation site Lys703 in human STAT1 is in close proximity to tyrosine 701, a
phosphorylation site required for STAT1 activation. A corresponding lysine residue is
conserved also in Stat92E (Lys713), but the sequence around it does not create a perfect
sumoylation consensus motif (I, Fig. 2A). The discovery that Stat92E contains a putative
SUMO-conjugation site prompted us to do further biochemical studies to investigate
Stat92E sumoylation.
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5.1.2 Stat92E is sumoylated in mammalian cells
Sumoylation is a highly dynamic modification and usually only a few target proteins are
sumoylated at a given time in the cell. This poses a challenge for detecting protein
sumoylation. The mammalian Cos-7 cell line is widely used in sumoylation studies
because of the well-defined SUMO-conjugation machinery found in these cells. To this
end, we chose to study Stat92E sumoylation first by overexpressing Flag-tagged Stat92E
together with either Flag-tagged, tandem-Flag-tagged SUMO-1 or HA-tagged SUMO-3 in
Cos-7 cells. Stat92E was immunoprecipitated from total cell lysates using an anti-Flag
antibody and immunoblotted with a Stat92E specific antibody. In the lanes with co-
transfected SUMO-1-Flag, SUMO-1-Flag-Flag or SUMO-3-HA, slowly migrading bands
at around 116 kDa were detected with the Stat92E antibody indicating that Stat92E is
SUMO-1/3-modied in Cos-7 cells (I, Fig. 1A). Furthermore, overexpression of the double
Flag-tagged SUMO-1 created a band shift corresponding to the size of the Flag-tag,
further indicating that the bands represent Stat92E-SUMO complexes, instead of other
possible post-translational modifications to Stat92E caused by the forced expression of
SUMO-1/3.
To further verify that the antibody was detectecting, Stat92E-SUMO-1/3 bands, Cos-7
cells were co-transfected with Stat92E-Flag and SUMO-1-GA-His, a mutant which
cannot be SUMO-conjugated. As expected, the 116 kDa band was not present in the
SUMO-1-GA-His lane when probed with the anti-Stat92E antibody. Sumoylation is a
reversible post-translational modification and SUMO is cleaved from target proteins by
specific SUMO proteases (SENPs) (Mukhopadhyay and Dasso 2007). Thus, we wanted
to study if the overexpression of SENP1 abolishes Stat92E sumoylation. To this end,
Cos-7 cells were co-transfected with Stat92E-Flag, SUMO-1-His and SENP1 WT  or  a
catalytically inactive SENP1 C603S mutant.  The SENP1 co-transfection totally abolished
the upper, slower migrating band detected by anti-Stat92E, whereas co-transfection of a
catalytically dead SENP1 C603S mutant slightly increased the amount of Stat92E-
SUMO-1 (I,  Fig.  1B).  These findings suggest  that  Stat92E can be sumoylated in  Cos-7
cells and SENP1 can cleave SUMO-1 from Stat92E.
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5.1.3 Stat92E is sumoylated in Drosophila S2 cells and lysine 187 is the acceptor site
for SUMO conjugation
As described above, Stat92E has a SUMO consensus site in its coiled-coil domain
between amino acids 186-189 (PKVE). To determine if this is the SUMO binding site,
we mutated lysine 187 to arginine. Stat92E K187R-Flag and Stat92E WT-Flag were then
transfected into Drosophila S2  cells  with  or  without  an  HA-tagged Drosophila SUMO
variant, Smt3. The expression of endogenous Stat92E was inhibited by adding a dsRNA
targeting Stat92E-3’-UTR to the cells. After cell lysis, Stat92E was immunoprecipitated
from the lysates with an anti-Flag antibody. As expected, Smt3 overexpression created a
band of ~ 116 kDa, which was detected with both the Stat92E specific antibody and an
HA-antibody detecting Smt3, indicating that Stat92E is also modificated by Smt3 in S2
cells. Moreover, the K187R mutation totally abolished this band, indicating that lysine
187 is the only sumoylation site in Stat92E (I, Fig. 2B).
5.1.4 Sumoylation negatively regulates Stat92E driven gene expression
In order to determine if SUMO attachment affects the transcriptional activity of Stat92E,
luciferase reporter assay experiments were carried out in S2 cells. Two independent luc-
reporters, TotM-luc and 10xStat92E-luc were used to detect JAK/STAT pathway activity.
In the absence of a Stat92E activating stimulus, overexpression of WT Stat92E and the
sumoylation deficient Stat92E K187R mutant equally increased the activities of both luc-
reporters (approximately 3-fold). When the JAK/STAT pathway was activated with co-
transfection of the pathway ligand Upd, Stat92E K187R displayed significantly increased
transcriptional activity on both of the Stat92E driven reporters. These data suggest that
sumoylation has an inhibitory effect on Upd-induced Stat92E-mediated gene
transcription (I, Fig. 3A and B).
PIAS proteins have been shown to promote SUMO conjugation to human STAT1 and
dPias has also been suggested to negatively regulate Stat92E-mediated signaling (Betz et
al. 2001, Rogers et al. 2003, Ungureanu et al. 2003). This prompted us to investigate if
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dPias could affect the sumoylation of Stat92E. As shown in original communication I,
Fig. 3C, dPias RNAi increased Stat92E driven TotM-luc reporter activity, supporting the
previously published data that dPias negatively regulates the Drosophila JAK/STAT
pathway (Betz et al. 2001). However, we were not able to detect any alterations in the
sumoylation status of Stat92E with dPias RNAi in our immunoblot studies (data not
shown), and therefore the possible role of dPias in Stat92E sumoylation remains unclear.
5.2 CG14225/ET and CG31716/Not4 as regulators of the Drosophila
JAK/STAT pathway (Articles II and III)
5.2.1 CG14225 and CG31716 are novel Drosophila JAK/STAT pathway regulators
found in a genome-wide RNAi screen in Drosophila S2 cells
In order to identify novel JAK/STAT pathway regulators, a genome-wide RNAi screen
was performed in Drosophila S2 cells. This screen is described in more detail in the
doctoral thesis of Jenni Kallio and in original communication II. The pathway was
activated by overexpressing the constitutively active Hopscotch mutant HopTum-l, and
expression from the Stat92E target gene TurandotM (TotM)-luc reporter was used as an
indicator of the activity of the JAK/STAT pathway. Act5C-?-galactosidase reporter was
used to monitor cell viability and transfection efficiency. In this set-up, 16,025 dsRNA
treatments were used to find genes which affect Drosophila JAK/STAT signaling. The
knockdown of seven genes repeatedly caused an over 50% decrease in TotM-luc activity,
indicating that these genes may act as positive regulators of the Drosophila JAK/STAT
pathway (II, Fig. 1C). The genes included the previously identified JAK/STAT pathway
members Stat92E and Hop, as well as four novel JAK/STAT pathway regulator candidate
genes: CG14225, CG31716, Med27 and Taf1. The seventh gene was a gene called enok,
which was also found in two previously published screens by Baeg et al. (2005) and
Müller et al. (2005). In addition to the candidates for positive regulators, the screen also
revealed one interesting putative negative regulator, kayak.
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To investigate, if these effects are specific for the TotM-promoter, or if they have a more
general affect on JAK/STAT signaling, dsRNA-mediated knockdown of the candidate
genes was studied with another Stat92E responsive luciferase promoter, 10xStat92E-luc,
containing five doublet repeats of Stat92E binding sites from the Socs36E gene enhancer
region upstream of the luciferase gene (Baeg et al. 2005). Like in the original screen,
RNAi targeting CG14225 and CG31716 significantly reduced 10xStat92E-luc activity
(Fig.  6 and III,  Fig.  1B).  Similarly to the original screen, kayak RNAi lead to a notable
enhancement in luciferase activity  also  on  the 10xStat92E-promoter (Fig. 6).
Interestingly, dsRNAs targeting Med27, Taf1 or enok had no effect on Stat92E-mediated
gene expression in this setting, indicating that these factors may have more selective roles
in JAK/STAT pathway regulation.
Figure 6. The effect of RNAi against the potential novel JAK/STAT pathway
regulators on HopTum-l-induced 10xStat92E-luc activity. CG14225 and CG31716
RNAi impairs JAK/STAT pathway mediated 10xStat92-luc activity, while kayak RNAi
results in the opposite effect. Enok, Med27 and Taf1 have  no  effect  on  JAK/STAT
pathway activity in this setting. Stat92E RNAi was used as a positive control. The error
bars indicate SD, calculated from three independent transfections. *p?0.05, **p?0.001,
n.s.= non significant.
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As shown in Fig. 6, kayak RNAi caused a notable enhancement in Stat92E responsive
10xStat92E-luc activity. This prompted us to study this gene in more detail. Kayak
encodes a protein homologous to mammalian FosB. Thus, we wanted to investigate if
FosB RNAi also affects the activity of the human JAK/STAT pathway. Human STAT1 is
a well-studied transcription factor essential for IFN-? signaling. In order to study if FosB
RNAi has an effect on STAT1 responsive GAS-luc activity, human HeLa cells were
transfected with either Scrambled (Scr) siRNA as a negative control, a siRNA targeting
Stat1 or a siRNA targeting FosB. Cells were stimulated by incubating them in the
presence of human IFN-? for 6 hours prior to lysis. In contrast to results obtained from
Drosophila S2 cells with kayak RNAi, FosB knockdown in mammalian cells seemed to
have a negative effect on STAT1-mediated reporter gene expression (Fig. 7). Of note, the
possible effect of FosB on STAT1 activating tyrosine 701 phosphorylation was studied in
HeLa cells as well. As a result, we did not detect any alterations in the STAT1 tyrosine
701 phosphorylation status with FosB RNAi, when compared to control scrambled
siRNA transfected cells at different IFN-? induction time points (data not shown).
Because of these negative results we decided not to study kayak/FosB further.
Figure 7. Effect of FosB siRNA on STAT1 mediated GAS-luciferase reporter
activity. Values are mean ± SD from three independent transfections, *p?0.05.
71
The candidate genes which had a positive effect on JAK/STAT signaling in the screen
were then studied under more physiological conditions in Drosophila S2 cells using
overexpression of the Dome receptor ligand Upd to activate the JAK/STAT pathway.
Strikingly, in this experimental setting dsRNA mediated RNAi against CG14225 had  a
significant positive influence on two independent Stat92E responsive luc-reporters,
TotM-luc and 10xStat92E-luc (described in the thesis of Jenni Kallio and in II, Fig. 2A
and B). This unexpected result prompted us to concentrate on this gene as a novel
regulator of the Drosophila JAK/STAT pathway. As in the original screen, dsRNA
treatment targeting CG31716 had a significant negative effect on both reporters, also
when induced with the overexpression of Upd, whereas the effect of knocking down the
remaining three genes of interrest differed depending on the promoter (Described in
thesis book of Jenni Kallio and II, Fig. 2A and B). Because of these context dependent
effects of enok, Med27 and Taf1 on Stat92E responsive promoters, we chose CG31716
for further studies. The goal of my thesis was to study, in detail, the molecular
mechanisms behind CG14225- and CG31716-mediated regulation of JAK/STAT
signaling.
5.2.2 CG14225 encodes a gp130 related transmembrane protein called Eye
transformer (ET) (Article II)
A sequence analysis revealed that CG14225 is a 3.3 kb gene containing three different
coding sequences, and interestingly, it is located next to Dome on the Drosophila X
chromosome. The protein product of the CG14225 gene is 713 amino acids long and
contains a putative transmembrane domain. The CG14225 protein shares structural
similarities with Dome mainly in its extracellular domains. Like Dome, the extracellular
part of CG14225 contains a putative sequence for a cytokine binding module (CBM).
CBM in vertebrate interleukin receptors consists of two FnIII domains, the N-terminal
domain is usually identifiable through four conserved cystein residues and the C-terminal
domain contains a conserved WSXWS motif (Bazan 1990). The conserved cystein
residues can also be found in the CG14225 sequence, but the WSXWS motif is
incomplite (NTLWS). In contrast to Dome, CG14225 lacks three additional extracellular
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FnIII domains near the transmembrane domain (II, Fig. 3A). According to our BLAST
results the closest human homologue for CG14225 is gp130 with 12.7% sequence
identity. The intracellular part of CG14225 was not found to share homology with any
known protein.
Our in vivo results showed that crossing flies carrying CG14225 RNAi  under  an  eye-
specific driver (ey-GAL4)  with  an Upd overexpressing fly strain causes severe eye
overgrowth in the offspring. These experiments are discussed in more detail in the
doctoral thesis of Henna Myllymäki (in preparation) and in II, Fig. 7C and D. Thus, the
protein encoded by CG14225 was named Eye transformer (ET).
5.2.3 ET negatively regulates Upd-induced Stat92E phosphorylation (Article II)
Stat92E activation requires Hop-mediated phosphorylation of a single C-terminal
tyrosine residue, which under physiological conditions is a response to Upd-mediated
Dome activation (Dearolf 1993, Binari and Perrimon 1994, Hanratty and Hou et al. 1996,
Yan et al. 1996a, Brown et al. 2001, Chen et al. 2002). According to our results, ET was
found to negatively regulate Upd-induced Stat92E-mediated gene responses. ET was
shown to interact with Dome and Hop, and furthermore, ET was found to function at the
level or upstream of the JAK/STAT pathway receptor Dome (discussed in detail in
original communication II, Fig. 4). Together with the sequence data, this suggests that ET
is a Dome-Hop complex associated transmembrane regulatory protein.
Next, we investigated if the negative effect of ET on Stat92E target gene expression is a
consequence of an altered Stat92E phosphorylation status. To this end, S2 cells were
transfected with ET dsRNA or control dsRNAs together or without Upd to activate the
JAK/STAT pathway. After cell lysis Stat92E phosphorylation was studied by
immunoblotting with a Stat92E specific antibody. Strikingly, an additional slower
migrating Stat92E band was detected in the lanes where Upd was transfected together
with ET dsRNA (II, Fig. 5B, upper panel). To verify that the observed band represents a
phosphorylated form of Stat92E, endogenous Stat92E was immunoprecipitated from
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lysates with an anti-Stat92E antibody and immunodetection was performed with an anti-
phospho-tyrosine specific antibody. As shown in original communication II, Fig. 5B (two
middle panels), the phospho-tyrosine specific antibody detects the corresponding band,
indicating that the band represents tyrosine phosphorylated Stat92E. Furthermore, the
band could be detected only weakly in the lanes with the GFP control dsRNA and was
totally abolished with RNAi against Stat92E or Hop. These results indicate that depletion
of ET causes hyperphosphorylation of Stat92E upon Upd induction. In addition to this,
the simultaneous transfection of a dsRNA targeting Dome or Hop together  with  an ET
targeted dsRNA almost totally abolished Stat92E hyperphosphorylation caused by the ET
RNAi, indicating that ET-mediated Stat92E regulation is dependent on Dome and Hop
(II, Fig. 5B, lower panel). Taken together, ET negatively regulates JAK/STAT-mediated
signal transduction at the level or upstream of Dome by inhibiting Upd-induced Stat92E
tyrosine phosphorylation.
5.2.4 CG31716 overexpression enhances JAK/STAT pathway mediated gene
responses in S2 cells (Article III)
As described earlier, CG31716/Not4 RNAi reduced the activities of the TotM-luc and the
10xStat92E-luc reporter genes when the JAK/STAT pathway was activated by both
HopTum-l and Upd overexpression. Furthermore, CG31716/Not4 RNAi was shown to
inhibit endogenous TotM expression, verifying that these results were not caused by
artifacts in the reporter gene assay (described in detail in III, Fig. 1E and F). In addition
to RNAi studies, we investigated the effect of CG31716/Not4 overexpression on Stat92E-
mediated gene expression. For this, S2 cells were transfected with CG31716/Not4 in the
pMT-V5 expression vector together with the TotM-luc or 10xStat92E-luc reporter
construct and with or without HopTum-l to activate the JAK/STAT pathway. As shown in
original communication III, Fig. 2A and B, CG31716/Not4 overexpression causes a
significant increase in Stat92E-dependent reporter gene activity, both in uninduced cells
and upon HopTum-l-mediated Stat92E activation. A repeat experiment where the pathway
was activated with Upd yielded similar results. In summary, forced CG31716/Not4
expression enhances Stat92E-responsive reporter gene expression in S2 cells, indicating
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that CG31716/Not4 positively regulates the Drosophila JAK/STAT pathway.  A  similar
effect on TotM and TotA gene expression was detected in CG31716/Not4 overexpressing
fly strains in vivo. Both genes were up-regulated in CG31716/Not4 overexpressing flies
compared to control flies under normal conditions. Septic injury caused by an
Enterobacter cloacae infection resulted in a significant increase in TotM expression in
CG31716/Not4 overexpressing flies compared to control flies. The effect on TotA
expression was less clear in this experimental setting (discussed in more detail in III, Fig.
3A and B).
5.2.5 Drosophila CG31716 gene encodes Not4, a protein related to mammalian
CNOT4 (Article III)
CG31716/Not4 was found to positively regulate Drosophila JAK/STAT signaling.
CG31716/Not4 gene encodes a 1051 amino acid protein that shares structural similarities
with the yeast and human CNOT4 proteins (Albert et al. 2000, Albert et al. 2002). The
domain structures of Not4 and human CNOT4 are illustrated in original communication
III, Fig. 4A. The most N-terminal domain of human CNOT4 is the RING domain, known
to harbor a Ubiquitin E3 ligase activity. Adjacent to this is the RRM domain that
mediates interactions with ssDNA and ssRNA. The zinc-finger domain mediates possible
DNA and protein interactions (Albert et al. 2002).  The N-terminus of Drosophila Not4
was found to resemble the N-terminus of human CNOT4, while the C-terminus of
Drosophila Not4 is less conserved and does not contain any identifiable domains.
5.2.6 Human CNOT4 regulates STAT1- and STAT6-mediated signal transduction
(Article III)
The mammalian JAK/STAT pathway is highly similar to the corresponding Drosophila
cascade. In order to study whether Not4 is a conserved regulator of the JAK/STAT
cascade, we investigated if siRNA-mediated knockdown of the Not4 human homologue,
CNOT4, affects STAT1-responsive reporter gene activity in human HeLa cells. As shown
in III, Fig. 3C, CNOT4 RNAi causes a significant reduction in GAS-luc activity upon
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IFN-? stimulation. We also observed a similar effect on STAT6-responsive Ig?-luc
activity after IL-4 induction (III, Fig. 3D). These results suggest that CNOT4 participates
in  human  JAK/STAT  signaling.  Of  note,  a CNOT4 siRNA treatment had no effect on
PG-13-luc activity (III, Fig. 3E), or on CMV-promoter driven ?-galactosidase values
used for monitoring transfection efficiency in the experiments, indicating that CNOT4
does not affect transcription in HeLa cells in a global manner.
5.2.7 Drosophila Not4 is a Stat92E interacting protein (Article III)
Because of the strong evidence that Not4 affects Drosophila JAK/STAT pathway we
established a stable Not4-pMT-V5 overexpression cell line for further studies. In order to
study if Not4 interacts with Stat92E, Not4-V5 overexpressing S2 cells and pMT-V5-HisA
control S2 cells were lysed, and endogenous Stat92E was immunoprecipitated from the
whole cell lysates with an anti-Stat92E antibody. After SDS-PAGE, co-
immunoprecipated Not4-V5 was visualized with an anti-V5 antibody. As shown in
original communication III, Fig. 5, Not4 does indeed co-immunoprecipitate with Stat92E.
Next, we investigated if the JAK/STAT pathway activation affects the Stat92E-Not4
interaction. We transfected Not4-V5 overexpressing S2 cells with increasing amounts of
the JAK/STAT pathway ligand Upd, and performed a co-immunoprecipitation assay with
the method described earlier. As a result we observed a consistent enhancement in the
Stat92E-Not4 interaction with different amounts of transfected Upd (III, Fig. 5B).
5.2.8 Not4/CNOT4 does not affect STAT tyrosine phosphorylation (Article III)
In study II, ET was found to regulate the tyrosine phosphorylation of Stat92E. To
investigate if Not4 is required for Stat92E activation, we studied how Not4 RNAi affects
the tyrosine phosphorylation status of Stat92E in S2 cells. As a result we did not observe
a difference in Upd-induced Stat92E tyrosine phosphorylation between Not4 dsRNA
treated and control GFP dsRNA treated cells either with an anti-Stat92E antibody or a
phospho-tyrosine-specific antibody (III, Fig. 6A). To validate this result with more
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detectable amounts of phosphorylated Stat92E, Not4-V5 overexpressig cells and control
pMT-V5-HisA cells were transiently transfected with a Flag-tagged Stat92E together  or
without HopTum-l to induce Stat92E phosphorylation. Cells were lysed and equal amounts
of Stat92E were immunoprecipitated from the lysates with an anti-Flag antibody and
immunoblotted with an anti-Stat92E specific antibody. HopTum-l overexpression caused a
considerable Stat92E band shift that was the same in Not4-V5 and pMT-V5-HisA cell
lysates. Furthermore, Not4-V5 overexpression on its own did not produce a detectable
band shift on the Stat92E immunoblot (III, Fig. 6B). In summary, these results suggest
that Not4 does not affect Stat92E tyrosine phosphorylation. Thus it affects Stat92E-
mediated gene responses through a different mechanism.
CNOT4 was found to affect STAT-mediated gene expression in human cells. To this end,
we also wanted to investigate if CNOT4 RNAi would mitigate STAT1 phosphorylation in
HeLa cells. In order to do this, Hela cells were transfected with either Scrambled (Scr) or
MyD88 siRNA as a negative control or with siRNA targeting CNOT4. Stat1 siRNA was
used as a positive control. Phosphorylation of endogenous STAT1 was induced by
incubating cells in the presence of hIFN-? for six hours prior to lysis.  As shown in Fig. 8,
CNOT4 RNAi had no significant effect on STAT1 tyrosine 701 phosphorylation when
compared to Scr or MyD88 siRNA transfected control cells, indicating that CNOT4 is not
indispensable for STAT1 phosphorylation in human cells.
Figure 8. CNOT4 RNAi does not alter IFN-?-induced tyrosine 701 phosphorylation
of human STAT1.
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5.2.9 Not4 is required for efficient Stat92E DNA binding (Article III)
Activated Stat92E translocates to the nucleus and binds to the consensus DNA sequence
TTCnnnGAA at the promoters of its target genes (Rivas et al. 2008, Yan et al. 1996a). As
discussed above, we did not observe any alterations in Stat92E phosphorylation in either
Not4 dsRNA treated cells or in Not4-V5 overexpressing cells, suggesting that Not4
functions downstream of Stat92E phosphorylation. Thus, we studied if Not4 affects
Stat92E DNA binding in S2 cells using an EMSA assay with probes containing a Stat92E
binding site from the TotM promoter. A HopTum-l transfection was used to induce Stat92E
phosphorylation and GFP and Stat92E dsRNA transfections were used as controls.
Interestingly, Not4 RNAi almost totally abolished Stat92E binding to the DNA probe
upon HopTum-l induction, indicating that Not4 is needed for Stat92E DNA binding (III,
Fig. 6C). As a conclusion, Not4 positively regulates the Drosophila JAK/STAT pathway
by enhancing Stat92E DNA binding.
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6. Discussion
6.1 Drosophila melanogaster as a model for studying the JAK/STAT
signaling cascade
Drosophila melanogaster has made an important contribution to our understanding of the
immune system as we know it. A famous example of this is the discovery of the Toll-like
receptors (TLRs), which are essential for the recognition of invading pathogens.
Originally, Drosophila Toll was found to mediate immune signaling and to be essential
for defending against fungal infections (Rosetto et al. 1995, Lemaitre et al. 1996).  Soon
after this, TLRs were reported to participate in mammalian immune signaling via Nf-?B
as well (Medzhitov et al. 1997). As for recognizing the importance of Drosophila in
biomedical research, the Drosophila researcher Jules Hoffmann was awarded the Nobel
Prize in physiology or medicine in 2011 together with immunologists Bruce Beutler and
Ralph Steinmann. The studies that lead to Hoffmann’s Nobel Prize concentrated on the
very foregoing Toll receptor. Drosophila in turn is an exceptional model organism for
genetic studies  due to its small size, short reproduction cycle and relatively short life
(Rämet 2012). Fruit flies are also cheap and easy to rear. Moreover, using Drosophila in
biomedical research is ethically less problematic than is the use higher organisms such as
rodents.
Like the Toll pathway, the JAK/STAT signaling pathway has been highly conserved in
evolution. Human JAK/STAT pathways consist of seven STATs and four JAKs, thus
making the cascades reduntant and complicated to sudy (Leonard and O'Shea 1998). The
corresponding cascade in Drosophila melanogaster is  much  simpler  consisting  of  only
one STAT transcription factor, Stat92E, one Janus kinase, Hopscotch (Hop), and a single
defined transmembrane  recepror, Dome (Binari and Perrimon 1994, Hou et al. 1996,
Yan et al. 1996a, Brown et al. 2001, Chen et al. 2002). These molecules seem to share
conserved domain architectures with their mammalian counterparts, and the signal
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transduction route follows a canonical tyrosine phosphorylation dependent pattern
originally described in the mammalian system (Binari and Perrimon 1994, Hou et al.
1996, Yan et al. 1996a, Leonard and O'Shea 1998). In addition to the common core
components, also the best defined JAK/STAT pathway regulators are found in
Drosophila: PIAS, SOCS and protein tyrosine phosphatase, the last of which was found
in two independent genome-wide RNAi screens (Betz et al. 2001, Callus and Mathey-
Prevot 2002, Karsten et al. 2002, Baeg et al. 2005, Müller et al. 2005). These findings
support the idea that the Drosophila JAK/STAT pathway is similar to the mammalian
cascade, thus the novel JAK/STAT pathway regulators found in Drosophila are likely to
be involved in the mammalian systems as well. Nevertheless, the results obtained from
Drosophila studies cannot, of course, be directly extrapolated to hold true for all species,
but need to be repeated in other organisms as well.
Two of the original communications (II and III) in this thesis are based on a genome-
wide RNAi screen conducted in Drosophila S2 cells, which was carried out to identify
genes  that  modulate  the  activity  of  the  JAK/STAT  pathway.  The  main  goal  was  to
identify genes that are also involved in human JAK/STAT signaling, in order to better
comprehend the biology of this disease related cascade. Of the novel Drosophila
JAK/STAT pathway regulators described in this thesis, the Not4 mammalian homologue
CNOT4 was also shown to be important for human STAT1- and STAT6-mediated gene
responses, functioning downstream of STAT phosphorylation. Although, the results from
Drosophila cells indicated that Not4 is reguired for Stat92E DNA binding, the
mechanism in mammalian cells may be different and warrants further studies. The screen
described in original communication II revealed that kayak RNAi had a positive effect on
TotM gene expression and a similar result was obtained from a 10xStat92E-luc reporter
assay, indicating that kayak is a potential negative regulator of Stat92E-mediated gene
expression. To find out if the effect was conserved in humans, a similar experiment with
an RNAi against the closest mammalian homolog, FosB, was conducted in human HeLa
cells, but this yielded an opposite outcome (Fig. 7).
80
6.2 Sumoylation in the regulation of transcription factor activity
Sumoylation is a post-translational modification with diverse consequences on the fate of
target proteins. To date numerous transcription factors have been reported to be regulated
through sumoylation, among these the human STAT1 and murine STAT5 transcription
factors (Rogers et al. 2003, Ungureanu et al. 2003, Van Nguyen et al. 2012). In both
cases sumoylation was found to repress the activity of these transcription factors. Despite
intensive studies, in most cases the molecular mechanisms for how SUMO conjugation
alters the activity of a transcription factor are yet to be described. In many cases SUMO
conjugation is associated with the recruitment of repressor proteins such as HDACs or
protein repressor complexes to the sumoylated substrates, like has been reported for
p300, Elk-1 and liver-enriched transcription-activating protein-1 (LAP-1) (Girdwood et
al. 2003, Yang and Sharrocks 2004, Wang et al. 2008).
In both mammals and in Drosophila the activity of the transcription factor Sp3 is strongly
inhibited by the SUMO modification (Sapetschnig et al. 2002, Stielow et al. 2008). An
RNAi-based genome-wide screen in Drosophila Kc167 cells revealed that Drosophila Sp3
is downregulated by a repressor complex, which is attracted by the Sp3 conjugated
SUMO. This complex was found to be composed of MEP-1, Mi-2 and Sfmbt, which
were found to interact with each other and SUMO (Stielow et al. 2008). This study shows
that like in mammals, sumoylation dependent chromatin-associated transcriptional
repression complexes are also present in insects.
In addition to mediating or interrupting transcription factor-protein interactions, SUMO
conjugation may also affect other post-translational modifications such as
phosphorylation or acetylation, like is the case for murine STAT5 (Van Nguyen et al.
2012). Sumoylation has also been reported to alter the subcellular localization of some
transcription factors (Gill 2005).
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6.3 SUMO as a regulator of STAT-mediated gene expression
Like its mammalian counterparts STAT1 and STAT5, Drosophila Stat92E too was found
to be a target for SUMO modification. While the SUMO acceptor lysine 701 in STAT1 is
located in the transactivation domain, just two amino acids from the indispensable
phosphorylation site, tyrosine 701, the sumoylation consensus sequence in Stat92E falls
within the predicted coiled-coil domain region in the N-terminus of the protein. Although
SUMO seems to inhibit both of these transcription factors, the molecular mechanism may
be completely different.  STAT1 sumoylation has been under intensive research from the
day it was discovered. Recent studies suggest that sumoylation and tyrosine 701
phosphorylation are mutually exclusive modifications, regulating STAT1 partitioning
between active and inactive states (Jakobs et al. 2007, Zimnik et al. 2009, Begitt et al.
2011, Droescher et al. 2011a). Analysis of the crystal structure of DNA bound STAT1
and STAT3 homodimers revealed that the coiled-coil domain consists of four ?-helices
pointing out from the STAT core structure (Becker et al. 1998, Chen et al. 1998). The
coiled-coil domain of mammalian STATs is known to mediate protein interactions and
participates in the nuclear export of STATs (Horvath et al. 1996, Begitt et al. 2000,
Mowen and David 2000). The function of the Stat92E coiled-coil domain or the Stat92E
crystal structure has not been studied, but it is possible that the coiled-coil domain of
Stat92E shares similar features with the mammalian STATs and is well exposed to
protein-protein interactions. Thus it is likely that conjugated SUMO (called Smt3 in
Drosophila) may interfere with the molecular interactions of Stat92E and proteins, such
as transcriptional co-activators, in the nucleus. Another possibility is that SUMO recruits
transcriptional repression complexes to the Stat92E-bound promoter site, like has been
reported for the sumoylated Drosophila transcription factor Sp3 (Stielow et al. 2008).
The IFN-?-induced nuclear localization of the sumoylation deficient human STAT1 has
been reported to be prolonged compared to wild type STAT1 (Ungureanu et al. 2005).
We studied if the sumoylation abolishing K187R mutation in Stat92E affected the
localization of Stat92E upon Upd or pervanadate induction, but there was no difference in
the cytoplasmic versus nuclear localization of WT Stat92E and Stat92E K187R in these
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experiments (data not shown). However, studying the time-dependent localization of a
transcription factor is technically challenging due to lack of cytokines whose amount and
timing can be controlled when used to activate the Drosophila JAK/STAT pathway.
Sumoylation has been suggested to increase the solubility of STAT by suppressing its
paracrystal assembly in the nuclei of cytokine stimulated cells (Droescher et al. 2011a).
Whether the tyrosine phosphorylated Stat92Es also have a tendency to polymerize into
nuclear paracrystals has not been studied. The possible role of paracrystallization in
Stat92E-mediated signaling and the role of sumoylation in this process are interresting
questions for further studies.
The effect of sumoylation on Stat92E DNA binding was not studied. The coiled-coil
domain of STATs is not thought to participate directly in promoter binding. The crystal
structures of DNA bound STAT1 and STAT3 homodimers support this notion by
proposing that coiled-coil domains point out from the complex without being in contact
with the DNA (Becker et al. 1998, Chen et al. 1998). Thus it is unlikely that SUMO
attachment to the coiled-coil domain would directly interfere with STATs ability to bind
DNA. Still, this does not rule out the possibility that attaching SUMO to the coiled-coil
domain changes the molecular structure of Stat92E in a way that leads to altered DNA
binding of the dimerized Stat92E. Although it is not likely that SUMO conjugation to the
N-terminal coiled-coil domain of Stat92E would affect the phosphorylation of Tyr711 or
block the phospho-tyrosine-SH2 domain mediated dimerization of activated Stat92Es,
these possibilities should also be addressed in future studies.
Targeting dPias with RNAi enhanced TotM-luc expression, supporting previously
published data that dPias negatively regulates Stat92E (Betz et al. 2001). RNAi against
Stat92E 3’-UTR, which was used as a positive control in the experiment, caused a
significant decrease in HopTum-l-induced TotM-luc expression. Interestingly, transfection
of Stat92E 3’-UTR dsRNA into the S2 cells increased the basal level of TotM-luc
expression (I, Fig. 3C). It has been suggested that Turandot stress genes are not entirely
under the control of the JAK/STAT pathway, but are cooperatively regulated by the
JAK/STAT and Imd pathways together with the MAPK kinase kinase (MAPKKK)
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Mekk1 (Brun et al. 2006). Most likely, the expression of TotM-luc is induced through
these additional pathways in response to the Stat92E 3’-UTR dsRNA transfection.
Although the Pias proteins have been shown to induce the sumoylation of human STAT1
(Rogers et al. 2003, Ungureanu et al. 2003), we did not observe a difference in the
sumoylation of Stat92E in dPias dsRNA and GFP control dsRNA treated S2 cells.
Although this data indicates that dPias is not indispensable for SUMO conjugation to
Stat92E, further dPias overexpression studies would clarify if dPias can promote Stat92E
sumoylation.
In original communication I, Stat92E was shown to be sumoylated on Lys187 and a
sumoylation deficient K187R mutant showed increased transcriptional activity compared
to wild type Stat92E on two independent Stat92E responsive promoters. This difference
was only detected when the JAK/STAT pathway was activated with Upd overexpression.
In summary, these data suggest that activated Stat92E is inhibited by sumoylation, but the
molecular mechanism remains enigmatic.
6.4 Genome-wide screens to identify genes that regulate the activity of the
JAK/STAT pathway
We characterized two novel components of the Drosophila JAK/STAT pathway, ET and
Not4. ET was shown to inhibit Upd-induced Stat92E tyrosine phosphorylation causing
repressed target gene expression and Not4 was suggested to enhance Stat92E DNA
binding to the TotM promoter. Furthermore, the mammalian homologue of Not4, CNOT4
was shown to be involved in STAT1- and STAT6-mediated reporter gene expression in
human cells. Both genes were found in an RNAi-based genome-wide screen carried out
in Drosophila S2 cells. Two similar RNAi based screens for novel JAK/STAT pathway
associated factors have been published earlier (Baeg et al. 2005, Müller et al. 2005).
Although the basic approach in all of the screens was similar, including the use of a
luciferase-reporter assay to monitor pathway activity, there was a huge divergence in the
findings.  Only enok was found in all of the three screens. The differences may be caused
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by several variables. The cell lines used in the screens were different: we used S2 cells,
while Baeg et al. used a derivative of S2 cells, a cell line called S2-NP and Müller et al.
used Kc167 cells in their screen. Also the assay design varied between the screens. The
luciferase reporter was different in all of the screens: while we used the TotM-luc
reporter, Baeg et al.  had  a 10xStat92E-luc construct, and Müller et al. monitored the
activity of the 6x2xDraf-luc, a reporter construct that contains six repeats of a 165 bp
fragment with two Stat92E binding sites from the promoter of the Stat92E target gene
raf. One significant difference between the screens was the mechanism of pathway
activation. S2-NP cells used by Baeg et al. express sufficient levels of endogenous Upd2
to activate the JAK/STAT pathway, while Müller et al. stimulated  the  pathway  by
overexpressing Upd, and we activated the pathway through the forced expression of a
constitutively active HopTum-l. There was also variation in induction and RNAi times
between the conducted screens: the S2-NP cells in the screen of Baeg et al. were lysed 96
hours posttransfection, Müller et al. used incubation time of 5 days (120 hours),  while in
our screen reporter activities were measured 72 hours after transfections. In addition,
different normalization approaches may add divergence to the outcome (Baeg et al. 2005,
Müller et al. 2005, Müller et al. 2008).
CG14225/ET RNAi was first found to decrease TotM-luc activity upon HopTum-l
induction, but interestingly, the opposite effect was observed in a more physiological
context when the pathway was activated with the Dome ligand Upd. Our further
biochemical studies revealed that ET downregulates Upd-induced Stat92E
phosphorylation, thus functioning as a negative regulator of the Drosophila JAK/STAT
pathway. Soon after we had published our article, another research group demonstrated
that ET (called Latran in their study) controls the JAK/STAT pathway-mediated cellular
immune response in the larval lymph gland (Makki et al. 2010). They too showed that
ET/Latran is a class I cytokine receptor-related protein, which is able to form heteromers
with Dome and can inhibit downstream Stat92E activation. Their study confirms the
importance of ET in the regulation of Drosophila immune signaling.
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The molecular mechanism for how ET regulates Stat92E phosphorylation still remains to
be explained, but a few posibilities can be envisioned. ET is a transmembrane protein
with a putative cytokine binding module in its extracellular domain. Therefore, one
possibility would be that ET functions as a decoy receptor on the cell surface, inhibiting
Upd binding to its normal receptor Dome. Evidence that short receptor variants may act
as dominant negative receptors has also been reported for the mammalian system, like in
the case of porcine prolactin signaling (Trott et al. 2011). According to our data, ET does
not affect Dome homodimerization or interfere with interaction between Hop and Dome,
instead ET was found to co-immunoprecipitate with both Hop and Dome. Thus it is
possible that ET forms complexes with Hop and Dome at the plasmamembrane. Through
its interactions with Dome, ET may directly disrupt Upd binding to Dome, or cause
conformational changes in Dome upon Upd binding leading to disturbances in Hop
activation.
STAT activation is mediated through tyrosine phosphorylation following dimerization
and translocation to the nucleus where STAT dimers bind DNA in order to activate the
transcription of STAT responsive genes (Schindler 1999).  STATs are not able to initiate
transcription on their own. Instead, interactions with other co-activators and regulatory
proteins are needed. This cooperation then leads to the recruitment and activation of the
RNA polymerase and transcriptional apparatus. STAT coregulators have been mainly
studied in mammalian systems, but similar factors are also likely to be present, at least to
some extent, in Drosophila cells.
Not4 was shown to be important for JAK/STAT pathway mediated signaling. According
to our co-immunoprecipitation experiments, Not4 interacts with Stat92E and Upd
overexpression enhances this interaction. Interestingly, Upd-induction also increased the
total amount of Not4 protein expressed by a methallothionein promoter. Of note, Stat92E
RNAi decreased Not4 protein levels in pMT-Not4-V5 overexpressing cells (data not
shown). Therefore it is possible that Upd-induction stabilizes the Not4 protein Stat92E-
dependently, rather than enhances the expression of Not4. Furthermore, we found that
Not4 was essential for optimal Stat92E DNA binding, but it did not influence the
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phosphorylation status of Stat92E. The exact molecular mechanism for how Not4 affects
Stat92E DNA binding or expression of Stat92E responsive genes still remains elusive,
but it is possible that Not4 is a component of the Stat92E enhanceosome complex.
Drosophila Not4, like its human homologue CNOT4, associates with a multifunctional
Ccr4-Not complex, but is not a stable component of the complex (Lau et al. 2009,
Temme et al. 2010). The Ccr4-Not complex, which has been mainly studied in yeast,
participates in many cellular events including DNA repair, histone methylation,
transcription elongation and initiation as well as mRNA degredation through poly-A tail
deadenylation (Bianchin et al. 2005, Mulder et al. 2005, Laribee et al. 2007, Mulder et al.
2007).  Furthermore, the N-terminal RING domain of CNOT4 has been reported to act as
a Ubiquitin E3 ligase, and is essential for the regulation of histone methylation through
polyubiquitintion of the demethylase Jhd2 (Laribee et al. 2007, Mersman et al. 2009).
Our results indicated that the RING domain of Drosophila Not4 is not needed for
JAK/STAT signaling, whereas the C-terminal part of Not4 was found indispensable (III,
Fig. 4). The C-terminal part of Not4 does not contain any known functional domains,
thus further studies are needed in order to reveal its mechanistic role in the regulation of
Stat92E-mediated signaling. Whether Not4/CNOT4 participates in the regulation of the
JAK/STAT pathway regulation on its own or as a part of the Ccr4-Not complex, also
remains to be investigated.
This study revealed three novel mechanisms for regulating the Drosophila JAK/STAT
signaling cascade: sumoylation of Stat92E, ET, which negatively regulates Stat92E
phosphorylation and a positive regulator Not4, which is needed for proper Stat92E DNA
binding. The mammalian homologue of Not4, CNOT4, was also found to participate in
JAK/STAT signaling in human cells. This demonstrates that mechanisms found in
Drosophila can be conserved in mammalian cells. The  main  findings  of  this  thesis  are
recapitulated in Figure 9, wherein they are referred to their corresponding original
communications with the Roman numerals.
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Figure  9.  The  main  findings  of  this  thesis  (I-III)  and  the  regulators  of Drosophila
JAK/STAT signaling. Sumoylation of Stat92E was found to inhibit JAK/STAT pathway
target gene transcription (I). ET negatively regulates Upd-induced Stat92E tyrosine
phosphorylation (II). Not4 interacts with Stat92E and is required for proper Stat92E DNA
binding (III).
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7. Conclusions
Our immune system constantly protects us from microbial challenge. In order to function
properly it relies on a sophisticated signaling system, in which soluble signaling
molecules, cytokines, play a crucial role. The JAK/STAT pathway transduces signals of
numerous cytokines and growth factors essential for various cellular functions. To
maintain cellular homeostasis, the activity of the JAK/STAT signaling pathway needs to
be under strict control. During the past decade, a growing number of studies have
confirmed that the JAK/STAT signaling cascade in Drosophila is regulated through
mechanisms similar to the mammalian system. This thesis was aimed at exploring novel
regulatory mechanism of the JAK/STAT pathway using Drosophila melanogaster as  a
model organism.
Like its mammalian counterparts STAT1 and STAT5, Drosophila Stat92E was found to
be a target for SUMO conjugation (original communication I). Further studies revealed
that sumoylation inhibits Upd-induced Stat92E target gene expression. Protein post-
translational modifications, such as phosphorylation, ubiquitination and other ubiquitin-
like modifications, like sumoylation, play a major role in the regulation of the
intracellular signal transduction cascades of the immune system. These modifications can
have diverse effects on their targets. The same modification to a target protein may have
completely different consequences for target protein behaviour, depending on the
position of the acceptor amino acid in the target protein.  Like in case of JAKs, tyrosine
phosphorylation is known to be essential for the regulation of kinase activity. This
regulation may be either positive or negative, depending on the phosphorylation site
within the protein. Sumoylation and ubiquitination are closely related post-translational
modifications, and both are associated with the downregulation of the JAK/STAT
pathway (Ungureanu et al. 2005, Ungureanu and Silvennoinen 2005). In some cases the
effects of these modifications may be completely opposite. Ubiquitination plays an
indispensable role in the activation of the Nf-?B cascades. In the canonical model for the
Nf-?B pathway, the activation of Nf-?B transcription factors requires the ubiquitin-
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proteasome system-mediated degradation of inhibitor of kappaB protein (I?B).
Ubiquitination of I?B is preceded by I?B kinase (IKK) complex-mediated serine
phosphorylation of the I?B, and the activation of this protein complex is dependent on the
K68-linked polyubiquitination of its regulatory subunit NEMO (Liu and Chen 2010).
Both SUMO and Ubiquitin are covalently linked to specific lysine residues within their
target  proteins.  This  enables  SUMO  and  Ubiquitin  to,  in  some  cases,  compete  for  the
same binding sites, thus having antagonistic effects on the target protein. The interplay of
post-translational modifications has a major role in the regulation of human STAT1
activation, as the sumoylation of Lys703 and the phosphorylation of Tyr701 have been
suggested to be mutually exclusive modifications. In addition, Ser727 phosphorylation
has a role in both the sumoylation and transcriptional activation of STAT1. Although the
molecular mechanism for how sumoylation inhibits Stat92E-mediated signaling remains
unknown, the Drosophila system offers an excellent model for future studies on the
physiology of sumoylation in the regulation of the JAK/STAT pathway.
ET and Not4 were characterized as novel JAK/STAT pathway regulators from a genome-
wide RNAi screen in Drosophila S2 cells. We found that ET is a transmembrane protein
that negatively regulates Upd-induced Stat92E tyrosine phosphorylation. This finding
opens up a completely new chapter in the regulation of JAK/STAT signaling. The
experiments described in original communication II were conducted only in Drosophila,
raising the question if a similar regulatory mechanism is also present in mammalian
signaling systems. In addition to the negative regulators studied in this thesis, we studied
Not4, which was found to function as a positive regulator of JAK/STAT-mediated gene
expression in Drosophila as well as in mammalian cell line (original communication III).
The RING domain of Not4 was found dispensable for Stat92E target gene expression.
This indicates that the function of Not4 in JAK/STAT signaling is not, at least directly,
based on Ubiquitin transfer. As Not4 was found to interact with Stat92E, it is possible
that it mediates interactions between Stat92E and other proteins such as transcriptional
coregulators or RNA polymerase II, which has been reported to interact with the Ccr4-
Not complex in yeast. Although our experimental data suggest that Not4 regulates
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Stat92E DNA binding, the exact molecular mechanism for how Not4 is utilized for
STAT-mediated signaling requires further studies.
This study has added two complitely novel components, ET and Not4, to the Drosophila
JAK/STAT pathway, revealing the complexity of this signaling cascade. The discovery
that SUMO has an evolutionary conserved role in the regulation of the JAK/STAT
pathway verifies the importance of this post-translational modification in cytokine
signaling. The findings of this thesis further demonstrate that Drosophila can be utilized
as a model organism to study complex signaling cascades. The present study provides
new aspects for further studies for solving the puzzles of cytokine signaling in
immunology.
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 Introduction 
 The JAK/STAT pathway is highly conserved in the 
evolution from invertebrates to humans. The JAK/STAT 
signaling cascade is essential for several biological pro-
cesses, including the control of  hematopoiesis and im-
mune responses, as well as for cellular homeostasis and 
embryonic development  [1, 2] . The human JAK/STAT 
pathway consists of 7 STATs and 4 JAKs  [3] . In  Drosoph-
ila melanogaster, the pathway employs only a single Janus 
kinase Hopscotch (Hop) and the transcription factor 
STAT92E as well as the receptor Domeless (Dome)  [2] , 
thus making  Drosophila a useful non-redundant model 
to study this pathway.
 The activation mechanism of the JAK/STAT pathway 
is shared by invertebrates and humans. In  Drosophila,  3 
secreted ligands (Unpaired 1–3, Upd1–3)  [4–6] induce the 
homodimerization of the Dome receptors allowing the 
Hop kinases to phosphorylate tyrosine residues in the re-
ceptors, thus creating docking sites for the SH2 domain 
of STAT92E. Following the interaction with Dome, 
STAT92E becomes phosphorylated by Hop, leading to 
the homodimerization and nuclear translocation of 
STAT92E. In the nucleus, STAT92E binds to its target 
DNA sequences and acts as activator of transcription for 
 Key Words 
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 Abstract 
 STAT92E is an essential transcription factor in  Drosophila me-
lanogaster for the development of several organs and the 
immune system. The JAK/STAT pathway employs different 
evolutionary conserved regulatory mechanisms to control 
biological processes. Numerous transcription factors in both 
mammals and invertebrates have been shown to be either 
activated or inhibited by a covalent modification with a small 
ubiquitin-like modifier (Sumo). Here, we show that  Drosoph-
ila STAT92E is modified by Sumo at a single lysine residue 187 
in S2 cells. Mutation of Lys187 increases the transcriptional 
activity of STAT92E, thus suggesting that sumoylation of 
STAT92E has a repressive role in the regulation of the JAK/
STAT pathway in Drosophila melanogaster. 
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several target genes such as  Tep 2 and  Turandot stress 
genes  [1, 7] .
 Cellular homeostasis requires tight regulation of the 
JAK/STAT signaling cascade, and deregulation or dis-
turbances of the pathway are associated with or cause 
several human diseases such as myeloproliferative dis-
eases, cancer, immune deficiencies, autoimmunity and 
allergy  [8–10] . In  Drosophila, deregulation of the JAK/
STAT pathway causes overproliferation of plasmato-
cytes, tumor formation and developmental abnormali-
ties  [2, 11] . The basic regulatory mechanisms of the JAK/
STAT pathway appear to be well conserved between  Dro-
sophila  and mammals. Previously known negative regu-
lators of the  Drosophila JAK/STAT pathway include a 
family of SOCS-like  Drosophila genes, dPIAS, also 
known as Zimp or Su(var)2–10, Ptp61F (protein-tyrosine 
phosphatase 61F) and an N-terminally truncated form of 
STAT92E (  NSTAT92E)  [12–15] . Transcriptional activ-
ity of STAT92E is inhibited by direct interaction with 
dPIAS, and the correct dPIAS/STAT92E ratio is crucial 
for normal hematopoiesis and organogenesis in  Dro-
sophila  [13] . PIAS1 was initially shown to interfere with 
the promoter-binding activity of tyrosine-phosphorylat-
ed STAT1 in mammals  [16] . PIAS1 functions also as an 
E3 ligase for small ubiquitin-like modifier (Sumo), and 
STAT1 was identified as a substrate for PIAS1-induced 
sumoylation. Sumoylation of STAT1 has an inhibitory 
effect on STAT1-mediated transcriptional activation  [17, 
18] .
 Several transcription factors in mammals as well as in 
 Drosophila are regulated by sumoylation. Sumoylation is 
a reversible post-translational modification in which a 
Sumo moiety is covalently conjugated to the lysine resi-
dues on target proteins through a process analogous to 
ubiquitination. The sumoylation pathway is conserved in 
all eukaryotic organisms and consists of E1-activating 
enzymes, E2-conjugating enzymes and E3 ligases as well 
as of the family of the Sumo cleaving proteases  [19, 20] . 
The Sumo conjugation pathway is less redundant in in-
vertebrates; for example, in vertebrates, 4 Sumo variants 
(Sumo 1–4) are present, while  Drosophila expresses only 
1 Sumo ortholog known as Smt3  [19] . Sumoylation can 
affect target proteins by multiple mechanisms, altering 
their subcellular localization, molecular interactions, sta-
bility or the enzymatic activity of the proteins  [20] . At the 
transcriptional regulation level, sumoylation is mostly 
associated with the repression of gene expression. The 
mechanism of Sumo-mediated transcriptional inhibition 
is often associated with the recruitment of various chro-
matin-modifying or -associated proteins or protein com-
plexes  [21] . For example, the transcriptional activity of 
 Drosophila Sp3 is inhibited by sumoylation-mediated re-
cruitment of a repression complex formed by MEP-1, 
Mi-2 and Sfmbt  [22] . This study aims to investigate 
whether sumoylation is involved in the regulation of the 
JAK/STAT pathway in  Drosophila. 
 Methods 
 Antibodies and Reagents  
 The following antibodies were used: anti-Flag M2 (Sigma-
Aldrich); anti-influenza hemaglutinin (HA) epitope antibody 
(Covance); anti- Drosophila STAT92E-N-terminus (dN-17; San-
ta Cruz); biotinylated anti-mouse (DakoCytomation, Glostrup, 
Denmark) and biotinylated anti-goat (DakoCytomation). Al-
so, streptavidin-biotin horseradish peroxidase conjugate (GE-
Healthcare), protein G sepharose (GE-Healthcare) and N-ethyl-
maleimide (Sigma-Aldrich) were used.
 Plasmid Constructs 
 STAT92E  (clone RE14194) was obtained from the Drosophila 
Genomics Resource Center (Indiana University, Bloomington, 
Ind., USA) and amplified by PCR using 5  -primer containing 
Not1 site and 3  -primer containing Flag epitope tag and Pme1
restriction site.  STAT92E was cloned into a pMT/V5-HisA ex-
pression vector (Invitrogen). PCR-amplified C-terminally Flag-
tagged  STAT92E was also cloned into Not1 and Kpn1 sites of the 
pcDNA3.1(–) expression vector. The pMT-STAT92E K187R-Flag 
was created by PCR mutagenesis with the following primers: 5  -
GGTATGGTCACACCCAGGGTGGAHCTGTACGAG-3  and 
5  -CTCGTACAGCTCCACCCTGGGTGTGACCATACC-3  . Su-
mo-1-Flag and Sumo-1-Flag-Flag were a kind gift from Dr. H. 
Yasuda. Senp1-Flag, Senp1 C603S, Sumo-1 GA-His and Sumo-1-
His as well as Sumo-3-HA were provided by Prof. J. Palvimo,  Tu-
randot M-luciferase  (TotM - luc),  Actin 5C-  -galactosidase report-
ers and Hop-Tum-l were provided by Prof. J.-L. Imler. Smt3-HA 
plasmid was a kind gift from Dr. A.J. Courey.  10xSTAT-luciferase 
reporter plasmid was a kind gift from Dr. E. Bach, and pMT-Upd 
plasmid was kindly provided by Dr. Michael Boutros.
 Cell Culture, Transfection and Immunodetection 
 Cos-7 cells were cultured at 37  °  C in Dulbecco’s modified Ea-
gle’s medium supplemented with 10% (vol/vol) fetal bovine se-
rum, 100 U/ml penicillin and 50 mg/ml streptomycin. S2 cells 
were cultured at 25  °  C in Schneider medium (Sigma-Aldrich) sup-
plemented with 10% (vol/vol) FBS, 100 U/ml penicillin and 50 mg/
ml streptomycin. Cos-7 cells (5  ! 10 6 ) were transfected by elec-
troporation with a total amount of 3.0   g plasmid DNA using 
Bio-Rad gene-pulser at 260 V and 960   F. Cells were lysed in 1% 
Triton X lysis buffer containing 5 m M N-ethylmaleimide  [17] . One 
milligram of protein from total cell lysates was subjected to im-
munoprecipitation, SDS-PAGE electrophoresis and Western blot-
ting as previously described  [17] . Approximately 1.5  ! 10 7 S2 cells 
were transfected with a total amount of 10   g DNA using poly-
ethyleneimine  [23] . Two hours after transfection, the medium was 
changed to a fresh medium containing 10   g of  STAT92E 3  -UTR 
 dsRNA to inhibit the expression of endogenous STAT92E, and 
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500   M  CuSO 4 to induce the expression of the pMT vector. The 
cells were lysed after 72 h and immunoprecipitations were carried 
out as described  [17] .
 RNA Interference 
 For RNA interference (RNAi) assay with endogenous 
STAT92E, double-stranded DNA was synthesized from the cDNA 
of the 3  -UTR of  STAT92E  using 2-step PCR with nested primers, 
the second primers containing a T7 promoter sequence at the 5  
end.  STAT92E 3  -UTR  dsRNA was synthesized from the product 
of the second PCR with the T7 MegaScript RNA polymerase (Am-
bion), according to the manufacturer’s instructions. dPIAS and 
GFP dsRNAs were created as above, but the PCR primers were 
designed in the middle of the protein coding sequence of the 
genes. dsRNAs were added to S2 culture medium 72 h prior to cell 
lysis.
 Luciferase Assay 
 S2 cells (1.0  ! 10 6 ) were transfected with 0.1   g  TotM-luc re-
porter plasmid or with 0.001   g  10xSTAT-luciferase reporter plas-
mid simultaneously with 0.1   g  Actin 5C-  -galactosidase, with or 
without 0.1   g pMT-Upd and with either 0.2   g empty pMT vec-
tor, pMT-STAT92E or pMT-STAT92E K187R using Fugene 6 
transfection reagent, according to the manufacturer’s instruc-
tions (Roche). CuSO 4 (500   M ) was added to the medium 24 h 
after transfection to induce the expression of the pMT vector. 
Cells were lysed after 72 h with reporter lysis buffer (Promega), 
according to the manufacturer’s instructions. The luciferase val-
ues were normalized against   -galactosidase values. 
 Results 
 STAT92E Is Modified by Sumo in Mammalian Cells  
 In order to investigate if  Drosophila STAT92E is a tar-
get for sumoylation, the initial experiments were per-
formed in mammalian Cos-7 cells with well-defined 
mammalian components of the sumoylation pathway. 
Cells were transfected with Flag-tagged STAT92E alone 
or together with Flag-tagged human Sumo-1, or tandem 
Flag-tagged human Sumo-1, or HA-tagged human Sumo-
3. Cell lysates were immunoprecipitated with anti-Flag 
antibody, and anti- Drosophila  STAT92E-N-terminal an-
tibody was used in immunoblotting. Anti-STAT92E anti-
body detected protein bands corresponding to the mo-
lecular mass of STAT92E ( fig.  1 a). In addition, slower
migrating bands were detected when STAT92E was
expressed together with Sumo-1 or Sumo-3, indicating 
that these bands are STAT92E-Sumo-1/3 conjugation 
complexes. The band shift of the slower migrating band 
with tandem Flag-tagged Sumo-1 compared with single 
Flag-tagged Sumo-1 corresponds to the size of a Flag-tag, 
showing that the upper bands are STAT92E-Sumo-1 
bands. The STAT92E-Sumo-1/3 complex is a branched 
chain molecule, and thus, its migration in the SDS-PAGE 
gel is abnormal, creating bands of approximately 116 kDa.
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 Fig. 1. STAT92E is sumoylated in Cos-7 cells.  a Sumoylation of 
STAT92E in Cos-7 cells by human Sumo-1 and human Sumo-3. 
Cos-7 cells were transiently transfected with STAT92E-Flag with 
or without different Sumo constructs as indicated. Cells were 
lysed 48 h after transfection. Equal amounts of lysates were
immunoprecipitated by using anti-Flag antibody, followed by 
SDS-PAGE and immunoblotting with anti-STAT92E antibody.
 b Senp1 desumoylates STAT92E. Cos-7 cells were transfected 
with STAT92E-Flag together with Sumo-1-His or Sumo-1 GA-His 
as indicated and with Senp1 or with catalytically inactive Senp1 
C603S. Cell lysis, immunoprecipitations and immunoblotting 
were carried out as described above. IP = Immunoprecipitation; 
WB = Western blot. 
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 To obtain further proof that the slower migrating 
STAT92E proteins are sumoylated, we investigated if the 
Sumo-specific protease Senp1 could remove Sumo mol-
ecules from STAT92E and subsequently eliminate the 
slower migrating bands. Cos-7 cells were transfected with 
STAT92E and His-tagged Sumo-1 constructs with or 
without Senp1 expression constructs. A catalytically in-
active mutant Senp1-C603S and a conjugation-deficient 
mutant of Sumo-1 (Sumo-1 GA-His) were used as con-
trols  [24] . As shown in  figure 1 b, expression of Senp1 
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LinkerDNA binding1 TAD
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+
–
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+
+
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–
+
c WB: anti-STAT92E
3-UTR dsRNA
STAT92E WT-Flag
+
–
–
–
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*
 Fig. 2. STAT92E is sumoylated at lys187.
 a Schematic domain structure of STAT92E 
based on sequence comparison with mam-
malian STATs. Amino acid sequence of the 
Sumo consensus site in the coiled coil do-
main is indicated. The Sumo consensus se-
quence is not complete in the C-terminal 
site, although it resembles the human 
STAT1 sumoylation site (Tyr711 is the crit-
ical phosphorylation site in the activated 
STAT92E).  b The K187R mutation abro-
gates sumoylation of STAT92E. S2 were 
transiently transfected with STAT92E 
WT-Flag or STAT92E K187R-Flag with or 
without Smt3-HA as indicated. Two hours 
after transfection, 10   g of  STAT92E 3  -
UTR  dsRNA was added to the medium to 
inhibit the expression of the endogenous 
STAT92E. Equal amounts of lysates were 
immunoprecipitated by using anti-Flag or 
anti-STAT92E-N-terminal antibodies fol-
lowing SDS-PAGE and immunoblotting 
with anti-STAT92E-N-terminal and anti-
HA antibodies.  c Effect of RNA interfer-
ence on endogenous STAT92E levels in S2 
cells by double-stranded RNA targeted on 
 STAT92E 3  -UTR. dsRNA was added to 
cells 2 h after DNA transfection. Unspe-
cific bands are marked with an asterisk.
IP = Immunoprecipitation; WB = Western 
blot. 
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abolished the protein band corresponding to Sumo-1 
conjugation of STAT92E, while the expression of Senp1-
C603S slightly increased the amount of sumoylated 
STAT92E. The Sumo-1 GA-His mutant was not attached 
to STAT92E, thus confirming the specificity of the con-
jugation reaction. Sumo-1-His and Sumo-1 GA-His ex-
pression levels were detected (data not shown). These re-
sults suggest that  Drosophila STAT92E can be sumoylat-
ed in cells. 
 STAT92E Is Sumoylated in Drosophila S2 Cells on 
Lysine 187 
 Next, we wanted to study if STAT92E is sumoylated 
also in a more physiological environment and  Drosophila 
S2 cells were used. Sumo is conjugated to a lysine residue 
in target proteins most often within a consensus sequence 
site,   KxE/D, where   is a large hydrophobic amino acid 
 [20] . The protein sequence analysis of STAT92E displays 
a single putative sumoylation site between amino acids 
186–189 (PKVE) ( fig. 2 a). To investigate if this is a Sumo- 
binding site in STAT92E, Lys187 was mutated to arginine. 
Flag-tagged STAT92E WT and Flag-tagged STAT92E 
K187R were transfected into  Drosophila  S2 cells with or 
without HA-tagged Smt3. The expression of the endoge-
nous STAT92E protein was inhibited using RNAi with 
 STAT92E 3  -UTR dsRNA ( fig. 2 c). S2 cell lysates were im-
0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
1.8
Re
la
tiv
e 
To
tM
-lu
c 
ac
tiv
ity
p < 0.05
pMT-V5-HisA STAT92E WT STAT92E K187R
Upd (–)
Upd (+)
a WB: anti-Flag
STAT92E
pMT-V5-HisA
STAT92E WT-Flag
STAT92E K187R-Flag
Upd
+
–
–
–
+
–
–
+
–
+
–
–
–
+
–
+
–
–
+
–
–
–
+
+
0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
Re
la
tiv
e 
10
xS
TA
T-
lu
c 
ac
tiv
ity
p < 0.05
pMT-V5-HisA STAT92E WT STAT92E K187R
Upd (–)
Upd (+)
b WB: anti-Flag
STAT92E
pMT-V5-HisA
STAT92E WT-Flag
STAT92E K187R-Flag
Upd
+
–
–
–
+
–
–
+
–
+
–
–
–
+
–
+
–
–
+
–
–
–
+
+
0
c
0.5
1.0
1.5
2.0
2.5
3.0
Re
la
tiv
e 
To
tM
-lu
c 
ac
tiv
ity
p = 0.05
GFP dsRNA dPIAS dsRNA STAT92E
3’-UTR dsRNA
Hop-Tum-l (–)
Hop-Tum-l (+)
 Fig. 3. K187R mutation increases STAT92E transcriptional activ-
ity.  a S2 cells were transiently transfected with the pMT-V5-HisA 
vector, STAT92E WT-Flag or STAT92E K187R-Flag together with 
 TotM-luc reporter and  Actin 5C-  -galactosidase with or without 
Upd to activate the JAK/STAT pathway. Twenty-four hours after 
transfection, 500   M CuSO 4 was added to the medium to induce 
expression of STAT92E and Upd from the pMT vectors. Seventy-
two hours after transfection, the cells were lysed with reporter 
lysis buffer and luciferase activities were measured and normal-
ized against   -galactosidase activities. The relative  TotM-luc ac-
tivity of Upd-induced STAT92E WT was set as one. Equal amounts 
of lysates were subjected to SDS-PAGE following immunoblotting 
with anti-Flag antibody in order to detect the expression of trans-
fected STAT92E WT and STAT92E K187R.  b K187R mutation 
increases STAT92E transcriptional activity on  10xSTAT-luc re-
porter. Transfections and lysis were carried out as in  a . The rela-
tive  10xSTAT-luc activity of Upd-induced STAT92E WT was set 
as one. Immunoblotts for cell lysates were carried out as described 
above.  c dPIAS RNAi increases  TotM-luc activity. S2 cells were 
transiently transfected with  TotM-luc reporter and  Actin 5C-  -
galactosidase  together with indicated dsRNAs and with or with-
out constitutively active Hopscotch (Hop-Tum-l) to activate the 
JAK/STAT pathway. Cells were lysed 72 h after transfection. Error 
bars indicate SEM, calculated from 3 independent transfections. 
WB = Western blot. 
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munoprecipitated with anti-Flag and anti-STAT92E an-
tibodies followed by Western blotting with anti-STAT92E 
and anti-HA antibodies. As shown in  figure 2 b, the 
K187R mutation abrogated the modification by Smt3, in-
dicating that Lys187 is the only sumoylation site in 
STAT92E. 
 K187R Mutation Increases STAT92E Transcriptional 
Activity 
 Sumoylation is known to regulate the activity of sev-
eral transcription factors, including human STAT1. 
Next, we wanted to study if sumoylation affects the tran-
scriptional activity of STAT92E. The transcriptional ac-
tivities of STAT92E WT and the sumoylation-deficient 
STAT92E K187R were analyzed in S2 cells using a re-
porter gene driven by the STAT92E-inducible stress gene 
 Turandot M  promoter. Expression of the Dome ligand 
Upd resulted in a 3-fold induction of transcription with 
endogenous JAK/STAT proteins. In the absence of Upd, 
the expression of both STAT92E WT and K187R induced 
transcription at similar levels, but upon Upd stimula-
tion, the sumoyl ation-deficient STAT92E mutant K187R 
showed a significantly higher level of transcriptional ac-
tivity ( fig. 3 a). Equal amounts of lysates were subjected 
to SDS-PAGE following immunoblotting with anti-Flag 
antibody to show that STAT92E WT and STAT92E 
K187R were expressed equally ( fig. 3 a, lower panel). To 
verify this observation, we used a reporter gene driven 
by a different STAT92E responsive element from the 
 SOCS36E enhancer region.  Figure 3 b shows that the 
STAT92E K187R mutant had an increased transcription-
al activity compared with STAT92E WT after Upd stim-
ulation with the  10xSTAT92E-luc reporter gene as well. 
Taken together, these results suggest that sumoylation 
has an inhibitory effect on STAT92E-induced gene ex-
pression. 
 Discussion 
 Sumoylation is a common posttranslational modifica-
tion for transcription factors, which in most cases has an 
inhibitory effect on transcription. In this study, we dem-
onstrate that STAT92E is subject to Sumo modification 
and that sumoylation appears to play a negative regula-
tory role in the  Drosophila JAK/STAT pathway. 
 Sumoylation has been challenging to study due to the 
highly dynamic and reversible nature of the modification 
resulting in low cellular levels of Sumo-modified pro-
teins. Also, the Sumo-modified fraction of STAT92E
was notably smaller than the unmodified STAT92E, and 
overexpression of STAT92E and Sumo was needed to
detect the Sumo-modified STAT92E. The results with 
Senp1 coexpression are in line with the specificity of 
Sumo conjugation. Sumo is deconjugated very rapidly by 
Sumo-specific proteases, and expression of the inactive 
Senp1-C603S resulted in increased levels of STAT92E su-
moylation, possibly due to competitive inhibition of en-
dogenous Senps.
 STAT92E was found to become sumoylated at Lys187. 
Human STAT1 is sumoylated at Lys703, which is local-
ized in the C-terminus close to the phosphorylated acti-
vating Tyr701 residue  [17] .  Drosophila STAT92E has a ly-
sine in a similar position (Tyr711-Lys713), but mutation 
of this lysine did not alter the amount of sumoylation 
when compared with STAT92E WT (data not shown). 
Thus, Lys187 appears to be the only sumoylation site in 
STAT92E. This lysine is not conserved in mammalian 
STATs, but there is a putative Sumo consensus site found 
at least in the coiled coil domain of human STAT2 
(Lys234). Sumoylation of human STAT2 has not been re-
ported. 
 Mutation of Lys187 resulted in increased transcrip-
tional activity of STAT92E, suggesting that sumoylation 
has an inhibitory effect on STAT92E. Removal of endog-
enous Sumo E3 ligase dPIAS by dsRNA increased the 
STAT92E activity on  TotM promoter approximately to 
the same level as K187R mutation in STAT92E ( fig. 3 c), 
suggesting that sumoylation of STAT92E is involved in 
dPIAS-mediated inhibition of STAT92E.
 The mechanisms of how sumoylation is affecting 
STAT92E are presently unknown, but several possible 
mechanisms can be envisioned. The sumoylation site 
Lys187 is localized in the coiled coil domain, which in 
the mammalian system is involved in nuclear transport 
of STATs. The coiled coil domain of STATs is composed 
of 4   -helixes that are pointing out from the DNA-bound 
STAT dimer, forming a hydrophilic surface able to in-
teract with other molecules  [9] . Thus, sumoylation of 
Lys187 may interrupt the interaction between STAT92E 
and its transcriptional coregulators or the proteins in-
volved in its nuclear translocation. Alternatively, su-
moylation may lead to the recruitment of histone deacet-
ylases to the promoter or allow the interaction with a 
transcription repression complex similarly to  Drosophi-
la  Sp3  [22] . The effect of sumoylation on DNA-binding 
properties of STAT92E was not analyzed, but the coiled 
coil domain is not contacting DNA, suggesting that di-
rect effects upon the promoter-binding activity are less 
likely. 
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 In the mammalian system, sumoylation has been im-
plicated in the regulation of interferon-induced gene re-
sponses. STAT1 and other coregulatory proteins have 
been shown to become sumoylated  [25] , but the physio-
logical role of this modification remains to be revealed. 
The sumoylation pathway is well conserved during evolu-
tion and the lower redundancy of the  Drosophila system 
provides a useful system for functional and mechanistic 
analysis of the pathway. Our findings that STAT92E is 
subject to Sumo modification imply that the  Drosophila 
system can now be utilized to investigate the physiologi-
cal function of sumoylation in JAK/STAT signaling.
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ABSTRACT JAK/STAT signaling pathway is evolu-
tionarily conserved and tightly regulated. We carried
out a reporter-based genome-wide RNAi in vitro screen
to identify genes that regulate Drosophila JAK/STAT
pathway and found 5 novel regulators. Of these,
CG14225 is a negative regulator structurally related to
the Drosophila JAK/STAT pathway receptor Domeless,
especially in the extracellular domain, and to the mam-
malian IL-6 receptor and the signal transducer gp130.
CG14225 coimmunoprecipitates with Domeless and its
associated kinase hopscotch in S2 cells. CG14225 RNAi
caused hyperphosphorylation of the transcription fac-
tor Stat92E in S2 cells on stimulation with the Drosoph-
ila JAK/STAT pathway ligand unpaired. CG14225 RNAi
in vivo hyperactivated JAK/STAT target genes on septic
injury and enhanced unpaired-induced eye overgrowth,
and was thus named the eye transformer (ET). In the
gastrointestinal infection model, where JAK/STAT sig-
naling is important for stem cell renewal, CG14225/ET
RNAi was protective in vivo. In conclusion, we have
identiﬁed ET as a novel negative regulator of the
Drosophila JAK/STAT pathway both in vitro and in vivo,
and it functions in regulating Stat92E phosphoryla-
tion.—Kallio, J., Myllyma¨ki, H., Gro¨nholm, J., Arm-
strong, M., Vanha-aho, L.-M., Ma¨kinen, L., Silven-
noinen, O., Valanne, S., Ra¨met, M. Eye transformer is a
negative regulator of Drosophila JAK/STAT signaling.
FASEB J. 24, 4467–4479 (2010). www.fasebj.org
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The evolutionarily conserved janus tyrosine ki-
nase/signal transducer and activator of transcription
(JAK/STAT) pathway controls responses to hematopoi-
etic cytokines that orchestrate inﬂammatory and im-
mune responses in mammals (1). In humans, selective
utilization of 4 different Janus kinases (JAKs) and 7
STAT transcription factors leads to speciﬁc changes in
the activity of a set of target genes providing complexity
for JAK/STAT-mediated responses. Disturbances in
JAK/STAT signaling may cause serious human diseases,
including cancer, polycytemia vera, severe immune
deﬁciencies such as SCID, autoimmunity, allergies, and
neurological defects (1–5).
Drosophila has been widely used as a model for
JAK/STAT signaling. The core signaling pathway is
conserved in evolution from ﬂies to humans, but Dro-
sophila has only 1 JAK, hopscotch (6, 7), and a single
STAT transcription factor, Stat92E (8, 9), making the
pathway simpler and less redundant. Like in mammals,
the Drosophila JAK/STAT pathway is also involved in
multiple processes, which include embryonic segmen-
tation, larval hematopoiesis and development of vari-
ous organs, regulation of stem cell maintenance, and
cellular proliferation. In addition, Drosophila JAK/
STAT signaling is required to control immune and
stress responses (7, 10; reviewed in refs. 11–14). After
septic injury, the activation of JAK/STAT pathway leads
to the expression of a number of genes, including
Turandot (Tot) stress genes in the fatbody (15–17).
JAK/STAT pathway activation is mediated by se-
creted cytokine-like molecules unpaired (upd), upd2,
and upd3 (18–20), which bind to the transmembrane
receptor Domeless (Dome) (21, 22). Dome shares
homology with members of the interleukin 6 (IL-6)
receptor family and, like the mammalian cytokine
receptors, forms dimers (22, 23). In the canonical
model of JAK/STAT signaling cascade, ligand binding
induces a conformational change in the receptor lead-
ing to activation of associated JAKs by auto- and/or
trans-phosphorylation. Activated JAKs phosphorylate
tyrosine residues in the receptors, thereby creating
docking sites for STATs, which subsequently become
phosphorylated by JAKs too. Activated STATs dimerize
and translocate in the nucleus, where they bind their
target sites in DNA and act as transcriptional activators
(8, 24). In Drosophila, the Socs36E (suppressor of cyto-
kine signaling 36E) gene is known to be a target gene
of the JAK/STAT pathway, forming a negative feedback
loop by inhibiting hop activity (25, 26). Drosophila
protein inhibitor of activated stat (dPIAS) is shown to
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be a negative regulator of the Drosophila JAK/STAT
pathway too, but the mechanism remains elusive (27)
compared to humans, where, for example, hPias1 is
shown to promote sumoylation of hStat1 (28).
JAK/STAT signaling has been studied in the Drosoph-
ila system because of its importance in human diseases.
S2 cell-based large-scale RNAi screening provides a
powerful tool to identify theoretically all genes re-
quired for given cellular function (29, 30). Two Dro-
sophila in vitro RNAi screens have been carried out to
ﬁnd genes involved in JAK/STAT signaling (31, 32),
and several new modiﬁers of this pathway have been
identiﬁed. Curiously, however, there were differences
between the sets of identiﬁed genes. To study regula-
tion of the Drosophila JAK/STAT signaling and to
elucidate the events involved in the signaling, we car-
ried out a genome-wide RNAi based in vitro screen in
Drosophila S2 cells. As the intracellular part of the
JAK/STAT pathway downstream of the JAK kinase is
particularly well conserved, we chose to activate the sig-
naling using the constitutively active form of theDrosophila
JAK kinase hopscotch (hopTum-l) (33, 34). Activity of the
pathway was monitored using a Stat92E responsive TotM-
luciferase (TotM-luc) reporter-based assay. We screened
16,025 dsRNAs for their effect on TotM reporter activity.
In addition to the known JAK/STAT signaling pathway
components, we identiﬁed 5 genes that regulated TotM
response in S2 cells. Of these, the CG14225 gene we call
eye transformer (ET) was identiﬁed as a negative regulator of
JAK/STAT signaling both in vitro and in vivo.
MATERIALS AND METHODS
dsRNA synthesis
The dsRNAs used in the RNAi screen were produced from a
commercial Drosophila genome RNAi library consisting of a
set of 13,625 PCR products with dual T7 promoter sequences
[Medical Research Council (MRC) Geneservice Ltd., Cam-
bridge, UK]. An additional 2400 dsRNAs were transcribed
from the S2 cell-derived cDNA library (35). Targeted dsRNAs
were synthesized from S2 cDNA essentially as described in ref.
36. pMT/BiP/V5-His/GFP plasmid (Invitrogen, Carlsbad,
CA, USA) was used as a template for the production of the
negative control GFP dsRNA. Primers used for targeted
dsRNAs were GFP 5-T7GCTCGGGAGATCTCC-3 and 5-
T7CTAGACTCGAGCGGC-3; Stat92E 5-T7CCGATT-
AGCCAACGC-3 and 5-T7GGACCCCAGTGATCT-3; hop
5-T7GGAGCAGCAGATAGC-3 and 5-T7GGCGGTAG-
AGGAACT-3;Dome 5-T7TAACGGCAAGAGCGC-3 and 5-T7
AGGTTCTGGCCAGGT-3; ET dsRNA1 5 -T7TGC-
GAAGGCAGGGCACAATAGAATC-3 and 5-T7CAAGT-
CTGGTTGGGCGTTTGTATCA-3; ET dsRNA2 5-T7CG-
GAGAATGCGTTGC-3 and 5-T7AGTTGGGCAGCTT-
GG-3; ET dsRNA3 5-T7GACATCCGGGATCGACG-3 and
5-T7CGTGGGCTCCTCTTCCG-3. Additional information
related to primers is presented in Supplemental Table S1.
Cell culture, transfections, dsRNA treatments, and
overexpression constructs
Drosophila S2 cells were cultured in Schneider medium (Sigma-
Aldrich, St. Louis, MO, USA) with 10% FBS, 100 U/ml
penicillin, and 100 g/ml streptomycin at 25°C. Transfec-
tions and dsRNA treatments were performed essentially as
described previously (37). We transfected 1.0  106 S2 cells
with 0.2 g of a constitutively active form of the Janus kinase
hopTum-l together with TotM-luc reporter plasmid for activating
the JAK/STAT pathway and for quantifying TotM expression,
respectively. Cells were also transfected with 0.2 g Act5C--
gal reporter plasmid for monitoring cell viability and trans-
fection efﬁency. We used 0.5 g of control and experimental
dsRNAs for RNAi. Reporter activities were measured 72 h
after transfection. Transfections with other reporters were
carried out similarly. CG14225 was cloned from S2 cell cDNA
to EcoRI and NotI sites of Drosophila expression vector pMT-
HisA. Protein production was induced by addition of CuSO4
to a ﬁnal concentration of 500 M 24 h prior to cell lysis.
Quantitative RT-PCR
Quantitative RT-PCR for TotM, TotA, and CG14225 and Act5C
levels was carried out using the QuantiTect SYBR Green
RT-PCR Kit (Qiagen, Valencia, CA, USA) and the ABI7000
instrument (Applied Biosystems, Foster City, CA, USA) ac-
cording to the manufacturers’ instructions. Primers used for
qRT-PCR were Act5C 5-CGAAGAAGTTGCTGCTCTGG-3
and AGAACGATACCGGTGGTACG; TotM 5-ACCGGAACA-
TCGACAGCC-3 and 5-CCAGAATCCGCCTTGTGC-3; TotA
5-CCCAGTTTGACCCCTGAG-3 and 5-GCCCTTCACACCTG-
GAGA-3; ET 5-CGGAGAAAGGAGCACCCA-3 and 5-GG-
GACTGCATCTCGCAGT-3.
Sequence analysis
Sequences were analyzed with the National Center for Bio-
technology Information (NCBI) Basic Local Alignment
Search Tool (BLAST; http://www.ncbi.nlm.nih.gov/). ClustalW
alignments (http://www.ebi.ac.uk/Tools/clustalw2/index.
html) were carried out in order to identify similar regions
between ET, Dome, and gp130.
Coimmunoprecipitation
S2 cells were transfected with constructs of cDNAs cloned in
the pMT/V5/HisA vector (Invitrogen). Protein production
was induced with CuSO4. The following tagged full-length
constructs were used: hopscotch-V5, Dome-myc, ET-myc, ET-
V5, and Dome-V5. Constructs were cotransfected in the
combinations shown and immunoprecipitated with Protein G
Sepharose beads (GE Healthcare, Little Chalfont, UK) or
Protein G Dynabeads (Invitrogen), separated, transferred to
nitrocellulose membrane, and detected essentially as de-
scribed previously (38).
Immunodetection
We transfected 5.0 106 S2 cells with a total amount of 3.0 g
of dsRNA and 1.0 g of pMT-upd plasmid or 1.0 g of empty
pMT-V5-HisA using Fugene6 reagent (Roche, Basel, Switzer-
land) according to the manufacturer’s instructions. Then
48 h after transfection, cells were treated with 500 M CuSO4
for 24 h. Cells were lysed in Triton-X lysis buffer. The protein
amounts were determined by a Dc protein assay kit (Bio-Rad
Laboratories, Hercules, CA, USA). The proteins were sepa-
rated by SDS-PAGE and transferred to a nitrocellulose mem-
brane (Protran; Schleicher & Schuell, Dassel, Germany).
Membranes were blocked with 5% milk in TBS-0.1% Tween
20, incubated with anti-Stat92E-N-terminal antibody (dN-17;
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Santa Cruz Biotechnology, Santa Cruz, CA, USA) or with
anti-phospho-Tyrosine antibody (PY99; Santa Cruz Biotech-
nology) and with a biotinylated anti-goat or anti-mouse
secondary antibody (DakoCytomation, Copenhagen, Den-
mark). Immunodetection was performed with the enhanced
chemiluminescence method (GE Healthcare). TBS buffer
containing 1% -mercapthoethanol and 0.2% SDS was used
for stripping. Phospho-Stat92E bands were quantiﬁed by
ImageQuant TL image analysis software (GE Healthcare) and
analyzed after background subtraction.
Fly stocks and maintenance
Drosophila stocks were kept on a standard mashed potato diet
at RT or at 25°C. The RNAi transgenic ﬂy stocks were
obtained from the Vienna Drosophila RNAi Center [VDRC;
Vienna, Austria; VDRC transformants 19756 (ET IR1), 100881
(ET IR2), and 43866 (Stat92E IR)]. UAS-RNAi ﬂies were
crossed over a fatbody-speciﬁc C564-GAL4 or ubiquitous
GeneSwitch-GAL4 driver ﬂies or to w1118 ﬂies for controls. In
ﬂies crossed over the GeneSwitch-GAL4 driver, the GAL4
construct was induced with Mifepristone (200 M). Week-old
offspring were used for experiments.
To study the eye phenotype, ﬂies carrying GMR-upd3
were ﬁrst crossed over ET IR1/CyO ﬂies. The F1 ﬂies with 1
copy of GMR-upd3 and 1 copy of ET IR1 were then crossed
over eye-speciﬁc driver ey-GAL4 to induce ET RNAi. The
offspring from the ﬁrst cross without the ET RNAi construct
were used as controls.
Fly infections
For Enterobacter cloacae infection, week-old ﬂies were pricked
with a thin tungsten needle dipped in a concentrated culture
of bacteria. Serratia marcescens feeding infection experiment
was performed as described previously (39, 40). Survival of
the ﬂies was recorded daily.
Data analysis
Statistical analyses of reporter assays and qRT-PCR results
were carried out using 1-way ANOVA. Statistical analysis of ﬂy
survival experiments was carried out using the log-rank (Man-
tel-Cox) test. Values of P  0.05 were considered to be
statistically signiﬁcant.
RESULTS
Luciferase-based reporter assay to monitor
JAK/STAT signaling pathway activity in Drosophila S2
cells
Under stressful conditions, including septic injury, sev-
eral Tot genes are expressed in the Drosophila fatbody,
the functional equivalent of mammalian liver (15, 16).
It has been shown that the activation of TotA is JAK/
STAT pathway dependent but is also partly regulated by
the Imd pathway and requires MAPKKK Mekk1 (17,
41). As shown in Fig. 1A, TotM-luc reporter activity is
induced by a constitutively active form of Janus kinase
hopscotch (hopTum-l) in Drosophila S2 cells. This induction
is STAT dependent, as RNAi targeting the transcription
factor Stat92E blocks the TotM expression. On the other
hand, RNAi targeting the Imd pathway transcription
factor Relish has no effect on hopTum-l-induced TotM
expression, demonstrating the speciﬁcity of our assay to
JAK/STAT signaling (data not shown). These results
indicate that hopTum-l-induced TotM-luc reporter activity
can be used to study the regulation of the JAK/STAT
pathway in Drosophila S2 cells.
Genome-wide RNAi analysis of the Drosophila JAK/
STAT pathway in Drosophila S2 cells
To identify all regulators of the JAK/STAT pathway
downstream of hop, we carried out a genome-wide
RNAi screen and monitored the effects of 16,025
dsRNA treatments on hopTum-l-induced TotM-luc re-
porter activity in S2 cells. The dsRNAs were produced
by in vitro transcription from a commercial Drosophila
genome-wide library (MRC Geneservice; 13,625 PCR
products), and an additional 2400 dsRNAs were tran-
scribed from S2 cell-derived cDNA library (35). S2 cells
were transfected with a hopTum-l expression vector and
TotM-luc-reporter together with experimental or con-
trol dsRNAs. Act5C--gal reporter was used to control
cell viability. The luciferase and -galactosidase activi-
ties were measured 72 h after transfection. dsRNA
targeting Stat92E and dsRNA targeting a gene encoding
Green Fluorescence Protein (GFP), which is not expressed
in S2 cells, were used as positive and negative controls
in each experiment, respectively. The luciferase and
-galactosidase values for GFP dsRNA-treated cells were
used as reference values for experimental dsRNAs. As
shown in Fig. 1B, most dsRNA treatments had little or
no effect on TotM-luc or Act5C--gal activity. Notably,
there were 7 dsRNA treatments that repeatedly de-
creased TotM-luc activity by more than 50% without
signiﬁcantly affecting Act5C--gal activity. These tar-
geted 2 known JAK/STAT pathway components
(Stat92E and hop), one gene previously shown to be
involved in JAK/STAT pathway regulation (enok) (31,
32), and 4 novel regulators (Taf1, CG31716, CG14225,
and Med27). Corresponding templates from the origi-
nal library were TA-cloned and sequenced. Based on
the sequencing results, we designed gene-speciﬁc prim-
ers and synthesized targeted independent dsRNAs
against these novel regulators to conﬁrm that the RNAi
phenotype had been due to presumed dsRNA and not
due to contaminating dsRNAs or any off-target effect.
As shown in Fig. 1C, all 5 targeted dsRNA treatments
decreased TotM-luc reporter activity comparably to the
library dsRNAs.
To ensure that the obtained results were not caused
by an artifact related to the reporter assay, we studied
the endogenous TotM and Act5C expression levels of
hopTum-l-transfected and dsRNA-treated S2 cells using
qRT-PCR (Fig. 1D). RNAi targeting any of the identi-
ﬁed genes resulted in at least a 50% reduction in
relative TotM expression level, indicating that these
genes are required for normal hopTum-l -induced TotM
response in S2 cells. Based on these results, enok, Taf1,
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CG31716, CG14225, and Med27 are potential regulators
of Drosophila JAK/STAT signaling, and these 5 genes
were subjected to further studies.
CG31716 and CG14225 are general modiﬁers of
JAK/STAT signaling, whereas enok, Med27, and Taf1
are more context sensitive
To assess the role of identiﬁed genes in JAK/STAT
signaling in more physiological context, we activated
the JAK/STAT signaling in S2 cells by overexpressing
the ligand upd, and we used TotM-luc reporter to
measure the pathway activity. As shown in Fig. 2A,
dsRNA treatments targeting enok, Taf1, and CG31716
reduced upd-induced TotM expression in a similar
manner compared to hopTum-l-induced TotM re-
sponse, whereas RNAi against Med27 showed no
effect. Intriguingly, RNAi targeting CG14225 caused
strong hyperactivation of the TotM reporter activity
in this setting.
Figure 1. Genome-wide RNAi screen to identify gene products required for
Drosophila JAK/STAT signaling. A) TotM-luc reporter activity is induced by hopTum-l
in a Stat92E-dependent manner in S2 cells. Expression of hopTum-l caused more
than 5-fold induction in the TotM-luc activity, which was blocked by RNAi targeting
Stat92E. S2 cells were transfected with TotM-luc reporter plasmid together with
hopTum-l and Act5C--gal reporter. ***P  0.001. B) Results of the genome-wide
RNAi screen of the Drosophila JAK/STAT signaling. Luciferase and -galactosidase
values are plotted on a log-scale. Light blue dots represent GFP dsRNA-treated
negative control samples, and Stat92E dsRNA-treated positive controls are shown in
purple. Samples located near the purple dots in the top left corner of the plot
represent most potential positive regulators of JAK/STAT signaling. S2 cells were
transfected with hopTum-l, TotM-luc, and Act5C--gal plasmids together with experi-
mental or control dsRNAs. In total, 16,025 independent dsRNAs for their effect on
TotM-luc reporter activity induced by hopTum-l were analyzed. C) Targeted dsRNA-
treatments against potential regulators of the Drosophila JAK/STAT pathway. To
conﬁrm the initial ﬁndings of the screen, independent dsRNAs targeting indicated genes were designed and tested for their
effect on hopTum-l-induced TotM-reporter activity as in panel A. All targeted dsRNAs decrease hopTum-l-induced TotM-luc
reporter activity by more than 50% in S2 cells as compared to GFP dsRNA-treated cells. D) Endogenous TotM expression
is reduced by dsRNA treatments targeting any of the 5 novel regulators of the Drosophila JAK/STAT pathway. dsRNAs
targeting indicated genes were transfected into S2 cells together with hopTum-l. Endogenous TotM expression levels were
measured by qRT-PCR and results normalized to Act5C expression values. All data are shown as means 	 sd, n  4. Values
of P  0.05 unless indicated otherwise.
Figure 2. CG31716 and CG14225 are general
modiﬁers of JAK/STAT signaling, whereas enok,
Med27, and Taf1 are more context sensitive. A)
RNAi targeting enok, CG31716, andTaf1 decreases
upd-induced TotM-luc activity in S2 cells, whereas
CG14225 dsRNA strongly enhances TotM-luc re-
sponse. B) RNAi targeting Med27 and CG31716
decreases upd-induced 10xStat92E-luc activity in S2
cells, whereas CG14225 and Taf1 RNAi enhances
the response. S2 cells were transfected with TotM-luc
(A) or 10xStat92E-luc (B) and Act5C--gal reporter
constructs together with indicated dsRNAs and upd
to induce the pathway. Data are shown as means	
sd, n  4, *P  0.05; **P  0.01; ***P  0.001.
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Next, we tested whether these novel regulators are
speciﬁc for regulating TotM expression, or whether
they affect JAK/STAT target genes in a more general
manner. To this end, we induced JAK/STAT signaling
by expressing upd, and we used 10xStat92E-luc reporter
consisting of a sequence containing a double Stat92E
binding site from a SOCS36E enhancer region multi-
plied 10 times, to measure the JAK/STAT pathway
activity (31). As shown in Fig. 2B, upd expression caused
3.1-fold induction in 10xStat92E-luc reporter activity.
This induction is strongly inhibited by dsRNA treat-
ments targeting CG31716 and Med27, suggesting that
these genes are required for Stat92E-dependent activa-
tion of target genes in Drosophila S2 cells. Interestingly,
RNAi targeting enok or Taf1 increased upd-induced
10xStat92E reporter activity, indicating that these gene
products have a more speciﬁc effect on regulating TotM
expression. Of note, as enok also had been identiﬁed
earlier as a negative regulator of Drosophila JAK/STAT
signaling (31, 32), our results with 10xStat92E-luc
reporter are in line with the earlier reports. CG14225
RNAi caused clear hyperactivation of 10xStat92E-luc
reporter also in this setting. Furthermore, CG14225
dsRNA treatment caused a strong increase in another
Stat92E-responsive reporter, 3  2xDraf-luciferase ac-
tivity (32) in response to upd expression in S2 cells
(more than 10-fold induction compared to GFP
dsRNA-treated controls, data not shown). These re-
sults related to the role of CG14425 in upd-induced
JAK/STAT signaling are in striking contrast com-
pared to our results with hopTum-l induction and
prompted us to study this gene in more detail.
CG14225/ET is a Dome-related gene that negatively
regulates the JAK/STAT signaling in Drosophila S2
cells
CG14225/ET is a 3.3 kb gene comprising 3 separate
coding sequences (Fig. 3A). It is located next to the
Figure 3. ET is a negative regulator of the Drosophila JAK/STAT pathway and is structurally related to Dome. A) Schematic
representation of gene and protein structures of CG14225/ET. The ET gene consists of 3 exons and has no UTR regions.
Sequence regions where ET dsRNAs (dsRNA1–3) were designed are shown. Domain structure of ET protein is illustrated and
compared to domain structure of Dome in the bottom panel. N-terminal ﬁbronectin-type III domain of the cytokine-binding
module (CBM N) and C-terminal ﬁbronectin-type III domain of the cytokine-binding module (CBM C) are highly conserved
in both proteins. The ﬁbronectin-type III (FnIII) domain triplet near the transmembrane domain in Dome is absent in ET. B,
C) RNAi targeting different regions of ET has a similar effect on both hopTum-l- and upd-induced 10xStat92E-luc activity. S2 cells
were transfected with 10xStat92E-luc reporter plasmid together with hopTum-l or upd constructs for induction of the pathway.
Two dsRNAs targeting different parts of the ET gene decrease hopTum-l-induced 10xStat92E-luc activity (B) and increase
upd-induced 10xStat92E-luc activity (C), compared to GFP dsRNA-treated controls in S2 cells. D) RNAi targeting ET strongly
decreases the amount of ET transcripts in S2 cells compared to GFP dsRNA-treated controls. Endogenous ET mRNA levels after
dsRNA treatments were measured using qRT-PCR. E) Overexpression of ET blocks upd-induced 10xStat92E-luc activity in S2
cells, but enhances hopTum-l-induced 10xStat92E-luc response. S2 cells were transfected with an ET overexpression construct or
an empty vector together with hopTum-l or upd to induce the pathway. All data are shown as means	 sd, n 4. *P 0.05; **P
0.01; ***P  0.001.
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Drosophila JAK/STAT pathway receptor Dome in the
genome. Furthermore, the ET gene encodes a 713 amino
acid type-I transmembrane protein that shares structural
similarities with Dome (11). Like Dome, ET has a cytokine
binding module (CBM) in the N terminus but lacks 3 FnIII
domains near the transmembrane domain. The CBM do-
main of vertebrate interleukin receptors is composed of 2
FnIII domains, containing 4 conserved cysteine residues in
the N-terminal domain and a conserved WSXWS motif in
the C-terminal domain (42). CBM in Dome and
CG14225/ET share these features, but the WSXWS motif is
incomplete in both (NTLWS/GSPWS). Intriguingly, al-
though Dome shares similarities with the mammalian inter-
leukin-6 (IL-6) receptor family members, ET’s closest hu-
man homologue is the signal transducing protein gp130
with 12.7% identity,mostly found in the extracellular region.
In mammalian IL-6 signaling, gp130 associates with IL-6
receptors that have bound their ligand and dimerizes, there-
fore allowing transduction of the signal to activate target
molecules, including JAKs and STATs (43). Thus, ET shares
structural similarities with Dome and mammalian gp130,
which plays an important role in regulation of JAK/STAT
signaling. The structure of the ET gene product explains in
part why we observed opposing results with ET RNAi de-
pending on what level the JAK/STAT pathway was activated
at, because with the transmembrane domain, ET is likely to
function at the level of Dome, thus epistatically between upd
and hop.
To verify that the observed ET RNAi phenotype was
not due to off-target effects, we generated another
dsRNA targeting the third exon of ET (the 3 different
dsRNAs targeting ET are shown schematically in Fig.
3A). As shown in Fig. 3B, both targeted dsRNAs
(dsRNA2 and dsRNA3) caused strong inhibition of
hopTum-l-induced 10xStat92E-luc reporter activity. Fur-
thermore, both targeted dsRNAs caused hyperactiva-
tion of the upd-induced 10xStat92E-luc reporter activity
(Fig. 3C), indicating that independent dsRNAs target-
ing ET cause similar phenotypes. Furthermore, hyper-
activation of 10xStat92E-luc reporter was also observed
when upd-conditioned medium (32) was added on ET
dsRNA-treated cells (data not shown). To conﬁrm
efﬁciency of RNAi on the ET mRNA level, we treated S2
cells with both targeted dsRNAs against ET and ana-
lyzed mRNA levels using qRT-PCR (Fig. 3D). Both
dsRNAs resulted in strongly decreased ET mRNA levels
compared to GFP dsRNA-treated control cells, indicat-
ing that these treatments effectively suppress ET expres-
sion in S2 cells. Taken together, these results indicate
that ET RNAi causes hyperactivation of upd-induced
JAK/STAT response in S2 cells.
To test whether overexpression of ET has an effect on
JAK/STAT signaling in S2 cells, we cloned ET to a
Drosophila expression vector. As shown in Fig. 3E,
overexpression of ET caused a marked decrease in
upd-induced 10xStat92E-luc reporter activity in S2 cells
and consistently with the RNAi phenotype results,
1.6-fold increase in hopTum-l-induced TotM-luc activity.
Of note, ET mRNA contains no UTR regions, and thus
it was not possible to carry out a rescue experiment
where endogenous ET would be knocked down by
dsRNA targeting the UTR regions and the resulting
phenotype would then be rescued by overexpression of
ET construct.
To analyze whether ET RNAi affects signaling cas-
cades in S2 cells in a more general manner, we inves-
tigated the Toll and the Imd pathway signaling in ET
dsRNA-treated S2 cells. ET RNAi did not signiﬁcantly
affect the heat-killed E. coli-induced Attacin (Imd path-
way target gene) reporter activity, and had only a minor
effect on Toll10b-induced Drosomycin (Toll pathway tar-
get gene) reporter activity in S2 cells (data not shown).
These results indicate that ET is not a general regulator
of signaling pathways in S2 cells, but its function is
more speciﬁc to the JAK/STAT pathway.
ET is an intrinsic component of the Dome receptor
complex, and it functions as a regulator of Stat92E
phosphorylation
Curiously, RNAi targeting ET caused different pheno-
types in TotM-luc and 10xStat92E-luc reporter assays
depending on whether hopTum-l or upd was used to
trigger the JAK/STAT pathway signaling. To investi-
gate the function of ET, we tested whether ET RNAi
phenotype can be suppressed by dual RNAi treat-
ments targeting known regulators of Drosophila JAK/
STAT signaling in S2 cells. S2 cells were treated with
ET dsRNA and with dsRNA targeting known compo-
nents of the JAK/STAT pathway, hop, Stat92E, or
Dome. The JAK/STAT pathway activity was measured
using TotM-luc reporter. ET RNAi caused a subtle
activation of the TotM-luc reporter activity (Fig. 4A),
suggesting that ET acts as a constitutive negative
regulator of the JAK/STAT pathway in S2 cells. RNAi
targeting any of the known Drosophila JAK/STAT
pathway components (Dome, hop, or Stat92E) pre-
vented this activation, which suggests that ET func-
tion is dependent on these components and that ET
acts upstream or at their level in S2 cells.
To gain a more mechanistic insight about ET-
mediated inhibition of JAK/STAT signaling, we co-
immunoprecipitated overexpressed V5-tagged com-
ponents of the Drosophila JAK/STAT signalosome
with myc-tagged ET in S2 cells (Fig. 4B). At ﬁrst, we
conﬁrmed the method by hop and Dome coimmu-
noprecipitation, and as expected, hop-V5 coimmuno-
precipitated with Dome-myc (Fig. 4B). Notably, both
hop-V5 and Dome-V5 coimmunoprecipitated with
ET-myc, suggesting that overexpressed ET interacts
directly with key regulators of the Drosophila JAK/
STAT signalosome in S2 cells. Of note, we were
unable to coimmunoprecipitate upd or Stat92E with
ET (data not shown).
To gain further insight to the molecular function of
ET, we analyzed whether ET suppresses JAK/STAT
signaling by affecting the dimerization of Dome. As
shown in Fig. 5A, Dome-Dome interaction, as analyzed
by immunoprecipitating V5-tagged Dome with myc-
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tagged Dome, was not affected by overexpression of ET
(or ET RNAi). Similarly, overexpression of ET (or ET
RNAi) did not alter the interaction between hop-V5 and
Dome-myc (Fig. 5A). These results indicate that ET is not
likely to function by preventing dimerization of Dome, or
by disrupting Dome-hop interaction in S2 cells.
Next, we studied whether ET affects the kinase
activity of the Drosophila JAK/STAT signalosome by
investigating Stat92E phosphorylation upon upd induc-
tion in S2 cells (Fig. 5B). S2 cells were transfected with
indicated dsRNAs and upd to activate signaling leading
to Stat92E phosphorylation. Then 72 h after transfec-
tion, S2 cell protein lysates were separated by SDS-
PAGE and analyzed by Western blotting with anti-
Stat92E N-terminal antibody. RNAi targeting ET caused
Stat92E band shift upon activation with upd compared
to GFP dsRNA-treated controls, suggesting hyperphos-
phorylation of Stat92E. To ensure that this upper band
represents a phosphorylated form of the protein,
Stat92E was immunoprecipitated from S2 cell lysates
with anti-Stat92E N-terminal antibody and detected
with phospho-tyrosine-speciﬁc antibody (Fig. 5B). Hy-
perphosphorylation of Stat92E was abolished when
Dome or hop dsRNA was cotransfected with ET dsRNA
(Fig. 5B), indicating that ET function is dependent on
these factors. Stat92E dsRNA strongly decreases the
signal demonstrating the speciﬁcity of the antibody.
Taking these data together, we see that ET is a
negative regulator of the JAK/STAT pathway in Dro-
sophila S2 cells. ET functions as a regulator of Stat92E
phosphorylation and is located functionally at the level
or upstream of the receptor Dome. Furthermore, ET
appears as an intrinsic component of the Dome recep-
tor complex as it coimmunoprecipitates with both hop
and Dome when overexpressed in S2 cells, but it does
not affect Dome dimerization or Dome-hop interac-
tion. The mechanistic function of ET is shown schemat-
ically in Fig. 5C.
ET negatively regulates Tot gene expression in vivo
ET functions as a negative regulator of JAK/STAT
signaling in vitro. JAK/STAT pathway is required for Tot
gene expression under stressful conditions in Drosophila
in vivo (17, 41). To investigate the role of ET in
JAK/STAT signaling in vivo, we crossed ﬂy lines carry-
ing UAS-RNAi constructs targeting ET (ET IR1 and ET
IR2) (44) over C564-GAL4 ﬂies, which drive GAL4
expression in the adult fatbody. Thereafter the relative
expression levels of both TotM and TotA in response to
septic injury with E. cloacae were measured in experi-
mental and control progeny ﬂies by qRT-PCR (Fig. 6A,
B). As expected, C564-GAL4-driven expression of UAS-
Stat92E RNAi strongly impaired both TotM and TotA
response to E. cloacae compared to controls crossed
over w1118 (Fig. 6A, B). On the contrary, C564-GAL4-
driven UAS-ET RNAi markedly enhanced both TotM
and TotA expression. These results are in agreement
with the results obtained using S2 cells and indicate
that ET negatively regulates Tot gene expression in
adult Drosophila. Of note, infection with E. cloacae did
not affect the level of ET expression, which suggests
that ET expression is not regulated by the JAK/STAT
(or the Imd) pathway (data not shown).
Genetic background may affect gene expression lev-
els under experimental conditions. To avoid bias
caused by genetic background, we analyzed the in vivo
ET RNAi phenotype using a drug-inducible ubiquitous
driver GeneSwitch-GAL4, which activates the expression
of the RNAi construct when Mifepristone is added to
the food vials. This enables monitoring the offspring
from each cross with and without expression of the
RNAi construct, therefore providing a genetically rele-
vant control. Figure 6C, D shows that in Mifepristone-
induced ET RNAi ﬂies, both TotM and TotA expression
in response to septic injury with E. cloacae are hyperac-
Figure 4. ET functions at the level or upstream of Dome and
coimmunoprecipitates with hop and Dome. A) ET functions
at the level or upstream of Dome. TotM-luc reporter was
activated by RNAi targeting ET. RNAi targeting known com-
ponents (hop, Stat92E, Dome) of the Drosophila JAK/STAT
pathway abolishes ET RNAi -induced TotM activity, indicating
that these components are located functionally downstream
of ET. Data are shown as means	 sd, n 4. *P 0.05. B) ET
coimmunoprecipitates with both hop and Dome. S2 cells
were transfected with either ET-myc or Dome-myc and
hop-V5 or Dome-V5. Immunoprecipitation (IP) was done
with anti-myc (
 myc) antibody and immunoblotting (IB)
with anti-V5 (
 V5) antibody. CuSO4 was used to induce the
expression of the constructs.
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tivated compared to control ﬂies with a drug-free diet.
As expected, Stat92E RNAi strongly inhibits both TotM
and TotA induction under these conditions, demon-
strating that the GeneSwitch-GAL4 driver was operative.
Tot gene expression is controlled jointly by the
JAK/STAT and by the Imd pathway on septic injury in
Drosophila (17, 41). By crossing UAS-ET RNAi ﬂies
over C564-GAL4 ﬂies and measuring Attacin B expres-
sion on E. cloacae septic injury in the offspring, we
conﬁrmed that the effect of ET RNAi on Tot gene
expression is not mediated by the Imd pathway (data
not shown).
ET RNAi is protective in a gastrointestinal infection
model with Serratia marcescens
Recently, the Drosophila JAK/STAT signaling has been
shown to be important for survival of the ﬂies after
intestinal bacterial infection (45, 46). In response to
infection or damage, enterocytes in the Drosophila mid-
gut produce upd, upd2, and upd3, which activate
JAK/STAT signaling in intestinal stem cells, leading to
cell division and regeneration of the gut epithelium
(45). Serratia marcescens is an entomopathogenic bacte-
rium that can infect Drosophila through the digestive
tract. It was shown that despite the local immune
response induced, S. marcescens infection causes disrup-
tion of the gut morphology, which contributes to death
of the ﬂies that follows in a few days (40). Thus, we used
the S. marcescens intestinal infection assay to study the role
of ET in microbial resistance in vivo (39, 40, 46). ET RNAi
lines (ET IR1 and ET IR2) were crossed over the Gene-
Switch-GAL4 driver line, and w1118 and Stat92E over Gene-
Switch-GAL4 were used as controls. As shown in Fig. 7, ET
RNAi ﬂies survived better in food contaminated with
S. marcescens than ﬂies in which RNAi was not induced by
Mifepristone. In contrast, ﬂies with induced Stat92E RNAi
were more susceptible than ﬂies with no RNAi induction
(Fig. 7A, B). These data support previous reports suggest-
ing that JAK/STAT signaling is involved in survival of the
ﬂies from S. marcescens infection in vivo, and that ET RNAi
enhances their resistance to S. marcescens. The enhanced
resistance against gastrointestinal infection may be due to
improved stem cell renewal caused by hyperactivated
JAK/STAT pathway (45), although it is plausible that the
protective effect of ET RNAi is caused by mechanisms
independent of JAK/STAT signaling.
Figure 5. ET RNAi causes hyperphosphorylation of Stat92E in response to upd expression in S2 cells. A) ET does not affect the
interaction between hop and Dome (top panel) or homodimerization of Dome (bottom panel). The effect of ET overexpression
or RNAi was studied by transfecting S2 cells with Dome-myc and hop-V5 or Dome-myc and ET-V5 or treated with ET dsRNA.
Immunoprecipitation (IP) was done with antimyc (
-myc) antibody and immunoblotting (IB) with anti-V5 (
 V5) antibody.
B) ET RNAi causes Stat92E hyperphosphorylation in response to activation of JAK/STAT signaling with upd (3 top panels). The
intensity of the phosphorylation bands of Stat92E is signiﬁcantly increased in ET dsRNA-treated samples compared to GFP
dsRNA-treated controls. Hyperphosphorylation of Stat92E is abolished when Dome or hop dsRNA is cotransfected with ET dsRNA
(bottom panel), indicating that function of ET is dependent on these factors. S2 cells were transfected with dsRNAs as indicated
with or without upd to activate the JAK/STAT pathway. Cells were lyzed 72 h after transfection, and proteins were separated by
SDS-PAGE and analyzed by Western blotting with anti-Stat92E N-terminal antibody. IP was done with anti-Stat92E N-terminal
antibody followed by SDS-PAGE and IB with antiphospho-Tyrosine antibody. After stripping, the same membrane was reprobed
with anti-Stat92E N-terminal antibody showing equal amounts of protein in the immunoprecipitates (middle panels).
C) Schematic representation of the canonical Drosophila JAK/STAT signaling (left) and the inhibitory function of ET (right).
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ET RNAi causes eye overgrowth in adult ﬂies
To gain more direct evidence that ET negatively regu-
lates JAK/STAT signaling in vivo, we investigated
whether ET RNAi affects upd-induced eye overgrowth.
JAK/STAT signaling has been shown to be important in
regulation of Drosophila eye imaginal disc development
(47, 48). This is demonstrated by the fact that hyperac-
tivation of the pathway by ectopic overexpression of the
ligand upd in the developing eye leads to distinct
overgrowth (48; Fig. 7C). Furthermore, the overgrowth
phenotype has been shown to be modulated by overex-
pression or removal of several JAK/STAT pathway
components and regulators (e.g., refs. 32, 48–50). To
this end, we tested whether ET RNAi affects eye devel-
opment. Expressing the ET RNAi construct under an
eye-speciﬁc driver (ey-GAL4) alone did not affect eye
development (Supplemental Fig. S1). However, when
these ﬂies were further crossed to GMR-upd3 ﬂies
that overexpress upd in the eye, the resulting offspring
had more severe eye overgrowth than ﬂies from the
same cross without ET RNAi (Fig. 7C and Supplemental
Fig. S1). To evaluate the eye phenotypes objectively, we
created a scoring system to quantify the observations.
Pictures of each ﬂy’s eyes were independently evaluated
by 5 experienced researchers from our group as a blind
test, and the eye phenotypes were given scores 0–5, 0
representing wild type and 5 the most severe pheno-
type. The results in Fig. 7D show that the eye phenotype
of ﬂies carrying both GMR-upd3 and ET RNAi con-
struct together with the ey-GAL4 driver is more severe
than that of ﬂies with only GMR-upd3. These results
suggest that ET regulates JAK/STAT pathway-mediated
eye overgrowth in Drosophila.
DISCUSSION
JAK/STAT signaling is involved in a variety of processes
in both Drosophila and mammals. To identify gene
products involved in regulation of Drosophila JAK/
STAT signaling, we carried out a genome-wide reporter
assay-based RNAi screen in S2 cells. A constantly active
form of hop (hopTum-l) was chosen for pathway activa-
tion in order to focus on the more evolutionarily
Figure 6. ET in vivo RNAi increases JAK/STAT pathway response. A, B) ET RNAi strongly increases TotM (A) and TotA (B)
expression in response to septic injury in Drosophila in vivo, whereas Stat92E RNAi abolishes Tot gene expression. Flies carrying
the UAS-RNAi constructs ET IR 1, ET IR2, or Stat92E IR (positive control) were crossed over either C564-GAL4 driver or w1118
ﬂies (negative control). The offspring were infected with E. cloacae to induce JAK/STAT signaling. TotM and TotA expression
levels were measured from extracted total RNAs by qRT-PCR. C, D) ET RNAi also dramatically increases TotM (C) and TotA (D)
expression with an inducible ubiquitous GeneSwicth-GAL4 driver as compared to ﬂies with the same genetic background with no
RNAi induction. In the positive control (Stat92E RNAi ﬂies), induction of RNAi abolished Tot gene expression, whereas in the
negative control (w1118) Tot gene expression was not affected by induction. In ﬂies crossed over GeneSwitch-GAL4 driver, RNAi
was induced by adding the drug Mifepristone to food vials, and ﬂies with a drug-free diet (uninduced) were used as controls.
All data are shown as means 	 sd, n  4. *P  0.05; **P  0.01; ***P  0.001.
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conserved intracellular part of the signaling cascade.
To identify the most important regulators, we subjected
the genes, whose RNAi repeatedly caused 50% de-
crease on the luciferase activity, to further studies. The
original ﬁndings of the screen were conﬁrmed in vitro
by several means using different dsRNAs, different
reporters, and different ways to induce the JAK/STAT
signaling. In this way, we identiﬁed 5 novel putative
regulators of Drosophila JAK/STAT signaling. This is a
reasonable number of gene products that can be di-
rectly involved in JAK/STAT pathway regulation and
probably excludes factors that affect JAK/STAT path-
way activity indirectly via crosstalk with other signaling
pathways. In addition, our screen found 2 previously
known intracellular components of the pathway, hop
and Stat92E, conﬁrming the validity of our screen.
Notably, we identiﬁed the gp130/IL-6R related trans-
membrane protein ET as a novel negative regulator of
Drosophila JAK/STAT pathway.
ET is a negative regulator of Drosophila JAK/STAT
signaling
Our RNAi screen was originally set out to identify novel
positive regulators of Drosophila JAK/STAT pathway. ET
RNAi caused strong decrease in hopTum-l-induced
TotM-luc activity in our primary screen. Curiously, when
the JAK/STAT signaling was induced using upd, the
ligand of the pathway, the phenotype of ET RNAi was
the exact opposite. In this setting, ET RNAi increased
the activity of all reporters tested (TotM-luc, 10xStat92E-
luc, and 32xDraf-luc) by at least 5-fold, indicating that
the RNAi phenotype was not reporter sensitive, and
therefore not likely to be highly context-dependent or
due to an artifact. Furthermore, overexpression of ET
in S2 cells also produced opposite luciferase assay
phenotypes with different activating molecules. Even
though these results are consistent with the RNAi
phenotypes observed, the reason for different pheno-
types of ET knockdown or overexpression observed
depending on the activating molecule remains specu-
lative. However, several pieces of evidence suggest
partial explanations for this phenomenon.
In the Drosophila genome, the sequence coding for
ET is located next to that of Drosophila JAK/STAT
pathway receptor Dome. ET polypeptide carries a puta-
tive transmembrane domain and shares sequence sim-
ilarity to Dome, especially in the extracellular domain
(11); therefore, ET is likely a result of gene duplication.
Both the proposed protein structure of ET and our
experimental data from double-RNAi and coimmuno-
precipitation assays suggest that ET functions on the
cell membrane, epistatically at the level upd and hop.
hopTum-l causes strong activation of Drosophila JAK/
STAT signaling, but this induction appears to take a
somehow pathological form. Interestingly, Dome was
not among the known components identiﬁed in our
screen for positive regulators. We therefore tested the
Figure 7. ET in vivo RNAi is
protective in a gastrointestinal in-
fection model and enhances eye
overgrowth phenotype caused by
ectopic upd expression. A, B) ET
RNAi protects the ﬂies from S.
marcescens infection. Two strains of
ET RNAi ﬂies, ET IR1 (A) and IR2
(B), show enhanced survival from
gastrointestinal infection caused by
S. marcescens as compared to ﬂies
with the same genetic background
with no RNAi induction. Flies with
induced Stat92ERNAi showdecreased survival, as well as eatermutant ﬂies, whichwere used as controls.ETRNAiﬂies were crossed over
the drug-inducible driver GeneSwitch-GAL4. Mifepristone was used to induce the expression of the RNAi construct. w1118 and Stat92E
RNAi ﬂies crossed over GeneSwitch-GAL4 ﬂies were used as an additional control. C) ET RNAi enhances upd-induced eye overgrowth.
Eye overgrowth phenotype caused by overexpression of upd in the developing eye (GMR-upd3) is more severe in ﬂies that also
express an ET RNAi construct with an eye-speciﬁc driver (ey-GAL4). D) The eye phenotype in ﬂies with ectopic expression of both upd
and ET RNAi in their eyes was signiﬁcantly more severe than in ﬂies with upd alone. Grades: 0  wild-type, 5  most severe eye
phenotype. n  8 for CantonS ﬂies and n  16 for GMR-upd3 and GMR-upd3  ET IR1 ﬂies. Data are shown as means 	 sd.
***P  0.001 vs. GMR-upd3.
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RNAi phenotype for Dome with both upd and hopTum-l-
induction in S2 cells. As expected, when upd was used,
Dome RNAi abolished reporter activity. In line with our
ET results, when hopTum-l was used to activate JAK/
STAT signaling, the phenotype for Dome RNAi was the
opposite, the reporter activity being doubled (data not
shown). These results implicate that the mutant hop is
likely to behave abnormally in Drosophila cells acting
independently of Dome, perhaps by using ET’s short
cytoplasmic tail as a docking site: This results in consti-
tutive activation of JAK/STAT signaling and may ex-
plain the hopTum-l-mutant phenotype. Using ectopic
expression of upd as an inducer of JAK/STAT pathway
provides more physiological information about ET’s
function, and thus we conclude that ET is a negative
regulator of the Drosophila JAK/STAT signaling.
ET’s exact molecular function in regulation of
Drosophila JAK/STAT signaling remains to be stud-
ied, but since it has putative cytokine binding motifs
in the ectodomain, it could function as a decoy
receptor that captures upd ligands from Dome. ET
could also inhibit Dome activation by forming a
nonsignaling heterodimer with Dome, or by inhibit-
ing Dome homodimer-hop signalosome in some
other manner. Since ET coimmunoprecipitated with
Dome but did not affect Dome homodimerization, or
interaction of hop with Dome, the latter statement
appears more likely.
Regulation of JAK/STAT signaling in Drosophila and
mammals: common mechanisms
The core JAK/STAT signaling pathway is evolutionarily
conserved. Because of its role in diverse cellular pro-
cesses, the JAK/STAT pathway needs to be strictly
controlled at different levels of the cascade. Several
regulatory mechanisms appear to be conserved from
ﬂies to humans, as many of the positive and negative
regulators of Drosophila JAK/STAT signaling have been
identiﬁed based on their homology with the mamma-
lian counterparts. The Drosophila model has also pro-
vided important information about regulation of the
JAK/STAT pathway. For example, the ﬁrst evidence for
the critical role of the JH2 pseudokinase domain in
regulation of JAK activity and hematopoietic homeosta-
sis was obtained in Drosophila (51). Of the known
conserved negative regulators of the JAK/STAT path-
way, SOCS36E is strongly induced by Stat92E, forming a
negative feedback loop. dPIAS, on the other hand,
interacts directly with Stat92E and affects its nuclear
functions. According to our results, ET negatively reg-
ulates pathway at the level or upstream to Dome and is
not induced via a negative feedback loop.
Both Dome and ET show homology with mammalian
IL-6 receptor family members and the signal transducer
gp130. In mammals, gp130 is able to form functional
signaling complexes with several cytokine receptors,
such as interleukin-6, leukemia inhibitory factor, ciliary
neurotrophic factor, oncostatin M, cardiotrophin-1, the
granulocyte colony-stimulating factor, IL-11, and IL-27
(43, 52–56). In these ligand-induced receptor com-
plexes gp130 mediates the activation signal to multiple
cytoplasmic signaling molecules via activation of JAKs
that are constitutively associated with gp130 cytoplas-
mic domain. In Drosophila, the signaling cascade is
simpler, and Dome is the only characterized JAK/STAT
pathway receptor (22, 23). Dome homodimerization is
needed for a proper upd-induced signal transduction
and Stat92E activation (23), but it is still unclear if
Dome participates in larger multisubunit receptor com-
plexes resembling those seen in mammals.
The role of ET in Drosophila in vivo
Notably, we also assessed ET’s role in Drosophila JAK/
STAT signaling in vivo. Two ET RNAi strains crossed
over a driver expressed in the fatbody and lymph glands
(C564-GAL4) or a ubiquitous drug-inducible driver
(GeneSwitch-GAL4) were tested by qRT-PCR for their
effect on JAK/STAT pathway target gene expression in
response to septic injury with E. cloacae. Both ET RNAi
lines showed a signiﬁcant increase in JAK/STAT path-
way-dependent stress response compared to controls,
indicating hyperactivation of JAK/STAT signaling.
More direct in vivo model to study JAK/STAT activity in
Drosophila is overexpression of upd in the developing
eye, which leads to eye overgrowth due to hyperacti-
vated JAK/STAT signaling (48). The eye overgrowth
phenotype is shown to be modiﬁed by overexpression
and removal of several JAK/STAT pathway components
and regulators (32, 48–50). Notably, overexpression of
upd together with ET RNAi construct under an eye-
speciﬁc driver ey-GAL4 lead to a signiﬁcantly more
severe eye overgrowth than overexpression of upd
alone. In addition, ET RNAi appears to have a protec-
tive role in an S. marcescens gastrointestinal infection
model. Enhanced JAK/STAT signaling activity may be
advantageous in S. marcescens-infected ﬂies for renewal
of the injured gut wall (45). Accordingly, Stat92E RNAi
ﬂies were more susceptible to infection in this assay. It
is possible, however, that the protective effect of ET
RNAi is due to another mechanism unrelated to JAK/
STAT signaling.
In summary, we identiﬁed 5 putative novel regulators
of Drosophila JAK/STAT signaling in this study. Of
these, ET is a negative regulator of JAK/STAT pathway
signaling both in vitro and in vivo. ET is involved in
Stat92E phosphorylation and coimmunoprecipitates
with Dome and hop. The exact molecular mechanisms
of how ET regulates Stat92E phosphorylation remains
to be studied.
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ABSTRACT The JAK/STAT pathway is essential for
organogenesis, innate immunity, and stress responses
in Drosophila melanogaster. The JAK/STAT pathway and
its associated regulators have been highly conserved in
evolution from ﬂies to humans. We have used a ge-
nome-wide RNAi screen in Drosophila S2 cells to iden-
tify regulators of the JAK/STAT pathway, and here we
report the characterization of Not4 as a positive regu-
lator of the JAK/STAT pathway. Overexpression of
Not4 enhanced Stat92E-mediated gene responses in
vitro and in vivo in Drosophila. Speciﬁcally, Not4 in-
creased Stat92E-mediated reporter gene activation in
S2 cells; and in ﬂies, Not4 overexpression resulted in an
8-fold increase in Turandot M (TotM) and in a 4-fold
increase in Turandot A (TotA) stress gene activation
when compared to wild-type ﬂies. Drosophila Not4 is
structurally related to human CNOT4, which was found
to regulate interferon-- and interleukin-4-induced
STAT-mediated gene responses in human HeLa cells.
Not4 was found to coimmunoprecipitate with Stat92E
but not to affect tyrosine phosphorylation of Stat92E in
Drosophila cells. However, Not4 is required for binding
of Stat92E to its DNA recognition sequence in the TotM
gene promoter. In summary, Not4/CNOT4 is a novel
positive regulator of the JAK/STAT pathway in Dro-
sophila and in humans.—Gro¨nholm, J., Kaustio, M.,
Myllyma¨ki, H., Kallio, J., Saarikettu, J., Kronhamn, J.,
Valanne, S., Silvennoinen, O., Ra¨met, M. Not4 en-
hances JAK/STAT pathway-dependent gene expression
in Drosophila and in human cells. FASEB J. 26,
1239–1250 (2012). www.fasebj.org
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 stress response
The Janus kinase/signal transducer and activator of
transcription (JAK/STAT) pathway has been well con-
served during evolution from ﬂies to humans. The
human JAK/STAT cascade transduces signals from
numerous hematopoietic cytokines and growth factors,
leading to changes in target gene expression (1).
Consequently, deregulation of the JAK/STAT pathway
has been associated with several diseases, including
cancer; myeloproliferative neoplasms; severe immune
deﬁciencies, such as severe combined immune deﬁ-
ciency; allergies; and autoimmunity (2–5).
The human JAK/STAT pathway consists of 4 JAKs
and 7 different STATs (6), whereas in the fruit ﬂy
Drosophila melanogaster, the JAK/STAT pathway consists
of only one cytokine receptor-like transmembrane pro-
tein, domeless (Dome); one Janus kinase, termed hop-
scotch (Hop); and a single STAT transcription factor,
Stat92E (7–11). In Drosophila, the JAK/STAT pathway
orchestrates a diverse set of developmental events and
cellular processes, including embryonic segmentation,
larval hematopoiesis, sex determination, organogene-
sis, and the regulation of stem cell maintenance (12–
14). As in mammals, the JAK/STAT pathway is also
required for the control of immune and stress re-
sponses, including viral defense in Drosophila and other
insects (15–16). An immune challenge induces the
expression of several JAK/STAT pathway target genes,
including the complement-like protein thioester-contain-
ing protein 2 (Tep2) and Turandot (Tot) stress genes
(17, 18).
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In the canonical model for JAK/STAT signaling,
pathway activation occurs when a secreted ligand binds
to a transmembrane receptor, leading to the dimeriza-
tion or multimerization of the receptor molecules. The
receptor-associated JAK molecules are then brought
into a position that allows them to transphosphorylate
each other and to phosphorylate tyrosine residues in
the cytoplasmic portion of the receptor molecules that
serve as docking sites for the Src homology 2 (SH2)
domains of cytoplasmic STAT molecules. The receptor-
bound STATs are activated by JAK-mediated tyrosine
phosphorylation, which induces the dimerization and
nuclear translocation of STATs. In the nucleus, STAT
dimers bind to speciﬁc enhancer elements in the DNA
and act as regulators of transcription (6). In Drosophila,
3 variants of Dome receptor ligands have been charac-
terized, named unpaired 1–3 (Upd1–3; refs. 19–21).
Upd binding to Dome leads to a rapid conformational
change in dimerized Dome molecules and to the
activation of the Drosophila JAK/STAT pathway (22).
The JAK/STAT pathway is tightly regulated in both
the mammalian and Drosophila systems, which share
many conserved regulatory factors. Known regulators
include a family of suppressor of cytokine signaling
(SOCS) molecules, consisting of 8 proteins in humans.
Human SOCSs are usually transcriptionally regulated
by the JAK/STAT pathway, and thus form a negative
feedback loop (23, 24). In Drosophila, Socs36E has been
reported to participate in JAK/STAT pathway regula-
tion in a similar manner (25). Protein inhibitor of
activated STAT (PIAS) proteins are known negative
regulators of the JAK/STAT pathway, and Drosophila
PIAS is shown to negatively regulate Stat92E, but the
mechanism for this is still elusive (26). In humans,
PIAS1 is known to affect STAT1 DNA binding and to
act as an E3 SUMO ligase in the sumoylation of STAT1
(27). Like its mammalian counterpart, Stat92E was
recently shown to be negatively regulated by a SUMO
modiﬁcation (28). Other known negative regulators of
the Drosophila JAK/STAT pathway are the protein-
tyrosine phosphatase 61F (Ptp61F) and an N-terminally
truncated Stat92E (N-Stat92E), which functions as a
dominant-negative form of Stat92E (29, 30).
Recently, a new negative regulator of the Drosophila
JAK/STAT pathway, called eye transformer (ET), was
found in a genome-wide RNAi screen (31). Here, we
characterize another novel regulator of the JAK/STAT
pathway, CG31716, which encodes the Drosophila Not4
protein. Drosophila Not4 shares homology with the
human CNOT4 protein. CNOT4 is a member of the
evolutionarily conserved multifunctional Ccr4-Not
complex, composed of 9 core subunits, originally found
in yeast (32). The Ccr4-Not complex takes part in
multiple cellular processes, including DNA repair, his-
tone methylation, regulation of messenger RNA
(mRNA) degradation, transcription initiation, and
transcription elongation in yeast (32, 33). CNOT4 is
also known to harbor a ubiquitin E3 ligase activity in its
N-terminal really interesting new gene (RING) domain
(34). In this study, we show that Not4 enhances JAK/
STAT-mediated gene responses in Drosophila both in
vitro and in vivo. Furthermore, we provide evidence that
CNOT4 also participates in the regulation of JAK/
STAT signaling in human cells.
MATERIALS AND METHODS
Plasmid constructs and double-stranded RNA (dsRNA)
synthesis
The Drosophila CG31716/Not4 cDNA (clone RE04975) was
purchased from the Drosophila Genomics Resource Center
(Indiana University, Bloomington, IN, USA), was ampliﬁed
by PCR using 5-CACACAGCGGCCGCATGAACGGCCTGAG-
CAGC-3 containing a NotI restriction site and 5-CACA-
CATCTAGAAACGAATTGACGGCTTTTTAAAAACG-3 con-
taining an XbaI restriction site, and was cloned into the
pMT-V5-HisA expression vector (Invitrogen, Carlsbad, CA,
USA). pMT-Stat92E-Flag (28), Hop tumorous-lethal (HopTum-l),
pMT-Upd, TotM-luc, 10XStat92E-luc, and Act5C--gal plasmids
(31), as well as -activated sequence-luciferase (GAS-luc), cytomeg-
alovirus--galactosidase (CMV--gal), and immunoglobulin (Ig)ε-
luc plasmids, have been described previously (27, 35). The
Not4 deletion constructs RING, RINGRNA recognition
motif (RRM), and C terminus were cloned from an existing
pMT-Not4 expression vector into the SpeI and XhoI sites
(RING, RINGRRM) or the XbaI and EcoRI sites (C
terminus) of the Drosophila expression vector pMT-V5-HisA.
The primers used for cloning the 3 deletion constructs were
RING, 5-CACACAACTAGTATGCCAGCTGACTTCAAGCCG-
CT-3 and 5-CACACACTCGAGAACGAATTGACGGCTTTTTA-
AAAACG-3;RINGRRM, the same forwardprimer as forRING
and 5-CACACAACTAGTATGACCAGCTTGGGGACAACC-3;C
terminus, 5-CACACAGAATTCATGAACGGCCTGAGCAGC-3
and 5-CACACATCTAGACAATTCATGTAAGTACATGCAGTCG-
3.Not4–5UTRdsRNAwas synthesized fromSchneider 2Drosophila
(S2) cell cDNA using primers 5-T7ATAGTTTGAGCTGTGG-3
and 5-T7TTGATTAGTGATGAAG-3; otherwise, theRNAi prim-
ers and dsRNA synthesis were as described elsewhere (31).
Cell culture, creation of stably overexpressing S2 cell lines
Drosophila S2 cells were cultured in Schneider’s medium
(Sigma-Aldrich, St. Louis, MO, USA), as described previously
(31). Stable pMT-V5-HisA control and pMT-Not4-V5-overex-
pressing cell lines were created by transfecting 5.0  106 S2
cells with 9.5 g of the pMT-V5-HisA or pMT-Not4-V5 plas-
mids together with 0.5 g of the pCoHygro plasmid. After
72 h, the medium was changed to Schneider’s medium
supplemented with 10% FBS, 100 U/ml penicillin, 100 g/ml
streptomycin, and 300 g/ml hygromycin-B (Calbiochem,
San Diego, CA, USA), and plates were cultured at 25°C. All S2
cell transfections were carried out with the FuGENE6 trans-
fection reagent (Roche, Basel, Switzerland), according to the
manufacturer’s instructions. HeLa cells were cultured at 37°C
in DMEM supplemented with 10% (v/v) FBS, 1% (v/v)
nonessential amino acids, 2 mM l-glutamine, 100 U/ml
penicillin, and 50 mg/ml streptomycin.
Luciferase assay
Transfections, dsRNA treatments, and TotM-luc/10xStat92E-
luc reporter activity measurements were carried out as de-
scribed previously (31). For luciferase assay experiments with
overexpressed Not4, 0.2 g of Not4-V5, Not4 deletion con-
structs, or a control plasmid was cotransfected into S2 cells;
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otherwise, the transfection and measurements were carried
out similarly to a protocol described earlier. HeLa cells
(0.1106) were transfected with 0.2 g of GAS-luc or Igε-luc
reporter plasmid with 0.1 g of the CMV--gal reporter
plasmid for monitoring cell viability and transfection efﬁ-
ciency simultaneously with 20 pmol of the indicated control
or experimental siRNA. After 24 h, cells were serum starved
for 24 h and stimulated with 100 ng/ml of human interfer-
on- for 6 h or human IL-4 for 24 h prior to lysis. Luciferase
and -gal values were measured as described previously (31).
Luciferase assays for the Toll and the Imd pathways were
carried out as described previously (36).
Fly stocks and infections
All Drosophila stocks were reared at 25°C on a standard
mashed potato diet [4% w/v mashed potato powder, 1.1%
w/v dried yeast, 6% w/v dark syrup, 1% w/v agar and 0.85%
w/v 10% methyl 4-hydroxybenzoate (Sigma-Aldrich) in etha-
nol].
The UAS-Not4 transgenic stocks were obtained from Best
Gene, Inc. (Chino Hills, CA, USA). To generate these, Not4
was ampliﬁed by PCR and cloned into a pUAST vector (37)
using the following PCR-primers: 5-CACACAGCGGCCG-
CATGAACGGCCTGAGCAGC-3, containing a NotI restric-
tion site, and 5-CACACATCTAGAAACGAATTGACGGCT
TTTTAAAAACG-3, containing an XbaI restriction site; for
Not4-myc, 5-GGCCGGTCTAGATTATTACAAGTCCTCTTCA
GAAATGAGCTTTTGCTCAACGAATTGACGGCTTTTTAAA-
AACG-3, containing a myc-tag sequence together with an
XbaI restriction site, was used as a 3-primer. Seven indepen-
dent transformant lines with a UAS-Not4 construct (lines
UAS-Not41 to UAS-Not47) incorporated into their genome and
6 lines carrying a UAS-NOT4-myc construct (lines UAS-Not4-
myc1 to UAS-Not4-myc6) were used to study the effect of Not4
overexpression in vivo. Using the UAS-GAL4 binary system
(37), we crossed UAS-Not4 overexpression lines with C564-
GAL4 driver lines, to achieve overexpression of Not4 in the fat
body of the progeny ﬂies, as described previously (31).
Activation of the JAK/STAT pathway by infecting 3- to 6-d-old
ﬂies with Enterobacter cloacae has also been described previ-
ously (31).
Total RNA extraction from ﬂies
For RNA extractions, 3 female and 3 male ﬂies per sample
were anesthetized with CO2 and snap-frozen on dry ice. Total
RNA was isolated by homogenizing the ﬂies in 300 l of TRI
reagent (Molecular Research Center, Inc., Cincinnati, OH,
USA) by grinding with a micropestle grinder and then
continuing with the RNA extraction according to the reagent
manufacturer’s instructions; 1;40 dilutions of the ﬂy total-
RNA samples were used for quantitative RT-PCR (qRT-PCR).
qRT-PCR
qRT-PCR for TotM, TotA, Not4, and Act5C levels was carried out
using the QuantiTect SYBR Green RT-PCR Kit (Qiagen, Valen-
cia, CA, USA) and the ABI7000 instrument (Applied Biosystems,
Foster City, CA, USA) according to the manufacturer’s instruc-
tions. The primers used for Not4 quantiﬁcation were 5-ATG-
GCAAAGAGGCGGCTG-3 and 5-GCTGCTTCTCGTTTCGGG-
3. Other primers (Act5C, TotM, TotA) were as described
previously (31).
Coimmunoprecipitation and immunodetection
For coimmunoprecipitation experiments, Not4-V5 expres-
sion from the stable pMT-Not4-V5-overexpressing S2 cells was
induced by adding 500 M CuSO4 into the Schneider’s
growth medium. After 48 h, cells were lysed with coimmuno-
precipitation lysis buffer (20 mM HEPES, pH 8.0; 100 mM
NaCl; 1% TritonX-100; 10% glycerol; 1 mM EDTA; and 50
mM NaF) supplemented with vanadate, PMSF, and aprotinin.
Protein concentrations were determined by a DC protein
assay kit (Bio-Rad Laboratories, Hercules, CA, USA), and
equal amounts of protein were immunoprecipitated with an
anti-Stat92E-N-terminal antibody (dN-17; Santa Cruz Biotech-
nology, Santa Cruz, CA, USA) at 4°C following incubation
with Protein G Sepharose beads (GE Healthcare, Little Chal-
font, UK). Coimmunoprecipitated proteins were separated by
SDS-PAGE, transferred to a nitrocellulose membrane (Pro-
tran; Schleicher & Schuell, Dassel, Germany), and immuno-
detected with an anti-V5 antibody (Invitrogen, Carlsbad, CA,
USA), as described previously (31).
Electrophoretic mobility shift assay (EMSA)
For EMSA, double-stranded DNA (dsDNA) probes were gen-
erated by annealing 5-CAAAAAAACAGTTCTTAGAATG-
CAATCAATAC-3 and 5-GTATTGATTGCATTCTAAGAAC-
TGTTTTTTTG-3 oligos containing the Stat92E binding site
(TTCTTAGAAT) from the TotM gene promoter region and
end-labeled by T4-polynucleotide kinase using [-32P]-labeled
adenosine triphosphate. S2 cells (5106) were transfected
with 2.0 g of HopTum-l or control plasmid together with 5.0
g of indicated dsRNAs. After 48 h, cells were lysed with
buffer containing 10 mM HEPES-KOH (pH 8.0), 10 mM KCl,
0.1% Nonidet P-40, 1 mM EDTA supplemented with 10 mM
NaF, 1 mM DTT, vanadate, aprotinin, and PMSF. After 1 min
of centrifugation at 10,000 g, the supernatant was collected as
a cytoplasmic extract. The pellet was then resuspended into a
buffer containing 20 mM HEPES-KOH (pH 8.0), 400 mM
NaCl, 10% glycerol, 1 mM DTT, and 10 mM NaF, supple-
mented with vanadate, aprotinin, and PMSF, and rotated at
4°C for 30 min following centrifugation for 3 min at 14,000
g in order to obtain a nuclear lysate. Cytoplasmic and nuclear
lysates were subjected to a binding reaction in a 3:1 ratio
together with the radiolabeled dsDNA oligo with or without
200 ng of an anti-Stat92E-N-terminal antibody (dN-17; Santa
Cruz Biotechnology) in binding buffer (20 mM HEPES-KOH,
pH 8.0; 50 mM NaCl; 10% glycerol; 0.01% Triton X-100; and
1 mM DTT) for 30 min at room temperature. DNA-probe-
bound proteins were then separated in a 6% PAGE in 0.5
TAE buffer, followed by autoradiography.
A dsDNA probe containing mutated Stat92E binding site was
generated by annealing 5-CAAAAAAACAGGGGAATCCCAG-
CAATCAATAC-3 and 5-GTATTGATTGCTGGGATTCCCCT-
GTTTTTTTG-3 oligos. For competition assay, an unlabeled
wild-type probe and unlabeled mutated probe were added to the
binding reactions together with the labeled wild-type probe.
Otherwise, the assay and analysis were carried out as described
above.
Data analysis
Statistical analyses of reporter assays and qRT-PCR results
were carried out using 1-tailed Student’s t test with Welch’s
correction or 1-way ANOVA. Values of P 	 0.05 were consid-
ered to be statistically signiﬁcant.
RESULTS
CG31716/Not4 positively regulates Stat92E-inducible
genes in S2 cells
The Drosophila gene CG31716, encoding the Not4 pro-
tein, was originally identiﬁed as a potential regulator of
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the JAK/STAT pathway in a genome-wide RNAi screen
in Drosophila S2 cells (31). To conﬁrm the initial
ﬁnding, we ﬁrst performed controlled Not4-knockdown
experiments. dsRNA-mediated RNAi targeting the Not4
resulted in a
50% decrease in TotM-luciferase values on
HopTum-l induction when compared to the effect of a
dsRNA targeting the green ﬂuorescent protein (GFP),
which was used as a control (Fig. 1A). This ﬁnding
prompted us to further investigate the role of Not4 in
the regulation of JAK/STAT-mediated signal transduc-
tion. First, a 10xStat92E-luc reporter consisting of a
sequence containing 10 doublets of Stat92E binding
sites from the SOCS36E promoter region was used to
measure the JAK/STAT pathway activity in response to
HopTum-l transfection. As shown in Fig. 1B, HopTum-l
expression induced robust 10xStat92E-luc activation,
which was strongly inhibited by Stat92E RNAi. Notably,
the dsRNA targeting Not4 caused a nearly 50% reduc-
tion in the 10xStat92E-luc activity compared to the GFP
RNAi control. To study the effect of Not4 RNAi on the
JAK/STAT pathway in more physiological conditions,
the pathway was activated by cotransfecting Upd, the
ligand of the transmembrane receptor Dome, together
with different dsRNAs and reporter plasmids. In this
setting, the activity of both of the Stat92E-dependent
luciferase reporters, TotM-luc and 10xStat92E-luc, was
signiﬁcantly reduced by a dsRNA treatment targeting
Not4 (Fig. 1C, D). dsRNAs against the previously pub-
lished JAK/STAT pathway regulator eye transformer (ET;
ref. 31) and against Stat92E were used as positive
controls and dsRNAs against GFP as a negative control.
To investigate whether Not4 RNAi affects gene ex-
pression in a more general manner, we induced Imd
pathway activity by adding heat-killed Escherichia coli to
S2 cells and measured the Imd pathway target-gene
Attacin promoter-driven luciferase activity. As shown in
Supplemental Fig. S1, Not4 RNAi did not affect Imd
pathway signaling in this setting. Of note, we observed
a minor decrease in Toll pathway activity with both
Stat92E and Not4 dsRNA treatments. In summary, Not4
RNAi does not have a general effect on gene expression
in S2 cells. The meaning of the results related to Toll
pathway signaling warrants further studies.
To verify that our results were not caused by artifacts
in the reporter analysis, we studied the effect of Not4
RNAi on the expression level of the endogenous
Stat92E target gene TotM in S2 cells using qRT-PCR. S2
cells were transfected with dsRNA targeting Not4 or
with control dsRNAs together with HopTum-l to activate
Stat92E. TotM expression levels were normalized
against endogenous Act5C expression levels. As shown
in Fig. 1E, Not4 RNAi signiﬁcantly reduces endogenous
Figure 1. Depletion of Drosophila Not4 inhibits Stat92E-mediated gene expression in S2 cells. A) TotM-luciferase reporter analysis
of dsRNA-treated S2 cells with constitutively active HopTum-l induction. Cultured S2 cells were cotransfected with the
TotM-luciferase reporter plasmid together with the Act5C--galactosidase reporter, the HopTum-l expression vector, and the
indicated dsRNAs. Not4 dsRNA results in a statistically signiﬁcant decrease in TotM-luciferase activity. Stat92E RNAi is shown as
a positive control. B) Luciferase reporter analysis using the 10xStat92E-luc reporter with or without HopTum-l overexpression with
indicated dRNAs. C) TotM-luc expression in response to coexpression of the ligand Upd. D) 10xStat92E-luc expression in
response to coexpression of Upd. E) Endogenous TotM gene expression in the presence of Not4 dsRNA. S2 cells were transfected
with the HopTum-l expression vector to activate the JAK/STAT pathway and dsRNAs as indicated. qRT-PCR was used to monitor
TotM-levels. F) Expression of endogenous Not4 in the presence of two separate dsRNAs targeting different sequences in Not4.
Not4 marks the dsRNA used in the original screen and validation (31), whereas Not4 5-UTR dsRNA is used in this study. S2 cells
were transfected with the indicated dsRNAs, and Not4 mRNA levels were measured by qRT-PCR. Error bars indicate sd from
3–6 independent transfections. *P  0.05; **P  0.01; ***P  0.001.
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TotM gene expression in S2 cells after HopTum-l induc-
tion, indicating that Not4 is required for Stat92E-
mediated gene expression. As shown in Fig. 1F, endog-
enous Not4 expression is efﬁciently inhibited by
transfected Not4 dsRNA in S2 cells.
To study the effect of Not4 overexpression on
Stat92E-mediated gene expression in S2 cells, we
cloned the CG31716/Not4 gene into the pMT-V5-HisA
expression vector. As shown in Fig. 2A, B, Not4 overex-
pression enhanced both TotM-luc and 10xStat92E-luc
reporter activities in response to HopTum-l induction in
S2 cells. Ectopic Not4 expression caused the activation
of both of the reporters without HopTum-l expression.
Similar results were obtained in response to Upd ligand
induction (Fig. 2C, D). In summary, Not4 RNAi de-
creases Stat92E-dependent reporter gene activation
and endogenous Stat92E target gene expression in
stimulated S2 cells, while overexpression of Not4 acti-
vates Stat92E-dependent reporter gene expression.
These results indicate that Not4 positively regulates the
Drosophila JAK/STAT pathway in S2 cells.
Overexpression of Not4 enhances Stat92E-dependent
gene expression in vivo
Next, we studied the effect of Not4 on JAK/STAT
pathway target gene expression in vivo in Drosophila. For
this, 8 independent UAS-Not4 transformant lines (UAS-
Not41 to UAS-Not47 and UAS-Not4-myc1) were crossed
with a C564-GAL4-driver strain, which activates trans-
gene expression in the fat body of progeny ﬂies. First,
expression of the transgene in the UAS-Not4/C564-
GAL4 ﬂies was veriﬁed by measuring the relative tran-
scriptional levels of Not4 in total RNA extracts with
qRT-PCR. The level of Actin mRNA was used for
normalization. In all ﬂies overexpressing Not4, we ob-
served a 4- to 15-fold increase in Not4 expression
compared to their respective w1118 controls. The aver-
age fold increase in Not4 expression was roughly 9-fold
(Supplemental Fig. S2A, B).
Overexpression of Not4 resulted in the up-regulation
of Stat92E target gene expression in S2 cells (Fig. 2).
Septic injury causes the JAK/STAT pathway-dependent
activation of TotM and TotA gene expression in adult
ﬂies, and we tested whether Not4 overexpression affects
TotM or TotA expression in vivo (17, 21). To investigate
this, we assayed UAS-Not4/C564-GAL4 adult ﬂies over-
expressing Not4 for TotM and TotA expression by per-
forming qRT-PCR and compared these expression lev-
els to those in control w1118, w1118/C564-GAL4, and
UAS-Not4/w1118 ﬂies. Both unchallenged ﬂies and ﬂies
infected with the gram-negative bacteria Enterobacter
cloacae were analyzed. In accordance with our in vitro
results, we found that both TotM and TotA expression
were signiﬁcantly up-regulated in Not4-overexpressing
UAS-Not4/C564-GAL4 ﬂies compared to control ﬂies
(Fig. 3A, B, open bars). The results shown were aver-
aged from all 8 UAS-Not4 lines. A signiﬁcant increase in
TotM levels was detected in all transgene-expressing ﬂy
lines, and a signiﬁcant increase in TotA levels was seen
in most lines, with the exception of lines UAS-Not43 and
UAS-Not45 (Supplemental Fig. S2C, D). On average, an
8-fold increase in the expression of TotM and an
4-fold increase in the expression of TotA were ob-
served in ﬂies overexpressing Not4 compared to the
progeny of the control cross without the GAL4-driver
(UAS-Not4/w1118; Fig. 3A, B, open bars).
To test whether Not4 overexpression affects TotM or
TotA expression after septic injury, ﬂies were infected
with E. cloacae. RNA from these ﬂies was extracted after
an incubation period of 16 h, and the transcription
levels of TotA and TotM were measured by qRT-PCR.
Again, the results of all of the 8 UAS-Not4 lines were
averaged. We observed an increase in TotA and TotM
Figure 2. Overexpression of Not4 enhances Stat92E-mediated gene expression in
S2 cells. A) S2 cells were transfected with the Act5C--galactosidase reporter and
the TotM-luc reporter together with the empty pMT-V5-HisA or pMT-Not4-
V5 plasmids with or without HopTum-l to activate the JAK/STAT pathway.
B) Luciferase reporter assay using 10xStat92E-luc with expression vectors as in A.
C, D) Overexpression of Not4 increases TotM-luc (C) and 10xStat92E-luc (D)
reporter activities both in the absence and presence of Upd induction. S2 cells
were transfected with the Act5C--galactosidase reporter together with the TotM-
luc reporter or the 10xStat92E-luc reporter, and the pMT-Not4-V5 expression
vector or the empty vector, and pMT-Upd, as indicated. Error bars indicate sd
from 3 independent experiments. *P  0.05; ***P  0.001.
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expression levels in response to septic injury in most ﬂy
strains. Following septic injury, there was on average a
2- to 4-fold increase in the expression of both TotM and
TotA in control ﬂies (Fig. 3A, B, shaded bars). In
infected ﬂies, Not4 overexpression signiﬁcantly elevated
TotM expression compared to the control cross (Fig.
3A), but no difference was detected in TotA expression
on septic injury (Fig. 3B). Of note, there was no
signiﬁcant difference in TotA or TotM expression levels
between uninfected and infected Not4-overexpressing
ﬂies. Similarly, no changes in Not4 expression were
observed in response to septic injury (Supplemental
Fig. S2A). Taken together, these results indicate that
Not4 also up-regulates Tot gene expression in D. mela-
nogaster in vivo.
Many regulatory factors of the JAK/STAT signaling
pathway have been conserved in evolution, and Drosoph-
ila Not4 shares homology with human CNOT4. This
prompted us to study whether CNOT4 also takes part in
the regulation of mammalian JAK/STAT signaling in
human cells. Interferon- (IFN-) is a cytokine impor-
tant for macrophage activation, and its transcriptional
responses are mediated through STAT1 (27). To study
whether CNOT4 takes part in STAT1-mediated signal
transduction, we used siRNA transfection to knock
down CNOT4 in HeLa cells with cotransfection of
STAT1 responsive GAS-luc and CMV--gal reporters.
After 24 h, cells were serum starved overnight and
stimulated with human IFN- for 6 h. After cell lysis,
GAS-luc activity was measured and normalized against
-galactosidase activity. As shown in Fig. 3C, human
CNOT4 RNAi signiﬁcantly decreases relative GAS-luc
activity, indicating that knockdown of CNOT4 impairs
human STAT1-mediated signal transduction. Further-
more, a similar effect was observed with interleukin-4
(IL-4) induced Igε-luc activity, indicating that human
STAT6 signaling is also modulated by CNOT4. To
control for any general effects CNOT4 might have on
gene expression in HeLa cells, we used a JAK/STAT
pathway independent p53-responsive PG-13-luc con-
struct, containing 13 synthetic p53 binding sites up-
stream of a luciferase gene. As shown in Fig. 3E, CNOT4
siRNA does not alter PG-13-luc activity either in the
presence of the p53 expression vector or in the pres-
ence of a control plasmid. Of note, the -gal expression
was not affected by the CNOT4 RNAi in our experi-
ments. These data suggest that CNOT4 positively regu-
lates JAK/STAT signaling in human cells.
Not4-mediated regulation of the Drosophila JAK/STAT
pathway is independent of the RING and the RRM
domains
Not4 is a 6.2-kb gene that produces a 1051-aa protein
that contains a RING-ﬁnger domain, an RRM that is
known to interact with single-stranded RNA (ssRNA)
and single-stranded DNA (ssDNA), as well as proteins,
Figure 3. Not4 overexpression
enhances JAK/STAT pathway-
mediated gene expression in
Drosophila in vivo, and CNOT4
RNAi inhibits JAK/STAT path-
way-mediated reporter gene ex-
pression in human HeLa cells.
A, B) qRT-PCR with primers
speciﬁc for either TotM (A) or
TotA (B) were used to quantify
target gene expression in total
RNA extracts from uninfected
and infected ﬂies overexpress-
ing Not4 in the fatbody. C) Effect of human CNOT4 depletion on IFN--induced GAS-luc activity. HeLa cells were transfected
with the GAS-luc reporter together with the CMV--gal reporter and the indicated siRNAs. After 48 h, STAT1-mediated
signaling was activated by adding 100 ng/ml of human IFN- to cells for 6 h prior to lysis. D) Effect of human CNOT4
depletion on IL-4-induced Igε-luc activity. HeLa cells were transfected with the Igε-luc reporter plasmid together with
CMV--gal and the indicated siRNAs. Activation of the STAT6-responsive Igε-luc promoter was induced by stimulating the
cells for 24 h with human IL-4. E) CNOT4 RNAi effect on PG-13-luc reporter activity. HeLa cells were transfected with the
PG-13-luc reporter together with the CMV--gal reporter and a p53 expression vector to activate the PG-13-luc reporter
expression. Error bars indicate sd from 3 independent transfections. *P  0.05; **P  0.01; ***P  0.001.
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and a Zn-ﬁnger domain mediating possible protein-
protein interactions (Fig. 4A). Drosophila Not4 shares
similar domain architecture with CNOT4 proteins from
yeast to humans (38). In contrast to the N terminus, the
C-terminal part of Not4 does not contain any known
secondary structures and is less conserved. The yeast
Not4 and the human CNOT4 have an E3 ubiquitin
ligase activity, as the RING domain on CNOT4 can
interact with ubiquitin-conjugating enzymes (UbcH5B,
UbcH6, and UbcH9 in humans; refs. 34, 39).
The RING domain harbors the essential function of
CNOT4, acting most likely as a mediator of ubiquitin
E3-E2 ligase interactions (34). We wanted to examine
whether the RING domain of Not4 is also important for
the JAK/STAT pathway in Drosophila cells. For this, we
generated 3 deletion mutants of the Not4 gene: dele-
tion of the RING domain (RING, aa 63–1051), dele-
tion of the RING domain and the RRM (RINGRRM,
aa 186-1051), and one construct containing both the
RING and RRM domains but missing the whole C-ter-
minal part (C terminus, aa 1–215). The proper ex-
pression of these constructs was determined by Western
blot (Fig. 4B). To study the effect of these deletions on
the Drosophila JAK/STAT pathway, the constructs were
cotransfected into Drosophila S2 cells together with the
TotM-luc reporter construct in addition to the HopTum-l
expression vector to induce the JAK/STAT pathway.
Samples were treated with Not4 5UTR dsRNA to block
expression of the endogenous Not4 or GFP dsRNA for
negative controls. An Act5C--galactosidase reporter
Figure 4. RING-ﬁnger and RRM domains in Not4 are not essential for JAK/STAT pathway regulation. A) Illustration of the
domain organization of human CNOT4, full-length Drosophila Not4, and Drosophila Not4 deletion constructs. Human
CNOT4 and Drosophila Not4 share 3 highly conserved domains: a RING-ﬁnger domain in the N terminus of the protein
followed by an RRM domain and a zinc-ﬁnger domain (ZF). We generated 3 different deletion constructs of Not4, of which
RING lacks the RING domain, RINGRRM lacks both the RING and the RRM domains, and C terminus lacks the whole
C-terminal part of the protein. The effect of these deletion constructs on reporter expression was then analyzed in S2 cells.
B) TotM-luc reporter analysis of S2 cells cotransfected with the TotM-luc reporter plasmid, the Act5C--gal reporter, the
HopTum-l, the indicated dsRNAs, and pMT-Not4 or the indicated Not4 deletion constructs. Error bars indicate se from 8
independent transfections. Expression of the wild-type Not4-V5 and indicated deletion constructs were veriﬁed using
Western blot analysis; asterisk indicates a nonspeciﬁc band. ***P  0.001.
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was used for normalization. Stat92E dsRNA-treated cells
were used as controls. Luciferase and -galactosidase
activities were measured at 72 h after transfection. As
shown in Fig. 4B, transfection with pMT-Not4 signiﬁ-
cantly increased TotM-luc reporter activity. Transfection
of the RING deletion construct caused a similar
increase in TotM-luc reporter activity, as did transfec-
tion with the intact gene (Fig. 4B). This suggests that
this deletion construct still has the domains and func-
tions required for the regulation of JAK/STAT target
gene expression. Transfection with the deletion con-
struct RINGRRM also resulted in an increase in
TotM-luc reporter activity compared to transfection with
an empty vector, albeit to a lesser extent than the
transfection with a full-length pMT-Not4 construct (Fig.
4B). Hence, Not4 lacking both the RING and the RRM
domains still retains some functions needed for the
positive regulation of JAK/STAT signaling. We also
studied the effect of Not4 deletion constructs on
10xStat92E-luc activity on Upd induction in S2 cells.
Similarly to the TotM-luc reporter, overexpression of
RING and RINGRRM deletion constructs caused a
signiﬁcant increase in 10xStat92E-luc activity when com-
pared to the transfection control, but the effect was
slightly smaller than that obtained with overexpression
of full-length Not4 (data not shown). Conversely, trans-
fection with the C-terminal deletion construct seemed
to have neither a positive nor a negative effect on
TotM/10xStat92E-luc reporter activity. These data sug-
gest that the Not4-mediated regulation of the Drosophila
JAK/STAT pathway is independent of the RING and
the RRM domains.
Drosophila Not4 interacts with Stat92E
It has been suggested that Not4 is localized in the cyto-
plasm of S2 cells (40). On the basis of our immunostain-
ing results from stable pMT-Not4-V5 overexpression S2
cells, the majority of the Not4 protein is indeed localized
in the cytoplasm in S2 cells, but a minor nuclear portion
was also detected (data not shown). To determine
whether Not4 interacts with Stat92E, S2 cells overexpress-
ing a Not4-V5 or a pMT-V5-HisA vector control were lysed,
and the endogenous Stat92E was immunoprecipitated
using an anti-Stat92E-N-terminal antibody. Immunopre-
cipitated proteins were separated by SDS-PAGE following
immunoblotting using an anti-V5 antibody to detect co-
immunoprecipitated Not4. As shown in Fig. 5A, Not4-V5
coimmunoprecipitates with endogenous Stat92E.
Next, we wanted to study whether JAK/STAT path-
way activation affects the Stat92E-Not4 interaction. For
this experiment, cells overexpressing pMT-Not4-V5
were transfected either with a vehicle or with increasing
amounts of pMT-Upd in order to activate the JAK/
STAT pathway. After 48 h, cells were lysed, and the
coimmunoprecipitation experiment was carried out as
described earlier. As shown in Fig. 5B, the amount of
Stat92E interacting with Not4 increases on Upd stimu-
lation. Also, the total amount of Not4-V5 was observed
to be higher after stimulation of cells with Upd. Of
note, Stat92E RNAi resulted in a decrease in Not4
protein levels in the stable Not4-V5 S2 cell line, indi-
cating that Stat92E may have a role in regulating Not4
protein stability (data not shown).
Drosophila Not4 enhances Stat92E DNA binding
without affecting Stat92E tyrosine phosphorylation
Activation of Stat92E by phosphorylation of the tyrosine
711 residue is considered to be essential for Stat92E
target gene transcription. To further study the mecha-
nism of how Not4 affects Drosophila JAK/STAT signal-
ing, we determined the Upd-induced tyrosine phos-
phorylation status of Stat92E in cells with Not4 RNAi
knockdown. S2 cells were cotransfected with Upd to
induce endogenous Stat92E tyrosine 711 phosphoryla-
tion together with dsRNAs targeting Not4 or GFP and
Stat92E or Hop as negative and positive controls, respec-
Figure 5. Drosophila Not4 interacts with Stat92E. A) Cultured pMT-V5-HisA-control S2 cells or pMT-Not4-V5 overexpression cells
were treated with 500 M CuSO4 for 48 h to induce the expression of Not4 from the pMT-Not4-V5 vector. Total cell lysates were
used for immunopecipitation with an anti-Stat92E antibody, or as a control, with an HA-antibody, and coimmunoprecipitated
Not4-V5 was detected with an anti-V5 antibody. Stat92E protein was equally expressed in both cell lines (bottom panel).
B) Overexpression of Upd results in increased Stat92E-Not4 interaction. pMT-Not4-V5 overexpression S2 cells were transfected
with either an empty vector (vehicle) or a Upd expression vector in order to activate the JAK/STAT pathway. Cells were treated
with 500 M CuSO4 for 48 h following cell lysis. Coimmunoprecipitation was carried out with an anti-Stat92E-N-terminal
antibody, followed by immunodetection with anti-V5. Middle panel shows Not4-V5 expression levels; bottom panel shows an
anti-actin immunoblot to demonstrate that equal amounts of protein lysates were subjected to SDS-PAGE analysis.
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tively. CuSO4 (500 M) was added to the medium to
induce the expression of Upd from the pMT vector
48 h prior to cell lysis. Equal amounts of protein lysates
were subjected to SDS-PAGE and immunoblotted with
anti-Stat92E. As shown in Fig. 6A, a weak, slower-
migrating Stat92E band, corresponding to tyrosine
phosphorylated Stat92E, was detected in Upd-induced
samples (compare lane 1 to lanes 2 and 3). As ex-
pected, this band is absent in Hop or Stat92E RNAi
samples. Interestingly, Not4 RNAi did not affect Stat92E
phosphorylation in this setting. To ensure that the
Stat92E is phosphorylated, endogenous Stat92E was
immunoprecipitated with an anti-Stat92E-N-terminal
antibody and immunoblotted with an anti-phospho-
tyrosine antibody. The amount of phosphorylated
Stat92E did not differ between cells with GFP and Not4
knockdown (Fig. 6A, bottom panel). To further study
the role of Not4 in Stat92E phosphorylation, we over-
expressed Not4 in S2 cells. S2 cells stably overexpressing
pMT-Not4-V5 or control S2 cells were cotransfected
with Stat92E-Flag together with HopTum-l to induce
Stat92E phosphorylation or with an empty vector as a
transfection control. Cells were treated with 500 M
CuSO4 and lysed after 48 h. Equal amounts of protein
were immunopreciptated with an anti-Flag antibody
and separated by SDS-PAGE, followed by immunode-
tection with an anti-Stat92E-N-terminal antibody to
detect immunoprecipitated Stat92E. As shown in Fig.
6B, there is a clear slower-migrating band in the
HopTum-l-induced samples (lanes 3 and 4), indicating
Stat92E phosphorylation. Forced Not4 expression did
not affect Stat92E phosophorylation in this setting.
Taken together, these results suggest that Not4 modu-
lates Stat92E target gene expression downstream of the
Stat92E phosphorylation event.
Tyrosine-phosphorylated Stat92E translocates to the
nucleus, where it binds to the Stat92E consensus se-
quence in the promoter regions of target genes. We
used EMSA to study whether Not4 has a role in the DNA
binding of Stat92E, using the sequence of the Stat92E
Figure 6. Not4 enhances Stat92E DNA binding without affecting Stat92E tyrosine phosphorylation. A) Not4 RNAi does not affect
tyrosine phosphorylation of Stat92E. S2 cells were cotransfected with different dsRNAs, and Upd to activate Stat92E
phosphorylation, as indicated. Cells were treated with CuSO4 to induce Upd expression 48 h prior to cell lysis. Total Stat92E was
detected by immunoblotting with an anti-Stat92E-N-terminal antibody (top panel). Phosphorylated Stat92E was detected by
immunoprecipitating Stat92E from total cell lysates using an anti-Stat92E-N-terminal antibody and immunoblotting with an
anti-phospho-tyrosine (anti-pTyr) antibody (bottom panel). B) pMT-Not4-V5-overexpressing S2 cells or pMT-V5-overexpressing
control S2 cells were transiently cotransfected with Stat92E-Flag in the presence or absence of the HopTum-l expression vector
to induce tyrosine phosphorylation of Stat92E. Equal amounts of total cell lysates were subjected to immunoprecipitation with
an anti-Flag antibody and immunodetection with an anti-Stat92E-N-terminal antibody. C) Not4 RNAi interrupts Stat92E binding
to its DNA-recognition sequence in the TotM-promoter in an EMSA analysis. S2 cells were transfected with the indicated dsRNAs
together with the HopTum-l or the empty vector as a control. Equal amounts (15 g) of cell lysates were incubated for 30 min
at room temperature in the presence of the EMSA probe with or without an anti-Stat92E-N-terminal antibody, as indicated.
Samples were separated in a 6% PAGE in 0.5 TAE. First lane represents the free probe only, without cell lysate. Equal amounts
of protein were subjected to immunoblotting with an anti-Stat92E-N-terminal antibody to detect Stat92E levels from the lysates
used in EMSA.
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binding site in the TotM-gene promoter region as a
probe. S2 cells were transfected with HopTum-l to in-
duce Stat92E phosphorylation and with dsRNA target-
ing Not4, or with GFP or Stat92E dsRNAs as controls. As
shown in Fig. 6C, there is a clear band (indicated by an
arrow), which likely represents the Stat92E-dsDNA-
probe complex, as this band is hindered by both the
anti-Stat92E antibody and by a dsRNA treatment target-
ing Stat92E. Furthermore, the intensity of this band is
strongly reduced by competing with an unlabeled wild-
type probe but not by competing with a probe contain-
ing a mutated Stat92E binding site (Supplemental Fig.
S3). No supershift was detected with the anti-Stat92E
antibody, likely because binding of the antibody to its
epitope blocks the DNA binding ability of Stat92E.
Notably, dsRNA treatment targeting Not4 markedly
reduced the intensity of this band compared to the GFP
dsRNA control, suggesting that Not4 regulates the DNA
binding ability of Stat92E. Taking these data together,
we conclude that Not4 modulates Stat92E DNA binding
without affecting Stat92E tyrosine phosphorylation.
DISCUSSION
The JAK/STAT pathway is regulated by a multitude of
mechanisms that can affect receptor expression or
shuttling, JAK kinase activity or receptor docking, phos-
phorylation of signaling proteins, chromatin modiﬁca-
tions, DNA binding, or the activity of transcription
factors. In the present study, we investigated the role of
Not4 in the regulation of JAK/STAT pathway-mediated
gene responses. Not4 RNAi was shown to cause an
50% decrease in JAK/STAT signaling using 2 inde-
pendent reporters, TotM-luc and 10xStat92E-luc, on
either HopTum-l or Upd induction in S2 cells. Further-
more, endogenous Stat92E-dependent TotM expression
was reduced in the absence of Not4 in S2 cells. Over-
expression of Not4 was associated with the hyperactiva-
tion of TotM-luc and 10xStat92E-luc reporter activities
on both HopTum-l and Upd activation. The Not4 over-
expression-induced hyperactivation of the 10xStat92E-
luc promoter was not as drastic as the hyperactivation of
the TotM-luc promoter on HopTum-l induction, suggest-
ing that Not4 may regulate Stat92E target genes differ-
ently depending on the promoter. In addition to
activating reporter gene expression in in vitro, Not4
overexpression caused strong hyperactivation of the
JAK/STAT pathway responsive TotM and TotA stress
genes in vivo in the fatbody of uninfected ﬂies, as well
as the hyperactivation of the TotM gene under septic
injury in E. cloacae-infected ﬂies.
The core components of the JAK/STAT signaling
pathway are highly conserved in evolution, and most of
the known regulatory mechanisms of JAK/STAT-medi-
ated signal transduction are similar in Drosophila and
humans. This appears to be the case also with Not4,
whose human homologue CNOT4 was shown in our
study to be essential for optimal STAT1, as well as
STAT6-mediated transcriptional activation in human
HeLa cells.
STAT-mediated target gene transcription requires a
variety of coactivators
In the canonical model for the JAK/STAT pathway,
STAT activation occurs through JAK-mediated tyrosine
phosphorylation following dimerization and transloca-
tion to the nucleus, where STAT dimers bind to DNA
enhancer elements in the promoters of target genes.
When bound to DNA, interactions between STAT,
other transcription factors, and many coregulatory pro-
teins, including chromatin modifying coactivators are
required to activate the basal transcription machinery
and RNA polymerase II to ﬁnally initiate the transcrip-
tion of the target gene. These include histone acetyl-
transferases CBP/p300, known to function as coactiva-
tors for all STAT family members in mammals (41–46),
as well as Tudor-SN (p100), known to bridge human
STAT6 to CBP (47). Of transcription factors, PU.1 is
essential for the proper activation of the Stat6 response
element in the Igε promoter and for Stat1-mediated
transcriptional activation of the high-afﬁnity Fc recep-
tor (48, 49). Although the molecular mechanisms for
how DNA-bound STAT dimers activate target gene
transcription have been extensively studied in mam-
mals, many aspects of this process remain enigmatic.
This holds true even more in Drosophila, where Stat92E-
associated transcriptional coregulators are completely
unidentiﬁed, but certainly existent.
Our data suggest that Not4 interacts with Stat92E in
S2 cells, and knocking down Not4 expression by RNAi
inhibits the DNA binding of Stat92E. Therefore, it is
possible that Stat92E binds DNA when it is in a complex
with Not4. Not4 may also mediate interactions between
Stat92E and other transcriptional coregulators or RNA
polymerase II, which has been reported to interact with
the Ccr4-Not complex in yeast, this interaction being
essential for proper transcriptional elongation (33).
Ccr4-Not complex in gene regulation
The Ccr4-Not complex is associated with transcription
and mRNA processing in many ways. In yeast, the
Ccr4-Not complex was recently shown to promote
histone H3 lysine 4 methylation (H3K4me3), a process
that has been associated with gene activation (50, 51).
Interestingly, the yeast Not4, and, furthermore, its
RING domain, were shown to be crucial in the regula-
tion of this process through the polyubiquitination of
the demethylase Jhd2 (39). In our study, a Not4 dele-
tion construct lacking the RING domain (RING) was
shown to affect Stat92E-dependent reporter gene ex-
pression to a similar extent as the full-length Not4. A
similar result was obtained with a deletion construct
lacking both the RING and the RRM domains
(RINGRRM) in the highly conserved N terminus of
Not4, indicating that neither the RING nor the RRM
domain is essential for the activation of Stat92E-medi-
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ated gene expression in S2 cells. This suggests that
Stat92E target gene activation does not require the
Not4 ubiquitin ligase activity or the RRM domain-
mediated ssRNA, ssDNA, or protein interactions. The
C-terminal domain that harbors STAT activation prop-
erties does not possess identiﬁable protein domains,
and the nature and mechanism of this regulatory
function need further study.
In human cells, CNOT4 has been shown to associate
with a 200-kDa protein complex, which is not stably
integrated in the Ccr4-Not complex but has the ability
to directly interact with the CNOT1 subunit of the
Ccr4-Not core complex (52). Also, it has been sug-
gested that Not4 is not a stable component of the
Ccr4-Not complex in Drosophila (40). Furthermore, it
was shown in the same study that knocking down Not4
has no detectable effect on the poly(A) tail length or
the rate of deadenylation of mRNA in Drosophila cells
(40). These data suggest that Not4 may also have
functions independent of the Ccr4-Not complex.
DNA binding of Stat92E was inhibited when Not4 was
knocked down in S2 cells by RNAi, indicating that Not4
positively affects Stat92E DNA binding. Furthermore,
the phosphorylation status of Stat92E was not altered by
Not4 RNAi or overexpression. This suggests that Not4
functions downstream of Stat92E phosphorylation in
the JAK/STAT signaling cascade, perhaps in either
nuclear transport or in the DNA binding of Stat92E in
the nucleus. Not4 has been reported to be cytoplasmic,
and our immunoﬂuorescence studies conﬁrm this, but
also identiﬁed a smaller nuclear portion of the protein
(data not shown). Of note, the distribution of Stat92E
in cytoplasmic and nuclear lysates of HopTum-l trans-
fected pMT-Not4-V5 overexpressing cells and HopTum-l
transfected control S2 cells was the same (data not
shown). Although a long stimulation time with HopTum-l
transfection forces Stat92E transcription factors to shut-
tle between active and inactive states within the cell, this
result indicates that Not4 more likely affects Stat92E
DNA binding than its cellular localization.
In summary, we have identiﬁed Not4 as a novel
positive regulator of the JAK/STAT pathway both in
vitro and in vivo in Drosophila and in human cells. The
well-conserved N-terminal RING and RRM domains of
Not4 are not required for JAK/STAT pathway regula-
tion in S2 cells. Not4 coimmunoprecipitates with
Stat92E, and it participates in Stat92E DNA binding.
The exact molecular mechanism for how Not4 affects
Stat92E DNA binding and Stat92E target gene tran-
scription remains to be studied both in Drosophila and
in mammalian systems.
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